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SUMMARY.
1. lev injection of isoprenaline in anaesthetised New
Zealand normotensive rats caused a hypotension and 
tachycardia which appeared to involve both an interaction 
with central beta2- adrenoceptors and a possible 
non-neuronal mechanism which may involve the release of a 
humoral transmitter into the bloodstream. These responses 
were attenuated to a greater extent by chronic oral
dosage, rather than acute pretreatment, with propranolol.
2. Hypotension and tachycardia induced by icv injection 
of isoprenaline or clenbuterol in the conscious New 
Zealand normotensive rat were attenuated by central 
propranolol.
3. Injection of adrenoceptor agonists into the
hypothalamus of the anaesthetised New Zealand normotensive 
rat indicated that activation of central alpha-
adrenoceptors caused hypertension whereas hypotension was 
a result of an interaction with central beta- 
adrenoceptors. An injection into the posterior
hypothalamus was more likely to produce hypotension than 
one into the anterior hypothalamus.
4. lev injection of isoprenaline in anaesthetised
Japanese Okamoto spontaneously hypertensive and Wistar 
Kyoto normotensive rats caused hypotension and
tachycardia. Hypotension was greater and tachycardia was 
less in Japanese Okamoto rats. In both strains,
pretreatment with propranolol attenuated or abolished 
these responses.
5. Hypotension and tachycardia induced by isoprenaline 
injected into the hypothalamus of anaesthetised Wistar and 
Japanese Okamoto rats was attenuated or abolished by 
pretreatment with propranolol.
6. lev injection of radiolabelled isoprenaline or 
propranolol indicated that leakage of drugs to the
periphery was much greater in conscious than anaesthetised 
New Zealand normotensive rats.
7. Responses observed following central administration of 
drugs depended upon a number of factors, including strain, 
site of injection, choice of anaesthetic and presence of 
anaesthesia.
8. This study concludes that central beta- adrenoceptors 
play a role in the maintenance of blood pressure and 
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The aim of this study was to investigate the role of 
central beta- adrenoceptors in the maintenance of blood 
pressure and whether action at these receptors by beta- 
adrenoceptor blocking drugs could contribute to their blood 
pressure lowering effect when used for the management of 
hypertension.
Although beta- adrenoceptor blocking drugs are used in the 
management of a variety of disease states, the precise 
mechanism of their action remains unclear. Beta- 
adrenoceptor blocking drugs employed in the control of 
hypertension appear to exert multiple actions, including 
the possibility of an action within the central nervous 
system. In order to investigate this of a central
action of beta- adrenoceptor blocking drugs, injections 
were made directly into the central nervous system of 
hypertensive and normotensive rats and any change in blood 
pressure and heart rate were recorded.
In this introduction, a brief account of nervous control of 
blood pressure and the disease hypertension will be given 
to illustrate the sites of action of beta- adrenoceptor 
blocking drugs. A review of the literature regarding 
central administration of adrenoceptor agonists and
3antagonists into several species will illustrate the 
discrepancy in results obtained by workers in this field of 
research. A summary of the role of the hypothalamus in 
cardiovascular regulation will be given as injections into 
the hypothalamus were made in this study. Finally, the 
spontaneously hypertensive rat as a model of human 
essential hypertension will be discussed.
1.1. Nervous control of blood pressure.
The efferent nerves supplying the cardiovascular system 
belong to the autonomic nervous system. The vasomotor 
nerves to the blood vessels are principally from the 
sympathetic division of the autonomic nervous system. 
Blood vessels, in general, are not innervated by the 
parasympathetic nervous system.
Almost all sympathetic vasomotor nerves are adrenergic, the 
transmitter noradrenaline producing vasoconstriction by 
acting on the alpha- adrenoceptors of the vascular smooth 
muscle. Many blood vessels, particularly those in skeletal 
muscle, are endowed with beta- adrenoceptors subserving 
vasodilatation, but these receptors are of the beta2- 
subtype and are relatively unresponsive to noradrenaline; 
adrenaline from the adrenal medullae has a greater effect 
on them.
4The level of the systemic arterial blood pressure is 
detected by pressure sensitive receptors, or baroreceptors, 
located at strategic points in the arterial side of the 
circulation. Deviations from a previously stable level of 
blood pressure affect these baroreceptors and elicit 
reflexes influencing the activity of the heart and blood 
vessels so as to compensate for the deviation such that the 
blood pressure tends to return to its initial level.
1.2. Central cardiovascular control centres.
Afferent nerves from the carotid sinus and aortic arch 
baroreceptors enter the medulla oblongata and form a 
descending tract on each side termed the tractus 
solitarius. The primary afferent axons form synaptic 
connections with cell bodies in the nucleus tractus 
solitarius, which surrounds the caudal end of each tractus 
solitarius; the medial portions of these nuclei are fused. 
The axons of the cell bodies of the tractus solitarius 
project into the medullary reticular formation.
Stimulation of the ventromedial reticular area produces 
depressor responses which are due to increased cardiac 
vagal activity and inhibition of activity in cardiac, 
vasomotor and adrenal sympathetic nerves. Stimulation of 
the lateral and rostral reticular areas produces pressor 
responses which are a result of increased activity in
5cardiac, vasomotor and adrenal sympathetic nerves and 
inhibition of cardiac vagal activity.
Efferent axons from neurones in the medial parts of the 
rostral reticular formation of the medulla oblongata join 
the reticulo-spinal tracts of the spinal cord and make 
synaptic connections with the cell bodies of preganglionic 
sympathetic neurones in the lateral horns of the 
thoracolumbar segments of the spinal cord. Neurones in the 
nucleus ambiguus within the ventromedial depressor area 
give rise to axons innervating preganglionic cardiac vagal 
neurones in the dorsal nucleus of the vagus.
The nucleus, tractus solitarius receives a descending 
pathway from the neocortex which modulates the input from 
baroreceptors before the connections with the reticular 
cardiovascular centres. Thus the sensitivity of the 
baroreceptor reflexes may be affected from the highest 
level of the central nervous system.
There are two main pathways for the ascending projections 
of baroreceptor input. One originates from the nucleus 
tractus solitarius and ventromedial reticular depressor 
area and runs to the hypothalamus with further projections 
to the amygdaloid nucleus and to the region of the septum 
pellucidum between the fornix and the corpus callosum. The 
other pathway passes through the centromedian nucleus to
6the thalamus and thence diverges to the anterior thalamic 
nucleus with further projections to the septum pellucidum, 
or to the dorsal thalamic nucleus with further projections 
to the fronto-orbital cortex. The interconnections between 
the hypothalamus and the reticular system of the medulla 
oblongata are concerned with the integration of the control 
of the cardiovascular system and are involved in the 
cardiovascular accompaniments of emotional reactions,
A close association exists between cardiovascular control 
centres and the distribution of noradrenaline containing 
neurones. Noradrenergic neurones concerned with
integrative cardiovascular control ascend from the medulla 
oblongata to the hypothalamus, hippocampus and limbic 
system and cerebral cortex. Descending axons of the 
reticulospinal tracts arise from noradrenaline containing 
and serotonin containing neurones in the medulla oblongata.
The nucleus tractus solitarius possesses a high density of 
adrenaline containing nerve terminals. Ascending and 
descending adrene-rc^ pathways exist in the central nervous 
system which are thought to be involved in cardiovascular 
control. The existence of an adrenergic, vasodepressor 
system has been proposed and the hypotensive action of 
clonidine has been attributed to the direct action of the 
drug on adrenaline receptors (Bolme et al, 1974; Fuxe et 
al, 1975).
7This is a very brief outline of the role of the central 
nervous system in the control of blood pressure. For 
further information regarding central cardiovascular 
pathways and central adrenoceptors involved in 
cardiovascular control, the reader is directed to review 
articles by Dampney (1981), Day and Roach (1974b) and Spyer 
(1982).
1.3. Hypertension and its management.
Hypertension in humans is a common abnormality which is 
associated with a high degree of early mortality and 
morbidity. It is identified with resetting of homoeostatic 
mechanisms for blood pressure regulation at a substantially 
higher level than is expected in the healthy population.
As this pressure load is carried for years, hypertrophy of 
the heart, accelerated sclerosis of blood vessels, and 
target organ damage occurs, particularly in the brain, 
kidney and heart. Systemic hypertension arises from a 
variety of disturbances in circulation, with either 
increased cardiac output, peripheral resistance, or both. 
Compensatory mechanisms are retained when hypertension has 
become fixed, but rather than adjusting pressure within a 
normal range, it is maintained at higher than normal 
pressure ranges.
8Hypertension may be divided into two types:
Primary, or essential, hypertension, in which the 
underlying cause is unknown.
Secondary hypertension, in which the elevation of blood 
pressure is a consequence of another disorder or can be 
assigned to a clearly identifiable cause, such as 
phaeochromocytoma or renal failure.
Hypertension is usually classed into three increasingly 
dangerous states: mild, moderate and severe. In mild 
hypertension, there is no clinically detectable impairment 
of either the heart or the kidneys; blood pressure is 
higher than normal, but otherwise nothing seems to be 
wrong. Increasingly high blood pressures bring increased 
complications. In moderate hypertension the kidneys are 
not working efficiently and the heart is having to work 
harder in the face of increased total peripheral 
resistance. Finally, in severe hypertension, the heart 
becomes enlarged, further deterioration of the kidneys has 
occurred and total peripheral resistance is further 
increased.
The actual level of blood pressure at which hypertension 
can be said to exist is arbitrary, since blood pressure can 
vary considerably between individuals eg. it is normal for
9blood pressure to increase with an increase in age. For 
practical purposes, it is only necessary to decide on the 
blood pressure at which antihypertensive therapy is to be 
instituted. This decision is based on the likely benefit 
to be obtained by lowering the blood pressure, the possible 
adverse effects of antihypertensive drug therapy and the 
presence of complications.
The prime purpose of antihypertensive treatment is to bring 
the blood pressure down to more normal levels. The idea is 
to lower the total peripheral resistance which should lower 
the load on the heart and improve blood flow through the 
kidneys. There is a wide variety of drugs which may be 
employed in the management of hypertension, practically all 
work through more than one mode of action. Usually, the 
first-line therapy used in hypertension is a drug which 
will increase the volume of urine produced, this also 
eliminates sodium from the body and lowers blood pressure. 
Other drugs which act at different sites in the body may 
also be useful if this first-line attack is ineffective.
These include various classes of drugs:
Calcium antagonists reduce vascular contractility by 
inhibiting the influx of calcium ions into the cell. They 
lower arteriolar resistance which leads to a fall in blood 
pressure. Verapamil has negative ionotropic and
10
chronotropic activity which may limit the reflex
tachycardia that normally occurs as blood pressure falls, 
but other calcium antagonists affect the heart to a lesser 
degree.
Central alpha- adrenoceptor agonists are capable of passing 
through the blood-brain-barrier and stimulating central 
alpha?- adrenoceptors in the medulla, decreasing
sympathetic outflow. In the periphery, stimulation of 
presynaptic alpha2- adrenoceptors invokes the negative 
feedback mechanism controlling the release of 
noradrenaline. The net effect is that the sympathetic 
vasoconstrictor influence is reduced, total peripheral 
vascular resistance decreases and blood pressure falls.
Alphal- adrenoceptor blockers selectively block vascular 
post-synaptic alpha 1- adrenoceptors, preventing the
contractile response of the arteriolar resistance vessels 
to noradrenaline. Arterial pressure is reduced and there 
is little or no reflex tachycardia. This beneficial effect 
is probably due to a lack of effect on presynaptic alpha2- 
adrenoceptors which leaves the negative feedback system 
intact and prevents excessive sympathetic activity.
ACE inhibitors inhibit the conversion of the relatively
inactive angiotensin I to the very potent vasoconstrictor 
angiotensin II. They lower systemic arteriolar resistance
11
and increase the compliance of large arteries. The 
secretion of aldosterone is also reduced, so the kidneys 
excrete more sodium and water. Mean diastolic and systolic 
pressure falls in all grades of hypertension. Blood flow 
in the cerebral and coronary vascular beds (where 
autoregulatory mechanisms predominate) is maintained and 
they are without spasmolytic activity. Consequently 
cardiovascular reflexes are retained and postural 
hypotension is rare.
Adrenergic neurone blockers prevent the release of 
noradrenaline from nerve terminals in response to 
sympathetic stimulation. Cardiac output and peripheral 
resistance are lowered, venous capacitance is increased and 
blood pressure falls.
Rauwolfia alkaloids deplete noradrenaline from its storage 
sites in the adrenergic nerves. Sympathetic activity is 
reduced, peripheral resistance is lowered and blood 
pressure falls.
Vasodilators cause direct relaxation of arteriolar vascular 
smooth muscle with a consequent lowering in peripheral 
resistance and a fall in blood pressure. However, heart 
rate, stroke volume and cardiac output are increased 
through reflex sympathetic stimulation.
12
Beta- adrenoceptor blocking drugs represent one of the most 
important contributions to antihypertensive therapy. Since 
this study is concerned with their mechanism(s) of action, 
they will be discussed in greater detail.
1.4. The use of beta- adrenoceptor blocking drugs in the 
management of hypertension.
Following results published by Powell and Slater (1958) 
showing that dichloroisoprenaline reduced the depressor and 
vasodilator actions of isoprenaline, pronethalol was 
synthesised at ICI PLC and its properties were described by 
Black and Stephenson in 1962. The next beta- adrenoceptor 
blocking drug to be developed was propranolol, which was 
found to be more active than, and did not display the 
carcinogenic activity associated with, pronethalol (Black 
et al, 1965). One of the first reports on the blood 
pressure lowering action of propranolol in man was that of 
Pritchard and Gillam (1964).
Since propranolol was first marketed in Britain, many other 
beta- adrenoceptor blocking drugs have been developed in an 
attempt to achieve more specificity, less side effects, 
etc., whilst propranolol has remained the standard agent to 
which all others are compared.
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Although beta- adrenoceptor blocking drugs have been used 
clinically for over 20 years in the management of 
hypertension, their precise mechanism of action is still 
unknown. It is known that the antihypertensive effect of 
these drugs is related to blockade of beta- adrenoceptors, 
since the dextro- isomers which do not bind to beta- 
adrenoceptors do not lower blood pressure (Rahn et al,
1974). Thus, the antihypertensive action of beta- 
adrenoceptor blocking drugs depends on the attenuation of 
the effects of sympathetic stimulation through competitive 
antagonism of catecholamines at beta- adrenoceptors.
It is not appropriate here to give a detailed account of 
all the theories postulated for the mechanism(s) of the 
antihypertensive action of beta- adrenoceptor blocking 
drugs, but a short summary is useful.
Reduction in cardiac output.
A reduction in cardiac output by beta- adrenoceptor 
blocking drugs becomes more apparent when sympathetic tone 
is enhanced, such as during exercise (Johnsson et al, 
1969). However, a reduction in cardiac output does not 
provide a sufficient explanation for the antihypertensive 
effect of beta- adrenoceptor blockade because this is 
immediately decreased whereas a reduction in arterial blood 
pressure is delayed. This, together with the fact that all
14
beta- adrenoceptor blocking drugs have similar 
antihypertensive effects but differing effects on cardiac 
output led Tarazi and Dustan (1972) to assume that their 
antihypertensive action could be the result of adaptive 
changes in vascular flow resistance resulting from 
persistently diminished cardiac output.
Resetting of baroreceptors.
Prichard and Gillam (1969) suggested that the continuously 
reduced stimuli following blockade of the cardiac beta- 
adrenoceptors would lead to a resetting of the 
baroreceptors at a lower level. This hypothesis was 
supported by animal studies (Booker et al, 1977; Tuttle and 
McCleary, 1978), but conflicting results in hypertensive 
patients that baroreceptor sensitivity remained unchanged 
by beta- adrenoceptor blockade suggest that the involvement 
of baroreceptors is uncertain.
Restoration of vascular relaxation sensitivity.
Although this hypothesis is based on many assumptions, it 
is consistent with clinical findings, particularly the slow 
onset and disappearance and the uniform pattern of the 
antihypertensive effect of all beta- adrenoceptor blocking 
drugs.
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Amer (1977) proposed that chronic blockade of vascular 
beta- adrenoceptors would allow the adenylate cyclase 
relaxation complex to recover from diminished 
responsiveness to known mediators such as histamine and 
prostaglandins, and thus counteract unopposed
vasoconstrictor tone. In addition to this, chronic beta- 
adrenoceptor blockade has been shown to increase the number
i
of beta- adrenoceptors and may enhance the responsiveness
i
to endogenous vasodilators.
Inhibition of renin release.
The sympathetic nervous system both stimulates and is 
stimulated by the renin-angiotensin system (Passo et al,
1971), and inhibition of renin release by a beta- 
adrenoceptor blocking drug should reduce the activity of 
both systems by breaking this vicious circle (Buhler et al,
1975). However, in several studies, no correlation between p\osrv^ o_ 
renin values and the extent of blood pressure reduction has 
been demonstrated (Morgan et al, 1975; Pederson and 
Kornerup, 1977).
Presynaptic inhibition of sympathetic transmission.
Stimulation of presynaptic beta- adrenoceptors is thought 
to facilitate noradrenaline release. Thus blockade should 
inhibit the release of neurotransmitter and reduce cardiac,
16
renal and vasoconstrictor nerve transmission as a whole.
Presynaptic beta- adrenoceptors have been implicated in the 
pathogenesis of hypertension. Adrenaline, the implicated 
natural stimulant of presynaptic beta- adrenoceptors, has 
been shown to enhance the release of noradrenaline in the 
rabbit (Hedler et al, 1982) and it causes hypertension in 
the rat, an effect that can be prevented by beta- 
adrenoceptor blockade (Majewski et al, 1981).
Many studies now suggest that the prejunctional beta- 
adrenoceptor is of the beta2 subtype (Majewski and Rand, 
1984) and since betai adrenoceptor selective blockers are 
equally effective as antihypertensives, this action could 
only be one of the many theorised.
A central nervous system effect.
This study is principally concerned with the possibility 
that the antihypertensive effect of beta- adrenoceptor 
blocking drugs may be via an action within the central 
nervous system, and so this theory will be examined more 
fully.
1.5. The central nervous system theory.
Beta- adrenoceptors in the brain play a role in modulating
17
central sympathetic outflow (Alexander et al, 1975; Bylund 
and Snyder, 1976; Day and Roach, 1973; Philippu and Kittel, 
1977). A reduction of central output of sympathetic tone 
due to an action of beta- adrenoceptor blocking drugs at 
central beta- adrenoceptors could therefore be one of the 
mechanisms by which they initiate a reduction in vascular 
resistance in order to lower arterial pressure (Day and 
Roach, 1973; Lewis and Hoeusler, 1975; Offerhaus and van 
Zwieten, 1974; Reid et al, 1974).
However, the physicochemical properties of the different 
beta- adrenoceptor blocking drugs as determinants of 
ability to cross the blood-brain-barrier and to penetrate 
into the cerebrospinal fluid compartment vary considerably, 
whereas onset and magnitude of blood pressure reduction is 
similar (Neil-Dwyer et al, 1981; Taylor et al, 1981). The 
majority of available information on the central actions of 
beta- adrenoceptor blocking drugs has been derived by use 
of unconventional routes of administration of the drugs by 
local microinjections in the brain and by superfusion 
techniques. In experiments in which the drugs were given 
via more conventional routes, as in intact man, controversy 
still surrounds the relative importance of central as 
opposed to peripheral receptor antagonism.
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1.5.1. Passage of beta- adrenoceptor blocking drugs across 
the blood-brain barrier.
There is no appreciable barrier to aqueous diffusion 
between cerebrospinal fluid and the extracellular fluid of 
brain tissue since the membrane lining the cerebral 
ventricles is permeable to hydrophilic substances of high 
molecular weight. Thus, the main factor governing whether 
a drug appears in the brain following peripheral 
administration is the passage across the blood-brain 
barrier.
The blood-brain barrier is not absolute and really 
represents a quantitative rather than a qualitative 
difference from other tissues in capillary permeability. 
The main structural feature underlying the relatively low 
permeability of most brain capillaries is the close 
application of the astrocytes to the basement membrane of 
the capillaries. Thus, a substance that penetrates to the 
interstitial fluid surrounding the neurones from the 
capillary blood has to penetrate the membranes of the 
astrocytes as well as the capillary endothelium. The 
barrier restricts protein-bound molecules and ions from 
gaining access to the central nervous system. The rate of 
entry of beta- adrenergic blocking drugs depends most 
closely on the lipid solubility of the non-protein-bound, 
unionised fraction of the drug.
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The logarithm of the partition coefficient of a beta-
adrenoceptor blocking drug divided by the organic and water
phase of a mixture of octanol and water provides a measure 
of its lipophilicity. The value of this logarithm ranges 
from 20.20 for propranolol (very lipophilic) to 0.02 for 
atenolol (very hydrophilic). The more lipophilic a given 
beta- adrenoceptor blocking agent is, the easier it will
equilibriate between the plasma compartment and the brain
tissue. This may explain why less incidence of central 
nervous system side effects are encountered using less 
lipophilic beta- adrenoceptor blocking agents such as 
atenolol rather than the more lipophilic propranolol 
(Arendt et al, 1984).
Bianchetti et al (1980) found that after intravenous 
injection in rats, propranolol was rapidly distributed to 
various brain areas, closely related to the level of 
vascularisation of the brain. The greatest amounts were
found in the cortex, followed by hippocampus, amygdala, 
hypothalamus and medulla. Since the blood in the brain had 
not been cleared prior to assay there may be some 
contribution from blood levels in this study.
Garvey and Ram (1975a) dosed rats orally for 14 days with
propranolol, pindolol or sotalol, all three producing 
persistent peripheral beta- adrenoceptor blockade.
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Determination of tissue distribution after 14 days found 
propranolol concentrated in the hippocampus and pindolol 
concentrated in the septum, with no significant central 
concentrations of sotalol.
Myers et al (1975) measured brain and plasma concentrations 
of propranolol in rabbits following intracerebroventricular 
(icv) injection and intravenous (iv) infusion of doses 
giving similar falls in blood pressure (0.2 mg/Kg icv and 1 
mg/Kg iv). The concentrations of propranolol in the 
hypothalamus were of the same order (4 micrograms (mcg)/g 
icv and 3 mcg/g iv) at two hours, the time of the maximum 
hypotensive effect. The hypothalamus-to-plasma
concentration ratio after iv infusion was 15:1. 
Brain-plasma ratio in man was measured and the average 
found to be 15:1, similar to that found in rabbits. The 
absolute values for hypothalamic propranolol concentration 
were 1-9 mcg/g, also similar to those associated in the 
latter species.
Cruickshank et al (1980) noted the presence of propranolol, 
metoprolol and atenolol in cerebrospinal* fluid following 
oral administration for 3-22 days. For both propranolol 
and metoprolol, high concentrations were found in the 
brain; the brain-plasma ratio was approximately 15:1. 
Atenolol appeared at much lower concentrations: the
brain-plasma ratio was approximately 0.1:1.
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Thus, there is good evidence that beta- adrenoceptor 
blocking drugs are able to gain access to the brain and 
that the proportion gaining access is dependant on lipid 
solubility.
1.5.2. Evidence for a central hypotensive action of beta- 
adrenoceptor blocking drugs.
In the search for the central sites of action of beta- 
adrenoceptor agonists and antagonists, conflicting results 
have been obtained, not least from the wide differences in 
species, injection sites and drugs examined. Some of the 
studies will now be discussed further to give the reader an
outline of results obtained by other workers prior to this
report. These have been collected into various sections,
each dealing with a separate species.
Dog.
Bhargava et al (1972) reported that, in anaesthetised dogs, 
bradycardia with hypotension occurred' following icv 
injection of noradrenaline (50-200 meg), but tachycardia 
with hypotension occurred on icv injection of isoprenaline 
(100-200 meg). The responses to icv injection of
noradrenaline were blocked by prior icv injection of 10 mg 
phenoxybenzamine, whereas those to icv isoprenaline were
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blocked by prior icv propranolol (2 mg). These responses 
were thought to be central effects since following 
bilateral vagotomy, removal of both stellate ganglia and 
transection of the upper cervical cord the responses were 
abolished. They concluded from these results, that central 
alpha- adrenoceptors were concerned with bradycardia and 
central beta- adrenoceptors with tachycardia, but that both 
types were concerned with hypotension.
In unanaesthetised dogs, Conway and Lang (1974) showed that 
icv isoprenaline (50-200 meg) produced tachycardia and a 
dose dependant hypotension. Icv injection of propranolol 
(600 mcg-2 mg) did not significantly alter heart rate or 
arterial pressure but abolished the responses to subsequent 
icv isoprenaline. However, the icv injection of
propranolol also abolished tachycardia and hypotension 
produced by iv isoprenaline (1-2 mcg/Kg), suggesting that 
leakage of propranolol from the cerebral ventricle had
occurred in the animals used in this study.
In anaesthetised dogs, Privitera et al (1979) demonstrated
dose dependant decreases in plasma renin activity and blood 
pressure after intracisternally injected dl- propranolol, 
an effect which was not seen following intravenous
injection of identical doses. Acute renal denervation 
abolished the renin suppressing action of intracisternal 
propranolol, this would not be expected if it were due to a
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direct action of propranolol on the kidney following 
leakage from the cerebrospinal fluid. However, both d- and 
1- propranolol injected intracisternally significantly 
lowered plasma renin activity and blood pressure to a 
similar degree, indicating the effects may be a result of 
local anaesthetic activity rather than beta- adrenoceptor 
blockade. Both isomers have equivalent local anaesthetic 
potencies whereas the d- isomer has about l/100th the beta- 
adrenoceptor blocking potency of the 1- isomer (Barrett and 
Cullum, 1968).
Perfusion of propranolol throughout the entire brain 
ventricular system (25 mcg/Kg/min for 30 minutes) in 
anaesthetised dog6 was found to decrease arterial pressure 
and heart rate and increase cerebrospinal fluid 
noradrenaline (Tackett et al, 1985). The hypotensive 
effect produced by propranolol was prevented by prior 
central administration of phentolamine (Tackett et al, 
1981). The authors suggested that the hypotensive response 
to centrally administered propranolol results from an 
action of the drug to release noradrenaline which then 
stimulates central alpha- adrenoceptors to decrease 
peripheral sympathetic nerve activity and lower arterial 
pressure. This suggests that centrally administered 
propranolol lowers arterial pressure through a presynaptic 
action of the drug at noradrenergic nerve terminals in the 
medullary area of the brain. This was based on
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observations that cerebrospinal fluid noradrenaline was 
elevated in all areas in which propranolol was
administered; however, restriction of propranolol to the 
fourth ventricle resulted in a hypotensive response which 
closely paralleled that seen with whole brain perfusion of 
the drug.
Cat.
Icv injection of noradrenaline (40 and 80 meg) consistently 
lead to sinus bradycardia and a slight depressor response 
in anaesthetised cats (Share and Melville, 1963). These 
doses induced marked pressor responses and
cardioacceleration in centrally reserpinised, vagotomised 
cats. Icv injection of adrenaline (40 meg) in centrally 
reserpinised cats induced significantly less pressor 
responses and cardioacceleration than did an equal amount 
of noradrenaline, but after spinal C2 section, the 
cardiovascular responses were similar to those observed 
with noradrenaline after spinal section.
Icv injections of picrotoxin were shown to activate central 
sympathetic mechanisms through a release of brain stem 
noradrenaline (Share and Melville, 1964), resulting in a 
marked pressor response and tachycardia in anaesthetised 
cats. Central pretreatment with dichloroisoprenaline did 
not significantly alter the pressor response (thought to be
25
alpha- adrenoceptor activation), but the degree of 
tachycardia was significantly reduced (thought to fall 
under the influence of beta- adrenoceptors). No blockade 
of tachycardia was observed following intravenous 
administration of dichloroisoprenaline (Share and Melville, 
1965).
In 1966, Gagnon and Melville injected isoprenaline into the 
cerebral ventricles of anaesthetised cats and reported dose 
dependant decreases in blood pressure with tachycardia. 
Pretreatment with pronethalol significantly reduced these
effects in both normal and vagotomised cats. These were 
totally abolished by spinal C2 section. They further
demonstrated that the responses to isoprenaline were
significantly reduced by icv propranolol (30 meg) but not 
affected by icv phenoxybenzamine (2 mg). They suggested 
the possible existence of specific central nervous system 
beta- adrenergic-like mechanisms mediating similar types of 
peripheral autonomic functions (Gagnon and Melville, 1967).
Philippu et al (1971) labelled the cat hypothalamus with 
14C noradrenaline and found that superfusion with
noradrenaline and adrenaline enhanced the release of 
radioactive amines from the hypothalamus and caused a dose 
dependant increase in peripheral blood pressure. 
Superfusion with phentolamine before superfusion with 
noradrenaline did not diminish the effect of noradrenaline
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on blood pressure, except at high doses which tended to 
cause ventricular haemorrhage. The results favoured the 
assumption that noradrenergic neurones of the hypothalamus 
may be of importance for the central regulation of blood 
pressure.
Share (1973) investigated the effects of icv propranolol 
and sotalol on directly (electrical stimulation of the 
dorsal medullary reticular formation) and reflexly 
(bilateral electrical stimulation of the cut central ends 
of the ulnar nerves) induced pressor and tachycardic 
responses in anaesthetised cats. The beta- adrenoceptor 
blocking drugs significantly inhibited the rise in heart 
rate following both types of stimulation, but had no effect 
on the pressor responses. Sotalol has no significant 
membrane stabilising activity and thus central beta- 
adrenoceptor blockade was likely to be responsible for the 
observed effects. Possibility of leakage to the periphery 
by the injected drugs was eliminated since the tachycardic 
response to intravenous adrenaline was unaffected.
Sustained falls in blood pressure and heatt rate following 
icv administration of several beta- adrenoceptor blocking 
drugs were reported in conscious normotensive cats by Day 
and Roach (1974a). The drugs used were dl- propranolol, 1- 
propranolol, dl- alprenolol, pindolol, practolol, ICI 
66082, sotalol and oxprenolol. A slight initial increase
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in blood pressure and heart rate was attributed to a 
membrane stabilising effect since it could be mimicked by 
the local anaesthetics procaine and lignocaine and by d- 
propranolol and d- alprenolol, which are both devoid of 
beta- adrenoceptor blocking activity. In these injections, 
no fall in blood pressure or heart rate was observed. That 
the depressor and bradycardic responses were not mediated 
by an action of the beta- adrenoceptor blocking agents in 
the periphery following leakage from the cerebrospinal 
fluid was suggested by the lack of alteration of the 
responses to intravenous isoprenaline in these animals.
Day and Roach (1974b) further demonstrated in conscious 
cats dose related increases in blood pressure and 
tachycardia following icv isoprenaline or salbutamol. In 
some animals, hypotension and tachycardia was observed 
after icv isoprenaline. These effects were abolished after 
icv beta- adrenoceptor blocking drugs but were unaffected 
by alpha- adrenoceptor blocking agents. Dose related falls 
in blood pressure and heart rate produced by icv 
noradrenaline were abolished after icv phentolamine but 
unaffected by icv propranolol. Icv adrenaline produced 
complex responses in untreated animals, but typical alpha- 
adrenoceptor mediated effects were obtained after prior icv 
treatment with propranolol and typical beta- adrenoceptor 
mediated effects after icv pretreatment with phentolamine. 
They speculated that at least some of the useful clinical
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properties of beta- adrenoceptor blocking drugs were a 
result of an action at central beta- adrenoceptors.
Philippu and Kittel (1977) and Philippu and Stroehl (1978) 
inserted a push-pull cannula into the posterior 
hypothalamus of anaesthetised cats, this was superfused 
through the cannula and electrically stimulated through its 
tip. Electrical stimulation elicited a frequency dependant 
pressor response and tachycardia. The responses were 
inhibited by superfusion with dose - dependant atenolol, 
practolol and metoprolol (betai- selective), propranolol 
and sotalol (non selective) and butoxamine (beta2- 
selective). Superfusion with isoprenaline or tazolol 
(betai- adrenoceptor stimulant) led to a concentration 
dependant enhancement in the pressor response, but 
salbutamol (beta2- adrenoceptor stimulant) was ineffective.
Thus, both betai- and beta2- adrenoceptors were implicated 
in these studies and suggested a possible hypothalamic 
target for the hypotensive action of beta- adrenoceptor 
blocking agents.
Babbit.
In pentobarbitone anaesthetised rabbits, adrenaline (10-200 
meg) and noradrenaline (50 meg) produced a fall in systemic 
blood pressure and heart rate when injected into the 
lateral cerebral ventricle (Toda et al, 1969). The
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responses induced by adrenaline were not significantly 
affected by bilateral vagotomy, but were abolished by 
transection of the spinal cord. Isoprenaline (50-200 meg) 
caused a fall in blood pressure and an acceleration of 
heart rate, whereas 200 meg phenylephrine caused a slight 
rise in blood pressure in association with a decrease in 
heart rate. In unanaesthetised rabbits, adrenaline
produced pressor and cardiostimulatory effects followed by 
depressor and cardioinhibitory effects. This would suggest 
a centrally mediated hypotensive action of adrenaline in 
anaesthetised rabbits but a hypertensive action in 
unanaesthetised rabbits. However, anaesthesia induced by 
pentobarbitone is thought to preferentially block pressor 
centres in the brain. Gutman et al (1962) showed that 
stimulation in the hypothalamus, the mesencephalon and the 
medulla of rabbits resulted in a rapid rise in blood 
pressure. Following administration of pentobarbitone, the 
blood pressure changes were either decreased or changed to 
a hypotensive action. Thus, the difference in responses to 
adrenaline may be an effect of the presence of anaesthesia.
Reid et al (1974) reported an initial rise in blood 
pressure followed by a prolonged fall following icv 
injection of propranolol in conscious rabbits. The initial 
pressor response was thought to be a membrane stabilising 
effect, since it was mimicked by d- propranolol and 
procaine, this pressor effect was abolished by
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pentobarbitone anaesthesia. Isoprenaline caused a
transient fall in mean arterial pressure which was 
abolished by pretreatment with central propranolol (Dollery 
et al, 1973) .
Anderson et al (1977) also observed an increase in mean 
arterial pressure, followed by a small fall, caused by 500 
meg propranolol icv in conscious rabbits. However, in 
contrast to Reid et al (1974), the same dose injected iv 
resulted in a lowering of mean arterial pressure greater 
than that following icv injection. This group demonstrated 
rapid leakage of propranolol from the cerebrospinal fluid 
to the bloodstream. Ten minutes after icv injection, there 
was significant blockade of cardiac beta- adrenoceptors for 
at least two hours, as determined from the degree of 
attenuation of isoprenaline induced tachycardia. This 
study consequently highlighted the problem of
differentiating between central nervous and systemic 
mechanisms following icv injection.
In conscious rabbits, Korner et al (1980) showed that high 
plasma concentrations of propranolol lowered the threshold 
pressure for inhibiting renal sympathetic nerve activity. 
Similar plasma concentrations of propranolol had little 
effect on aortic nerve baroreceptor activity. The authors 
concluded that propranolol was acting centrally to 'reset' 
the renal sympathetic baroreflex.
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Hat.
Lavy and Stern (1970) applied propranolol in powdered form 
(1000 meg) into various central nervous system structures 
of the anaesthetised rat. They observed a fall in heart 
rate, especially from the anterior hypothalamus and 
reticular formation. Injection of isoprenaline (20 meg) 
into the anterior hypothalamus gave rise to tachycardia. 
The authors suggested that an antagonistic effect of 
propranolol and catecholamines existed in the rat central 
nervous system.
Intracisternal injection of isoprenaline in anaesthetised 
rats caused a decrease in blood pressure, whereas 
noradrenaline produced a transient increase (Ito and 
Schanberg, 1974). Intracisternal propranolol produced a 
pressor response at low doses but this was converted to a 
depressor response as the dose was increased. The pressor 
response was antagonised by subsequent intracisternal 
injection of isoprenaline but potentiated by noradrenaline.
In 1974, Struyker Boudier et al showed that injection of 
noradrenaline (3-100 nmol) into the anterior hypothalamus 
of anaesthetised rats resulted in a dose related fall in 
blood pressure and heart rate. The depressor effects were 
mimicked by phenylephrine and clonidine and abolished by
32
phentolamine, suggesting that stimulation of alpha-
adrenoceptors in the anterior hypothalamus caused a fall in 
blood pressure and heart rate. Noradrenaline injected into 
the ventricles also caused a fall in blood pressure and
heart rate, but the magnitude was significantly reduced. 
Injections of noradrenaline into the posterior and medial 
hypothalamus induced no cardiovascular change, or only a 
small increase in blood pressure without affecting heart 
rate.
Adrenaline (0.3-30 nmol) was found to reduce blood pressure
and heart rate when injected into the anterior hypothalamus
of anaesthetised rats (Struyker Boudier and Bekers, 1975). 
Adrenaline was found to be 10 times more potent than 
noradrenaline in inducing these intrahypothalamic effects 
on cardiovascular parameters. Immediately after injection 
of adrenaline, a small increase in blood pressure was 
observed, this was not dose dependant and was thought to be 
caused by leakage of some adrenaline into the peripheral 
circulation.
The central antihypertensive effects of propranolol in the 
conscious spontaneously hypertensive rat were studied by 
Sweet and Wenger (1976). A transient increase in arterial 
pressure was produced by icv injection of both dl- 
propranolol and d- propranolol. This increase was followed 
by a significant lowering of blood pressure at 24 hours.
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These responses were not mimicked by systemically injected 
propranolol nor icv injected procaine. It would appear 
from these results that the hypotension produced by icv 
propranolol was independent of peripheral beta- 
adrenoceptor blockade and membrane stabilising activity.
However, the membrane stabilising activity could not be 
completely ruled out since propranolol is 3 times more
potent as a local anaesthetic than procaine, and the 
authors did report a slight hypotension following icv 
procaine. If membrane stabilisation was involved, these 
results would correlate with the findings of Kelliher and 
Buckley (1970) in anaesthetised cats, but would differ from 
the results of Reid et al (1974) in rabbits and Day and
Roach (1974a) in cats.
Ozawa and Uematsu (1975) studied the cardiovascular effects 
resulting from intracisternal injections of sympathomimetic 
amines in the anaesthetised rat. Noradrenaline showed 
variable blood pressure responses which were blocked by 
phentolamine. Isoprenaline caused a fall in blood pressure 
with tachycardia, which was reduced after treatment with 
propranolol. Adrenaline showed both centrally mediated 
alpha- and beta- sympathomimetic effects. Tyramine caused 
mixed blood pressure responses, presumably due to a release 
of noradrenaline and adrenaline, and these responses were 
partially blocked after treatment with phentolamine or 
propranolol. The authors suggested that both alpha- and
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beta- sensitive adrenergic zones may exist on the vasomotor 
centre of the pons and medulla, and both noradrenaline and 
adrenaline might play a physiological role as the 
neurotransmitters controlling blood pressure in the rat.
In conscious spontaneously hypertensive rats, Nomura (1976) 
reported a dose dependant fall in blood pressure following 
icv isoprenaline which was neither blocked by propranolol 
nor practolol, but was blocked by phentolamine, suggesting 
that isoprenaline was exerting an effect at alpha- 
adrenoceptors. The beta2- adrenoceptor agonists,
salbutamol and orciprenaline, caused a central pressor 
response which was blocked by propranolol. As these 
responses were significantly increased in spontaneously 
hypertensive rats, the author suggested the involvement of 
central alpha- and beta2- adrenoceptors in the hypertensive 
state.
Borkowski and Finch (1977) reported that, in conscious 
spontaneously hypertensive rats, adrenaline (1-20 meg icv) 
caused a dose related fall in blood pressure and heart 
rate. Pretreatment with phentolamine (100 meg icv) did not 
significantly antagonise the effects, while pretreatment 
with propranolol (100 meg icv) completely abolished the 
bradycardia and reversed the hypotension. The responses to 
icv adrenaline were reproduced to a greater extent in 
anaesthetised animals (Borkowski and Finch, 1978), but they
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were not antagonised by pretreatment with propranolol or 
oxprenolol. This points to a modification by anaesthesia 
of adrenaline induced responses and their antagonism by 
beta- adrenoceptor blocking agents. In a further study, 
they compared the cardiovascular effects of centrally 
administered clonidine and adrenaline in the anaesthetised 
spontaneously hypertensive rat. The data indicated that 
different central mechanisms were involved in mediating the 
hypotension and bradycardia induced by centrally 
administered clonidine and adrenaline, and did not support 
the theory that the hypotensive effects of clonidine were 
mediated by central adrenaline receptor activation.
Cohen et al (1979) reported a central hypotensive activity 
of d- and 1- propranolol, pindolol and isoprenaline 
injected icv in anaesthetised rats. The response to d-
propranolol was reduced, suggesting both a membrane 
stabilising and a beta- adrenoceptor blocking effect 
involved in the hypotension produced. In the case of beta- 
adrenoceptor blocking agents, the fall in blood pressure 
resulted from the simultaneous decrease of cardiac output 
and peripheral vascular resistance, whereas isoprenaline 
induced hypotension was due solely to a fall in peripheral
vascular resistance, the intensity of which was reduced by 
the increase in cardiac output.
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The suggestion that a contribution of both beta- 
adrenoceptor blockade and membrane stabilising activity are 
involved in the effect of beta- adrenoceptor blocking drugs 
was supported by Allott et al (1982). The authors 
investigated the effects of beta- adrenoceptor blocking 
drugs (injected through a stainless steel cannula 
electrically insulated except for the tip) on the pressor 
response to electrical stimulation of an area immediately 
dorsal to the posterior hypothalamus in anaesthetised rats. 
They found that 1-, dl- and d- propranolol inhibited the 
pressor responses but that the betai- adrenoceptor 
selective blocker, atenolol, did not. The 1- isomer was
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more active than the racemate but only about 4 times more 
potent than the d- isomer, whereas d- propranolol has only 
about l/100th the beta- adrenoceptor blocking potency of 
the 1- isomer (Barrett and Cullum, 1968).
Peres-Polon and Correa (1984) observed a fall in blood 
pressure following icv injection of isoprenaline (1-20 meg) 
in anaesthetised and conscious rats. Pretreatment with 
propranolol (40-200 meg) partially antagonised the 
hypotension, whereas pretreatment ' with 40 meg 
phenoxybenzamine or 100 meg phentolamine potentiated the 
depressor response. They reported the possibility of a 
propranolol insensitive mechanism involved in the depressor 
effect of isoprenaline since, even at very high doses, 
propranolol was ineffective at reducing the maximal
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depressor response to isoprenaline. The existence of a 
central alpha- adrenoceptor mediated pressor mechanism, 
opposing the beta- adrenoceptor mediated depressor 
mechanism, was highlighted because alpha- adrenoceptor 
blocking agents potentiated the hypotension produced by 
isoprenaline and central administration of such drugs 
caused a marked, long lasting reduction in basal blood 
pressure levels in anaesthetised rats.
Icv injection of noradrenaline (10-20 meg) was found to 
reduce blood pressure in anaesthetised rats but to elicit 
hypertension in conscious rats (Correa et al, 1985). The 
pressor response in conscious rats was found to be blocked 
following hypophysectomy and following pretreatment with 
d(CH2 )sTyr(Me)AVP, a potent and specific vasopressin 
antagonist (Sawyer et al, 1981), suggesting an involvement 
of vasopressin in the cardiovascular response. Central 
pretreatment with histamine antagonists also blocked the 
pressor response to noradrenaline, favouring the idea of a 
histaminergic mechanism mediating the pressor response. 
From the results obtained, the authors suggested that two 
major systems were activated by icv administration of 
noradrenaline in the rat:
1. A pressor pathway, sensitive to anaesthesia, involving 
the release of a hypophyseal factor but not activation of 
the sympathetic nervous system. This pathway is mediated
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by a histaminergic mechanism with the involvement of both 
Hi and H2 receptors.
2. A depressor pathway which is apparent under anaesthesia 
and masked in the awake animal.
Injections of adrenaline (10-20 meg icv) were found to
1
produce only depressor responses in both anaesthetised and
■ ■ 1 ■
conscious rats, whereas 20-100 meg normetanephrine (an 
alpha- adrenoceptor agonist) produced only pressor 
responses in both groups of animals (Peres-Polon and 
Correa, 1987). They concluded that a direct correlation 
existed between alpha- and beta- adrenoceptor agonist 
potencies and the occurrence of pressor or depressor 
responses caused by icv administration of catecholamines. 
This was supported by the fact that propranolol blocked the 
depressor responses and phentolamine blocked the pressor 
responses induced by icv injection of catecholamines. It 
is possible that alpha- adrenoceptor mediated pressor 
responses predominate in awake animals, whilst a beta- 
adrenoceptor mediated depressor mechanism, less evident in 
the awake rat, is greatly facilitated by Anaesthesia.
Summary.
Following a survey of the literature concerning injection
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of adrenoceptor agonists and antagonists, it is apparent 
that there is a wide variability in the results obtained. 
This may be generally explained by the use of conscious or 
anaesthetised animals, choice of anaesthetic, route of 
administration and even location of an injection within a 
single ventricle.
In general, hypotension and bradycardia are observed 
following central injection of beta- adrenoceptor blocking 
drugs, although whether this is a result of blockade of 
central beta- adrenoceptors or a membrane stabilising 
effect is unclear. In addition, following injection into 
the cerebral ventricles, it is difficult to assess how much 
of the injected drug has leaked to the peripheral system 
and is blocking peripheral beta- adrenoceptors.
The effects of centrally applied adrenoceptor agonists 
presents no less a conflicting spectrum of responses. The 
presence of anaesthesia appears to mask pressor responses 
in some studies; Gutman et al (1962) showed that pressor 
responses were more susceptible to anaesthesia than 
depressor responses, and this was observed in some of the 
studies reported here.
For a tabulation of responses to centrally applied drugs in 
various species, the reader is directed to Philippu (1980).
40
1.6. Selective beta- adrenoceptor agonists and
antagonists.
There are beta- adrenoceptor agonists and antagonists that 
are said to be selective for either betai- or beta2- 
adrenoceptors. Although termed selective, these substances 
usually have a higher activity at one type of beta
I
adrenoceptor with some residual activity at the other.
In this study, selective beta- adrenoceptor agonists and 
antagonists were used to differentiate the sub-type of 
beta- adrenoceptor involved in the responses observed. A 
short review of some of the properties of the newer 
molecules will be made since they are not as well known as 
other, well-documented drugs.
Xamoterol (ICI 118,587) was found to possess an approximate 
100-fold selective affinity for betai- adrenoceptors (Mian 
et al,1985). It increases heart rate by about 43% of the 
maximum increase produced by isoprenaline and is a 
competitive antagonist of the chronotropic and vasodilator 
effects of isoprenaline on the heart and blood vessels 
(Nuttall and Snow, 1982). Because of its high selectivity 
for betai- adrenoceptors when compared to more standard 
betai- adrenoceptor agonists such as dobutamine, it was 
decided to use xamoterol in this study.
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Clenbuterol was chosen as a selective beta2- adrenoceptor 
agonist because it is likely that it can pass into the
brain following peripheral administration. It is highly 
lipophilic, and following chronic treatment with
clenbuterol a significant decrease in the beta-
adrenoceptor density of the cerebral cortex of the rat has 
been reported (Hall et al, 1980; Ordway et al, 1987). 
Clenbuterol has been shown to have a higher affinity for 
beta2- adrenoceptors (Waldeck and Widmark, 1985) and exerts 
local anaesthetic activity in high concentrations 
(Engelhardt, 1976).
ICI 118,551 is a selective beta2- adrenoceptor antagonist 
with an in vitro beta2/betai- selectivity ratio of 123 and
has a membrane stabilising action similar to that of
propranolol (Bilski et al, 1983).
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1.7. The role of the hypothalamus in cardiovascular 
regulation.
Cardiovascular responses were first elicited from the 
hypothalamus by Karplus and Kreidl (1909). Since then, the 
localisation of specific 'cardiovascular' sites in the 
hypothalamus and the course of descending hypothalamic 
pathways involved in cardiovascular regulation have been 
investigated in a large number of studies (for reviews, see 
Calaresu et al, 1975; Ciriello and Calaresu, 1977). 
However, the search for hypothalamic neurones specifically 
associated with cardiovascular responses ha6 met with 
limited success, primarily because of the function of these 
neurones (Hayward, 1977).
High levels of propranolol have been detected in the 
hypothalamus following iv injection in conscious rabbits 
(Bakke et al, 1974), anaesthetised cats and dogs (Garvey 
and Ram, 1975b) and conscious rats (Elghozi et al, 1979). 
This suggests that the central hypotensive action of 
propranolol may be, at least in part, the result of an 
action in the hypothalamus.
The presence of beta- adrenoceptors in the hypothalamus was 
demonstrated by Philippu and Kittel (1977) and Philippu and 
Stroehl (1978) using anaesthetised cats. They concluded 
that both betai- and beta2- adrenoceptors were present in
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the posterior hypothalamus and that they were involved in 
the pressor response elicited by electrical stimulation of 
the hypothalamus.
Bogaert and Schepper (1979) showed that the hypotensive 
activity of the paraventricular nucleus was enhanced by 
clonidine, methyldopa and propranolol. Clonidine was 
thought to actively stimulate the neurones of the 
paraventricular depressor nucleus and elicit a direct 
central hypotension, whereas methyldopa and propranolol 
enhanced the depressor properties of the paraventricular 
nucleus.
Pardini et al (1986) isolated discrete areas of the rat 
hypothalamus which facilitated reflex bradycardia. 
Administration of atropine indicated that the facilitation 
was primarily parasympathetic in nature. This facilitation 
followed stimulation of the ventromedial or anterior 
hypothalamic areas.
Kanna and Yamashita (1985) demonstrated that stimulation of 
the paraventricular nucleus lead to facilitation and 
inhibition of neurones in the nucleus tractus solitarius. 
This confirmed earlier anatomical and electrophysiological 
studies on the reciprocal connection between the nucleus 
tractus solitarius and the paraventricular nucleus 
(Calaresu and Ciriello, 1980; Conrad and Pfaff, 1976;
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Kannan and Yamashita, 1983). The results also gave support 
to the hypothesis that the paraventricular nucleus is 
involved in the neural control of the cardiovascular 
system.
Finally, the posterior hypothalamus has been implicated in 
the pathogenesis of hypertension in the spontaneously 
hypertensive rat. Winternitz et al (1984) showed that at 5 
and 7 weeks of age, the noradrenaline content of the 
posterior hypothalamus was significantly greater in the
hypertensive than in control Wistar-Kyoto rats. These 
changes occurred before there was a significant difference 
in blood pressure between the two groups. The increase in 
noradrenaline content occurred in the absence of a
concomitant change in noradrenaline turnover, suggesting 
that in the spontaneously hypertensive rat the 
noradrenergic input to the posterior hypothalamus was 
increased. Electrical stimulation of the posterior 
hypothalamus of spontaneously hypertensive rats was shown 
to result in an exaggerated pressor response in comparison 
to both normotensive and DOCA-salt hypertensive rats 
(Juskevich et al, 1978; Takeda and Bunag, 1978). In 
addition, lesioning of the posterior hypothalamus of
spontaneously hypertensive rats was found to result in a
reduction in blood pressure that was significantly greater 
than the depressor effect of a comparable lesion in 
normotensive controls (Bunag and Eferakeya, 1976).
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Taken together, studies in the spontaneously hypertensive 
rat suggest that abnormalities of central cardiovascular 
regulation involving the posterior hypothalamus play a role 
in the pathogenesis of hypertension in this particular 
strain.
1.8. The genetically hypertensive rat as a model of 
clinical essential hypertension.
Discoveries in the field of hypertension have often been 
the result of reasoning from the similarity of phenomena 
recorded in animals and man. However, most animal models 
of human disease are more or less bad approximations of a 
poorly understood derangement in man. Important
differences have been shown to exist amongst the strains of 
genetically hypertensive rats in terms of their sensitivity 
to salt, the participation of blood pressure elevating and 
blood pressure lowering systems, and the time of onset of 
hypertension.
In 1963, Okamoto and Aoki introduced a new model of 
experimental hypertension that required no physiological, 
pharmacological or surgical intervention. This
spontaneously hypertensive rat was developed by meticulous 
genetic (brother to sister) inbreeding that uniformly 
resulted in 100% of the progeny having naturally occurring
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hypertensive disease (Okamoto and Aori, 1963; Okamoto et 
al, 1966). In the spontaneously hypertensive rat, elevated 
blood pressure was detected at birth when measured with the 
Survo-Null micropipette transducer system (Bruno et al, 
1979). Hypertension in this strain was achieved within 3 
generations. Since then, several expert panels have 
reported that the spontaneously hypertensive rat is an 
excellent model of experimental hypertension that could 
serve as a counterpart for clinical essential hypertension 
(Onderfriend and Spector, 1972).
In the spontaneously hypertensive rat, hypertension is 
'clinically' very similar to essential hypertension in man. 
Both have their apparent onsets very early in life. Their 
elevated arterial pressure is mediated through a slow and 
progressively increased total peripheral resistance which 
demands cardiac and vascular adaptation. Eventually, 
cardiac failure, strokes and renal lesions result in a 
shortened life span by about one-third in both forms of 
hypertension. In both genetic diseases (especially 
hypertension in the rat) neural mechanisms seem to 
predominate in the early stages, whereas in the later and 
more complicated phases, structural, renal, endocrine, 
humoral and metabolic mechanisms, including some less well 
studied mechanisms (such as kallikrein-kinin,
prostaglandins and vasopressin) may also participate. In 
both forms of hypertension there seems to be susceptibility
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for aggravation of the disease by excess dietary sodium, 
stress and other environmental factors. Also, both 
naturally occurring diseases are responsive to 
antihypertensive agents. (For a detailed review, see
Trippodo and Frohlich, 1981).
McGiff and Quilley (1981) argued that the spontaneously 
hypertensive rat was not the closest animal model for 
essential hypertension in man. This argument was based on 
the potential importance of a blood pressure lowering 
mechanism observed in most species, including man,
intimately related to renal prostaglandins. This mechanism 
in the rat rather than being antihypertensive, may 
contribute to elevation of blood pressure.
The fact remains that the causes of human essential 
hypertension and genetic hypertension in the rat are 
enigmas, and so extrapolation from studies in the
spontaneously hypertensive rat to the human disease may be 
inexact.
The majority of studies on hypertensive rats have been 
carried! on the Japanese Okamoto strain, but there are many 
hypertensive strains available. The New Zealand strain of 
Smirk seems to be most similar to the Japanese strain but 
has not been studied as broadly (Smirk and Hall, 1958;
Phelan, 1968; Phelan and Simpson, 1987). This strain of
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genetically hypertensive rat is derived from a non-inbred 
closed colony of albino rats. Matings were made between 
animals with above average blood pressures and it was found 
that the increase in blood pressure was about 2 mmHg per 
generation for the first 20 generations of inbreeding. In 
this respect, these contrast strongly . with the Japanese 
Okamoto strain, in whom blood pressure increased more 
rapidly in the first three generations of inbreeding.
In summary, it would appear that the hypertensive rat model 
is a good model for the study of hypertension, as long as 
the following are remembered:
1. It is unlikely that both forms of naturally occurring 
hypertension are identical expressions of genetically 
determined hypertensive disease.
2. Both forms of hypertension are polygenic in origin and 
are influenced by environmental factors.
3. Since the control of normal arterial pressure in both 
man and rat is multifactorial, it follows that certain 
pressor mechanisms may well operate in one form of genetic 
hypertension that do not necessarily occur in the other.
4. Owing to the well grounded physiological concept that 
as one regulatory factor becomes altered other homoeostatic
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mechanisms must become involved secondarily, it follows 
that similar adoptive alterations in regulatory mechanisms 
necessarily will occur in both forms of genetic 
hypertension.
1.9. Aims of the thesis.
This study was designed to examine further the possible 
role of beta- adrenoceptors in the central regulation of
mechanism of action contributing to the antihypertensive
In this investigation, the effects of centrally injected 
beta- adrenoceptor blocking drugs on the cardiovascular 
responses to central administration of alpha- and beta- 
adrenoceptor agonists were observed in the rat. The 
investigation was conducted using the following methods:
1. Injection of beta- adrenoceptor blocking drugs and 
beta- adrenoceptor agonists into the cerebral ventriclesof 
conscious and anaesthetised rats.
2. Injection of alpha- and beta- adrenoceptor agonists 
into the hypothalamus of the anaesthetised rat with 
previous injection of beta- adrenoceptor blocking agents 
into the cerebral ventricle.
blood pressure and thus of a central
action of beta-/adrenoceptor blocking drugs.
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3. Long term oral dosing with a beta- adrenoceptor 
blocking agent, followed by central administration of a 
beta- adrenoceptor agonist.
4. The use of hypertensive and normotensive anaesthetised 
rats to examine any alteration in responses owing to the 
presence of hypertension.
In addition, the study attempted to quantify the amount of 
leakage of drug to the periphery following central 
administration, and hence try to differentiate between 







2.1.1 Injection of drugs into the left lateral cerebral 
ventricle of anaesthetised New Zealand normotensive rats.
Male New Zealand normotensive rats, weighing 180 - 200g,
were anaesthetised with a mixture of Hypnorm/Hypnovel i.p. 
(Flecknell and Mitchell, 1984) such that each rat was 
injected with 5mg midazolam hydrochloride, lOmg fluanisone 
and 0.315mg fentanyl citrate per Kg body weight. When 
unconscious, the rats were placed on a heated blanket 
(Bioscience Ltd. rvW.
OJ=' 3 "1°C- o^_ cx_ cqcjtcO ^toVoq. .
The trachea was cannulated to facilitate artificial 
respiration if required. The left carotid artery was 
cannulated with a polyethylene tube (ref: 200/300/030,
Portex Ltd.) connected to a physiological pressure 
transducer (Gould), the whole being filled with heparinised 
saline (1000 units heparin/ml, 0.9% w/v sodium chloride). 
The transducer was coupled to a strain gauge coupler type 
7179 (Narco Biosystems Inc.) and the output was fed to a 
3-channel pen recorder (Physiograph Mark III, Narco 
Biosystems Inc.) and to a Biotachometer coupler type 7302 
(Narco Biorvster-.s Ini:.) which derived heart rate from the 
blood pressure pulse. The right jugular vein was 
cannulated with a saline-filled polyethylene tube
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(ref: 200/300/020, Portex Ltd.) for the intravenous
injection of drugs.
The head of the rat was placed in a small animal
stereotaxic instrument (DKI 900, David Kopf Instruments).
The head was manoeuvred such that the ear bars lay in the
external auditory meatus of the ear. The head was then 
centralised within the frame by reference to the 
calibrations on the ear bars. The upper teeth were hooked 
over the incisor bar and the nose clamp was gently 
tightened.
The atlas of Konig and Klippel (1963) was used for 
injections into the cerebral ventricle of anaesthetised 
rats. For this atlas, the incisor bar is adjusted to 2.4mm 
below the interaural line (an imaginary line passing
through the centre of the ear bars).
Location o£ the cannula in the left lateral cerebral 
ventricle.
The stereotaxic instrument consists of a rigid metal fra^e 
on which is mounted a carrier which can be finely 
controlled in three planes (See figure 1). Prior to 
injection of drugs, the tip is located at stereotaxic zero, 
this being the mid-point of the ear bars. The co-ordinates 
at this point are recorded in the following planes:-
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Figure 1. Position of the rat correctly mounted in the 
David Kopf small animal stereotaxic instrument. 










The rat brain atlas of Konig and Klippel has an arbitrary 
horizontal plane zero of 4.9mm above the inter-aural line; 
this must be added to the horizontal measurement taken from 
stereotaxic zero before the atlas co-ordinate may be 
calculated (see Pellegrino and Cushman, 1971 for a detailed 
discussion of the stereotaxic technique).
After the head of the animal had been mounted in the 
stereotaxic frame, the skull was exposed by a midline 
incision extending about 20mm back from the eyes. The 
underlying tissue adhering to the skull was scraped away.
The tip of the cannula was manoeuvred to the position on 
the skull directly over the area to be injected, and a hole 
was made in the skull using a model drill (Precision 
Petite). The following co-ordinates were used to locate 
the tip of the cannula in the left lateral cerebral 
ventricle according to the atlas of Konig and Klippel
AP +3.29mm 
L -4.40mm
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Figure 2. Site of injection into the left lateral 
cerebral ventricle in anaesthetised rats.
(Reproduced without permission from Konig and Klippel, 
1963)
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The cannula was attached to a length of polythene tubing 
(ref: 800/100/140/100, Portex Ltd.) which had previously
been filled with a solution of the drug to be injected. A 
fixed volume of solution was injected using a microlitre 
syringe according to the appropriate dosing schedule. 
Following injection, blood pressure and'heart rate were 
monitored for 20 minutes.
2.1.2 Injection of drugs into the hypothalamus of the 
anaesthetised New Zealand normotensive rat.
Male New Zealand normotensive rats, weighing 180 - 200g, 
were surgically prepared as in Section 2.1.1. The
following co-ordinates were used to locate the tip of the 
cannula in the anterior nucleus of the hypothalamus 
according to the atlas of Konig and Klippel:
AP +6.00mm 
L -0.74mm
H -2.40mm (See figure 3)
The following co-ordinates were used to locate the tip of 
the cannula in the posterior nucleus of the hypothalamus 
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Figure 3. Site of injection into the anterior nucleus of 
the hypothalamus in the anaesthetised rat.





H -2.40mm (See figure 4)
Where injections were made into both the cerebral ventricle 
and the hypothalamus, both holes were drilled through the 
skull prior to any injection of drugs.
2.1.3 Injection of drugs into the left lateral cerebral 
ventricle of anaesthetised Wistar rats.
Male Wistar rats (University of Bath strain), weighing 180 
-220g, were anaesthetised with either Hypnorm/Hypnovel i.p. 
or sodium thiobutobarbitone 150mg/Kg i.p. (Inactin,BYK). 
The surgical procedure was as in section 2.1.1.
The tip of the cannula was located in the left lateral 
cerebral ventricle at: AP +3.29, L -4.40, H -0.04mm (Konig 
and Klippel, 1963).
2.1.4 Injection of drugs into the hypothalamus of 
anaesthetised Wistar rats.
Male Wistar rats (University of Bath strain), weighing 180 
- 200g, were anaesthetised with sodium thiobutobarbitone 
150mg/Kg (Inactin, BYK). These were then surgically
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Figure 4. Site of injection into the posterior nucleus of 
the hypothalamus in the anaesthetised rat.
(Reproduced without permission from Konig and Klippel, 
1963)
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prepared as in section 2.1.1. The tip of the cannula was 
located in the anterior hypothalamus at AP +6.00, L -0.74, 
H -2.20mm (Konig and Klippel, 1963). The tip of the 
cannula was located in the posterior hypothalamus at: AP
+3.50, L -0.40, H -2.20mm (Konig and Klippel, 1963).
2.1.5 Injection of drugs into the cerebral ventricle of
anaesthetised Japanese Okamoto spontaneously hypertensive 
rats.
Male Japanese Okamoto rats, weighing 180 - 220g, were
anaesthetised with either Hypnorm/Hypnovel i.p. or sodium 
thiobutobarbitone lOOmg/Kg i.p. (Inactin, BYK). The 
surgical procedure was as in section 2.1.1. The tip of the 
cannula was located in the left lateral cerebral ventricle 
at: AP +3.29, L -4.40, H -0.04mm (Konig and Klippel, 1963).
2.1.6 Injection of drugs into the hypothalamus of 
anaesthetised Japanese Okamoto spontaneously hypertensive 
rats.
Male Japanese Okamoto rats, weighing 180 - 200g, were
anaesthetised with sodium thiobutobarbitone lOOmg/Kg i.p. 
(Inactin.. *>»K , inese were surgically prepared as in
section 2.1.1. The tip of the cannula was located in the
anterior hypothalamus at: AP +6.00, L -0.74, H -2.20mm 
(Konig and Klippel, 1963). The tip of the cannula was
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located in the posterior hypothalamus at: AP +3.50, L
-0.40, H -2.40mm (Konig and Klippel, 1963).
2.1.7 Injection of drugs into the cerebral ventricle of 
conscious New Zealand normotensive rats.
2.1.7.1 Manufacture of cannulae.
The cannula for arterial blood pressure recording was made 
by joining together approximately 19cm of polythene tubing, 
internal diameter 0.4mm and external diameter 0.8mm (ref: 
800/100/140/100, Portex Ltd.) to a 5cm length of polythene 
tubing, internal diameter 0.28mm and external diameter
0.61mm (ref: 800/100/100/100, Portex Ltd.), using the heat 
of a soldering iron. A single strand of copper wire, 
external diameter 0.2mm was passed through the tubes at the 
point of the join to maintain tubular patency during the 
heating procedure. The join was checked by filling the 
tubes with purified water before passing a small ring of 
polycarbonate film over the length of the larger gauge 
tubing down to the level of the join where the surface of 
the tubing had been widened by the heating process. The 
narrower bore tubing was the bent into a J-shape in 
near-boiling water close to the join.
The intravenous cannula was made from a single 20cm length 
of polythene tubing, internal diameter 0.4mm and external
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diameter 0.8mm (ref: 800/100/140/100, Portex Ltd.). This 
was then bent into a J-shape approximately 5cm from one 
end, and a "stop" was manufactured close to the bend by 
attaching a small piece of autoclave tape to the tubing. 
(See figure 5 for a diagrammatical representation of the 
cannulae.)
2.1.7.2. Implantation of arterial and venous cannulae
Male New Zealand normotensive rats, weighing 180-230g, were 
anaesthetised with a mixture of Hypnorm/Hypnovel i.p., such 
that each received 4mg midazolam hydrochloride, 8mg 
fluanisone and 0.252mg fentanyl citrate per Kg body weight.
When unconscious, the rat was shaved vertically over the 
abdomen and dorsally at the base of the neck. These areas 
were cleaned with chlorhexidine gluconate solution 0.05% 
(Hibitane, ICI P.L.C.). Midline incisions were made at the 
base of the neck (approximately 5mm long) and the abdomen 
(approximately 4cm long) and the abdominal muscles were cut 
along the line of the media alba. The intestines were 
exteriorised and covered with gauze soaked in saline. A 
stainless steel trochar (15cm long, internal diameter 1mm) 
was pushed gently and vertically through the psoas muscle 
r ~ 1. .• ; *L-. • ' : v to exteriorise at the incision at
the back of the neck. The cannulae were then passed 
through the trochar and the trochar removed. The
intraarterial cannula was filled with heparinised saline
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Figure 5. Construction of polythene cannulae for 
intraarterial and intravenous cannulation in the conscious 
rat.
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(1000 unite heparin/ml), the intravenous cannula being 
filled with non-heparinised saline. Each was anchored to 
the psoas muscle with a single stitch.
The connective tissue surrounding the abdominal aorta was 
gently separated with cotton wool and the abdominal aorta 
was clipped at a level rostral to the iliolumbar artery. A 
small hole was made in the aortic wall with a 25G
hypodermic needle at a level directly opposite the suture 
holding the cannula in the psoas muscle. The tip of the
cannula was inserted into the hole, the artery clip was 
removed and the cannula pushed gently further along the
artery such that approximately 2cm of tubing was inside the
vessel
The end of the intravenous cannula was cut to form a sharp 
tip and this was pushed gently through the connective 
tissue and vena cava wall into the vessel lumen at a level 
such that the venous cannula sat just below the arterial 
cannula (See figure 6).
The incisions in the abdominal muscle and overlying skin 
were closed with surgical silk sutures. The neck incision 
was closed around exser;*.orised cannulae which were in
turn trimmed to a length of approximately 2cm. The ends 
were sealed by inserting a 12mm stainless steel pin.
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Figure 6. Cannulation of abdominal blood vessels.
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The rats were then left to recover on a heated blanket for 
24 hours. After the surgical procedure, the rats were 
housed individually to prevent chewing of the catheters by 
cage companions.
The cannulae were flushed daily, the arterial cannula with 
heparinised saline (200 units/ml heparin), the venous 
cannula with non-heparini.sed saline.
2.1.7.3. Implantation of intraventricular cannulae.
The intraventricular cannulae were made by attaching a 5cm 
length of polythene tubing (ref: 800/100/140/100, Portex 
Ltd.) to an 8mm length of stainless steel tubing, external 
diameter 0.5mm. The system was filled with artificial 
cerebrospinal fluid of the following composition (mM): NaCl 
127.65, KC1 2.55, CaCl2.2H20 1.26, MgCl2.6H20 0.93, NaHCOa 
23.7, NaH2PC)4 1.51, glucose 3.38. This is a modification 
of that used by Merlis (1940). The end of the polythene 
tubing was then heat-sealed.
The cannula was mounted in the carrier of the stereotaxic 
f~ame. The incisor bar was adjusted to 5.0 mm above the
interaui^i s:___ iments the atlas of
Pellegrino and Cushman was used. This allows co-ordinates 
to be measured with reference to the skull landmark bregma
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(the point at which the coronal suture crosses the sagittal
suture).
Two days following implantation of arterial and venous 
cannulae, the rats were again anaesthetised with a 
Hypnorm/Hypnovel mixture such that each received 2.5mg 
midazolam hydrochloride, 5mg fluanisone and 0.158mg 
fentanyl citrate per Kg body weight. When unconscious, the 
rats were immediately placed on a heated blanket and the 
head centralised in the stereotaxic instrument using the 
ear and incisor bars. The skull was exposed by a midline 
incision extending about 20 mm back from the eyes and by 
scraping away the underlying tissue. The tip of the
cannula was located directly over the bregma landmark, and 
the lateral co-ordinate was noted. The tip of the cannula 
was then moved -1.8 mm on the lateral plane and a hole 
drilled in the skull at this point, using a model drill. 
The tip of the cannula was lowered into the hole until it 
touched the surface of the brain, the horizontal plane 
reading was then taken and the tip of the cannula was 
located in the cerebral ventricle by lowering 3.2 mm (see 
figure 1 ).
The cannula was fixed in position by applying •-* 
amount of methylmethacrylate polymer cement (How Medica 
Ltd.) to the skull and cannula surface. Bonding to the 
skull was facilitated by prior cleaning of the surface with
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Figure 7. Site of injection into the cerebral ventricle of 
conscious New Zealand rats.
(Reproduced without permission from Pellegrino and 
Cushman, 1967)
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acetone. The skin incision was then closed with surgical' 
silk sutures and the animals left to recover on a heated 
blanket for 24 hours.
2.1.7.4. Measurement of blood pressure and heart rate in 
the conscious rat, and injection of drugs.
One or two days following implantation of the 
intracerebroventricular cannula, when the animals were 
completely recovered, they were removed from their home 
cage and placed in a smaller cage for the duration of the 
experiment. The movement of the rats was not restricted 
within the cage but no food or water was provided at this 
stage.
The intraarterial cannula was connected via an 8 mm length 
of thin bore stainless steel tubing to a length of 
polythene tubing (ref: 200/300/030, Portex Ltd.). This, in 
turn, was connected to a physiological pressure transducer 
(Gould) and blood pressure and heart rate were measured as 
described in section 2.1.1.
Injections into the cerebral ventricle were made by means 
of a 100 microlitre Hamilton syringe, the needle of which 




All drugs for central injection were dissolved in 
artificial cerebrospinal fluid. All drugs for intravenous 
injection were dissolved in normal saline. Dosing
schedules were the same for all animals, irrespective of 
strain, type of anaesthetic or whether anaesthetised or 
not. Specific doses in individual experiments are given in 
the appropriate section of the results. These are 
expressed as their salts unless otherwise stated.
2.2.2. Effect of icv pretreatment with beta- adrenoceptor 
blocking drugs on the response to icv adrenoceptor 
agonists.
The dose of adrenoceptor agonist was contained in 
5 microlitre (mcl) artificial csf and was injected at 2 
mcl/minute. Where appropriate, the dose of beta-
adrenoceptor blocking drug was dissolved in 10 mcl 
artificial csf and also injected at 2 mcl/minute, 
commencing 15 minutes before injection of the adrenoceptor 
agonist. When more than one drug was injected into the 
cerebral ventricle, the cannula was removed from the animal 
between injections and thoroughly washed through with
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artificial csf before being loaded with the next solution 
and relocated in the cerebral ventricle.
2.2.3. Effect of iv beta- adrenoceptor blocking drug 
pretreatment on the response to icv adrenoceptor agonists.
The dose of adrenoceptor agonist was dissolved in 5 mcl 
artificial csf and injected at a rate of 2 mcl/minute. 
Where appropriate, the dose of beta- adrenoceptor blocking 
drug was dissolved in 0.5 ml saline and was injected at a 
rate of 0.1 ml/minute starting 15 minutes before the 
injection of the adrenoceptor agonist. The hole in the 
skull to facilitate icv injection was drilled before 
starting the iv injection.
2.2.4. Effect of chronic oral dosing with propranolol on 
the responses to icv isoprenaline.
The dose of propranolol was given as a single oral dose
j
daily for 14 days in a volume of 5 ml distilled water/Kg 
body weight. On the day of the experiment, the final dose 
was given 1 hour before injection of anaesthetic. 
Isoprenaline was dissolved in 5 mcl artificial csf and 
injected at 2 mcl/minute.
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2.2.5. Effect of icv beta- adrenoceptor blocking drug on 
the responses to intrahypothalamic adrenoceptor agonist.
The dose of adrenoceptor agonist was dissolved in 1 mcl 
artificial csf and injected at 0.4 mcl/minute. The dose of 
beta- adrenoceptor blocking drug was dissolved in 10 mcl 
artificial csf and injected at 2 mcl/minute, starting 15 
minutes before injection of the agonist. Both holes were
drilled in the skull directly over the injection sites
before any injections were made. The cannula was
thoroughly washed with artificial csf between injections.
2.2.6. The effect of chronic oral dosing of beta- 
adrenoceptor blocking drugs on the responses to 
intrahypothalamic injection of adrenoceptor agonists.
The dose of beta- adrenoceptor blocking drug was given as a 
single oral dose daily in a volume of distilled water 
5ml/Kg body weight. On the day of the experiment, the
final dose was given 1 hour before injection of the 
anaesthetic. The dose of adrenoceptor agonist was
dissolved in 1 mcl artificial csf and injected at 2 
mcl/minute. In some animals, icv injection of propranolol 
preceding injection of the adrenoceptor agonist was made.
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2.3. Severance of vagus nerves and spinal cord transection 
at the C2 level.
Male New Zealand rats, weighing 180 - 230 g, were
anaesthetised with Hypnorm/Hypnovel and cannulated as 
described in section 2.1.1. Prior to mounting the head of 
the animal on the stereotaxic apparatus, the vagus nerve 
running alongside the carotid artery was cut on both sides. 
The spinal cord was transected at the C2 level. Icv 
injections were then carried out as in section 2.2.2.
2.4. Pretreatment with 6-hydroxydopamine and its effect on 
icv injections of propranolol and xamoterol.
Male New Zealand normotensive rats, weighing 180 - 230 g, 
were anaesthetised with ether and injected with 60 mg/Kg 
6-hydroxydopamine into the tail vein. 24 hours later, 
these animals were given icv injections of propranolol and 
xamoterol as described in section 2.2.2.
!
2.5. Evaluation of leakage of drugs from the brain 
following icv injection.
Radiolabelled isoprenaline or propranolol were injected
into the cerebral ventricle of the rat and subsequent
counting of radioactivity in various organs allowed
evaluation of the amount of drug present.
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2.5.1. Principles of liquid scintillation counting.
The liquid scintillation counter used was a 1215 Rackbeta 
II (LKB Wallac).
There are a number of factors which contribute to a count 
value obtained with a liquid scintillation counter:
1. Counts from radioactivity in the sample.
2. Counts due to background radiation (cosmic rays,etc.)
3. Loss of counts due to the limited efficiency of the 
light collection system and photomultiplier tube (p.m.t.)
4. Loss of counts due to quenching (chemical or colour) in 
the scintillator.
5. Counts due to chemiluminescence in the scintillator.
6. Counts due to "noise" in the detection system i.e. 
thermal noise in the p.m.t.
In order to calculate disintegrations per minute (d.p.m.) 
from counts per minute (c.p.m.), the effects due to factors 
2 - 6  must be removed from the measured c.p.m.
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In the case of the Rackbeta, these factors are handled in 
the following manner:
Two p.m.t.'s are used in coincidence which eliminates most 
of the effects due to background, chemiluminescence and 
noise.
Efficiency and degree of quenching are measured for known 
standards and then appropriate corrections applied to the 
values obtained for unknown samples. For a standard sample 
the c.p.m. measured Ni is related to the d.p.m. A via the 
efficiency Ei.
Thus Ei% = Ni X 100 
A
where i indicates the channel or energy window in which the 
measurement is made.
Efficiency values were obtained for different degrees of 
quenching by using a previously prepared series of 10 
quenched samples. The result is a curve of efficiency 
versus degree of quenching. The Rackbeta uses the spline 
function to fit a curve to the standard points, providing a 
method of fitting the points without having to assume any 
particular functional relationship between the efficiency
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and quenching. This procedure is performed automatically 
by the microcomputer which controls the Rackbeta and the 
programme is stored in the memory of the machine. The 
d.p.m. value for an unknown sample is then obtained by 
first measuring the sample c.p.m. and the channels ratio. 
Then using the channels ratio and the quench curve the 
value of efficiency is calculated. Finally the d.p.m. is 
calculated from:
A = Ni X 100 
Ei%
2.5.2. Construction of the quench curve.
Ten ml Optiphase 'Safe', the liquid scintillant, was added 
to each of 10 vials. Optiphase 'Safe' is a multipurpose 
liquid scintillation cocktail suitable for use with both 
aqueous and non-aqueous samples (LKB Scintillation 
Products). To each vial was added a standard volume of the 
radioactive material such that the total number of counts 
in the unquenched vial would approximate to the maximum 
expected from the subsequent studies, The first vial was 
capped without the addition of any quenching agent.
From preliminary studies, it was found that whole blood was 
likely to produce the greatest amount of quenching and 
consequently increasing amounts of untreated blood were
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added to the vials according to the following series: 5r 
10, 15, 20, 30, 50, 75, 100 and 150 mcl. Following
addition of the whole blood, the vials were capped and the 
samples loaded into the scintillation counter for quench 
calibration. The counts in each vial were measured and the 
quench calibration was constructed and stored in the 
memory.
A fresh calibration was constructed for each isotope used.
2.5.3. Radioisotopes used in the study.
For studies using isoprenaline, the radioisotope used was 
dl- [7-3H] isoprenaline hydrochloride, specific activity 48 
mCi/mg, radioactive concentration 1.0 mCi/ml (Amersham 
International P.L.C.). A concentrated solution of 'cold',
i.e. unlabelled, isoprenaline was added to the radioactive 
solution to achieve the desired final amount of 
isoprenaline/ml solution for icv injection.
For studies using propranolol, two separate isotopes were 
used. Blood content was measured using dl-[4-3H] 
propranolol hydrochloride, specific activity 67 mCi/mg, 
radioactive concentration 1 mCi/ml (Amersham International 
P.L.C.). Tissue content was measured using dl-[14C] 
propranolol hydrochloride, specific activity 38.4 
microCi/mg supplied as solid from ICI P.L.C. The reason
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for this difference was that the 14C propranolol had too' 
low a specific activity to be detected in whole blood in 
the amounts present.
The required amount of 'cold' propranolol was added to the 
solution of tritiated propranolol, whereas the *4C labelled 
propranolol was simply dissolved in artificial csf to the 
required concentration.
2.5.4. Collection of samples for radioactivity
measurement.
Male New Zealand normotensive rats, weighing 180 - 230 g, 
were anaesthetised with a mixture of Hypnorm/Hypnovel and 
surgically prepared as in section 2 .1 .1 .
Following icv injection of the radiolabelled solution, 0.2 
ml of blood was removed from the animal every 2 minutes via 
the intra-arterial cannula. At a given time following icv 
injection, the animal was killed by cervical dislocation 
and the following organs were removed: brain, heart,
lungs, liver, kidney.
Clean vials were filled with 10 ml Optiphase 'Safe'. One 
hundred mcl aliquots of whole blood were added to the vials 
and thoroughly mixed. The amount of radioactivity in the 
samples was counted by the Rackbeta liquid scintillation
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counter with reference to the pre-constructed quench 
calibration curve.
The organs removed from the body were weighed and then each 
was homogenised in 7 ml 0.32 M sucrose solution. One 
hundred mcl aliquots of the homogenate were added to vials 
containing Optiphase 'Safe" and the radioactivity in the 
samples was counted. From the amount of radioactivity in 
these aliquots, the amount present in the whole organs and 
total blood volume could then be calculated.
These studies were also carried out in conscious animals; 
no serial blood analysis was made but analysis of tissue 
content was carried according to the above method. A 
specified time after icv injection, rats were decapitated, 
a small blood sample collected, and the organs removed.
2.6. Dose response curve to intravenous isoprenaline.
I
Male New Zealand normotensive rats, weighing 180 - 230 g,
were dosed daily with a single oral dose of propranolol 60 
mg/Kg in distilled water. A dose - response curve to 
intravenous isoprenaline was constructed for three groups 
of animals:
1. Control rats which received distilled water for 14 
days.
81
2. Rats given 60 mg/Kg propranolol daily for 14 days, the 
final dose given 1 hour before anaesthesia.
3. Rats given 60 mg/Kg propranolol daily for 14 days, the 
final dose being given on the day before experiment.
Animals were anaesthetised with Hypnorm/Hypnovel and the 
carotid artery and jugular vein were cannulated for 
measurement of heart rate and injection of isoprenaline 
respectively (Section 2.1.1.). Serial concentrations of 
isoprenaline were made in normal saline, the maximum volume 
injected for a single dose being no greater than 0.4 ml.
Following each injection of isoprenaline, the increase in 
heart rate was noted, and this was allowed to return to the 
baseline value before another dose was injected. The dose 
of isoprenaline was doubled each time until a maximum 
response was recorded.
2.7. Non - invasive recording of systolic blood pressure 
using the tail - cuff method.
The tail - cuff method allows measurement of blood pressure 
in the tail artery of the rat employing non - invasive 
techniques.
Rats were placed in a heated chamber and maintained at
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38 +/- 2°C for 10 minutes. These were then removed from, 
the chamber and a tail cuff and pneumatic pulse transducer 
(Narco Biosystems Inc.) were applied to the tail. The tail 
cuff was then inflated by a programmed
electrosphygmomanometer (PE - 300, Narco Biosystems Inc.) 
up to a pressure of 200 mmHg and then deflated back to 
zero. The pneumatic pulse transducer monitored the pulse 
pressure, which was recorded on a flat bed recorder (JJ 
Instruments). The systolic blood pressure of the animal 
was taken as that pressure at which the pulse was seen to 
disappear and a flat trace obtained. In order to minimise 
errors due to any movement of the rat during recording, the 
blood pressure was measured 3 times over a 10 minute 
period. The animals were then returned to their home cage 
for 24 hours.
The next day, the same rats were anaesthetised with 
Hypnorm/Hypnovel mixture such that each received 5 mg
midazolam hydrochloride, 10 mg fluanisone and 0.315 mg 
fentanyl citrate per Kg body weight. The systolic blood
pressure was then monitored whilst the rats were
anaesthetised. This gave some indication of the degree of 
depression of blood pressure caused by anaesthesia.
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2.8. Histological techniques for verification of injection 
site of central injections.
Although the stereotaxic technique allows accurate and 
reproducible cannula placements, there may be some 
variation between animals and this requires that placements 
are verified following experimentation.
2.8.1. Verification of icv injection site.
Five mcl of a 1% w/v aqueous solution of Evans Blue dye was 
injected into the injection site. The animal was kept 
alive for five minutes, and during this time, 10 mg of 
sodium pentobarbitone (Sagatal, May and Baker) was injected 
i.p. to deepen anaesthesia.
The animal was removed from the stereotaxic instrument and 
the chest was opened. The descending aorta was clamped 
behind the left lung. A blunted 19G needle was inserted 
through the left ventricle and up into the ascending aorta 
where it was clamped in position. The right ventricle was 
cut to allow escape of blood and fluid from the system. 
Forty ml of 10% formol saline (9 g NaCl + 100 ml 40%
formaldehyde, made up to 1 litre with distilled water) was 
injected into the left ventricle. The brain was then
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removed from the skull and verification of successful icv 
injection performed by gross dissection.
For verification in conscious animals, these were 
anaesthetised with Hypnorm/Hypnovel prior to injection of 
the dye, and the procedure outlined above carried out.
Verification of icv injections in conscious and 
anaesthetised animals was carried out after every fifth 
experiment. Figures 8 and 9 are photographs of brain 
sections from anaesthetised and conscious rats following 
injection of dye into the cerebral ventricle.
2.8.2. Verification of injections into the hypothalamus.
Since the target for injection into the hypothalamus was 
much smaller, it was deemed necessary to verify the 
injection site in every other animal. One mcl of dye was 
injected following experimentation, and the brain removed
j
as in section 2 .8 .1 .
jj
Following removal from the skull, the brains were stored in 
10% formol saline for at least 7 days. Sections of 24 
micron thickness were cut on a freezing microtome from a 
block of brain containing the injection site. Sections 
were examined by low-power microscopy and compared with the 
appropriate saggital section in the stereotaxic atlas.
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Figure 8. Injection o£ Evana Blue dye to indicate aite o£ 
injection into the lateral cerebral ventricle of 
anaesthetised rats. (See also figure 2, this chapter)
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Figure 9. Injection of Evans Blue dye to indicate site of 
injection into the cerebral ventricle of conscious New 




Mean arterial pressure was calculated from the blood 
pressure trace using the following formula:
MAP = systolic bp - diastolic bp + diastolic bp
3
Data were analysed for statistical significance by
Students' t-test for unpaired comparisons.
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This chapter has been divided into sections, each dealing with 
a series of experiments related by site of injection, strain 
of rat or presence of anaesthesia.
Each section has three parts, the first a description of the 
experiments and their results, the second, graphical 
representation of the results and the third a discussion of 
the results in that section. A general discussion will be 
given at the end of the chapter.
For ease of cross-reference, at the end of most headings in 
this chapter, the section in the Materials and Methods chapter 
describing the dosing schedule has been indicated in
parentheses.
Group data are expressed as mean +/- standard error of the 
mean.
Graphs involving injection of adrenoceptor agonists and
pretreatment with beta- adrenoceptor antagonists commence at 
the beginning of the injection of adrenoceptor agonist.
The group size is presented in parentheses in the graph key
and this is followed by the mean starting blood pressure and 
heart rate values for the group immediately before injection
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of adrenoceptor agonist.
3.1. Measurement of systolic blood pressure by the tail cuff 
method. (2.7.)
The resting systplic blood pressure of a representative sample 
of New Zealand normotensive rats was found to be 143 +/- 3 
mmHg, n = 28. Similarly, that of a representative sample of 
New Zealand hypertensive rats was found to be 156 +/- 3 mmHg, 
n = 27. Following injection of Hypnorm/Hypnovel, the systolic 
blood pressures were 124 +/- 5 mmHg and 152 +/- 7 mmHg
respectively.
Measurement of systolic blood pressure of unrestrained rats by 
the tail cuff method revealed two important facts:
1. The systolic blood pressure in unanaesthetised rats was 
not significantly different between 'hypertensive' and 
'normotensive' animals.
When the strain was described by Phelan (1968), the average 
blood pressure for hypertensive males was 175 mmHg, that of 
the normotensive males 115 mmHg. It was clear that the colony 
of New Zealand, rats held at Bath University was no longer 
divisible into hypertensive and normotensive animals. The 
reason for this may be that matings had been carried out 
between animals with unrecorded blood pressures over several
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generations. This particular strain of genetically1
hypertensive rat had been initially achieved by successive 
mating of rats with above average blood pressure, the increase 
in each generation being approximately 2 mmHg for the first 20 
generations of inbreeding (Phelan and Simpson, 1987). it is 
feasible that matings between rats with unrecorded blood 
pressure could lead to a loss of hypertension in the colony.
At the beginning of this study, the normotensive animals from 
the New Zealand colony were used as an alternative model of 
normotension to repeat some of the work which had previously 
used Wistar rats. After much work had been done using these 
animals, some experiments were repeated using the New Zealand 
hypertensive animals. It was at this time that the loss of 
hypertension in the colony was discovered. This necessitated 
the use of Japanese Okamoto spontaneously hypertensive rats as 
the model of hypertension with Wistar Kyoto rats as 
normotensive controls. Since only the normotensive rats from 
the New Zealand colony were used in this study, they have been 
referred to in this chapter as simply 'New Zealand rats'.
2. The anaesthesia produced by Hypnorm/Hypnovel did not 
produce an excessive fall in blood pressure.
The falls in systolic blood pressure caused by anaesthesia 
were 19 and 4 mmHg for 'normotensive' and 'hypertensive' rats 
respectively. It is possible this could be a result of the
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absence of stress in the anaesthetised animal when the' 
systolic blood pressure was recorded.
It was decided that the combination of Hypnorm and Hypnovel 
would be suitable as an anaesthetic in this strain since it 
produced good surgical anaesthesia, could be administered by a 
single intraperitoneal injection and appeared to have minimal 
effect on resting blood pressure.
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3.2. Intracerebroventricular (icv) injection of beta-'
adrenoceptor agonists in the anaesthetised New Zealand rat and 
the effect of pretreatment with beta- adrenoceptor blocking 
agents.
3.2.1. Icv injection of beta- adrenoceptor blocking agents.
Icv injection of 30 micrograms (meg) propranolol produced a 
large fall in heart rate, the maximum of 44 beats per minute 
(bpm) occurring 10 minutes after start of injection. This was 
accompanied by a slight increase in mean arterial pressure of 
15 mmHg.
Atenolol (30 meg) injected icv had little effect on either 
heart rate or blood pressure, the maximum fall in heart rate 
was 8 bpm at 15 minutes with an accompanying change in mean 
arterial pressure of 3-4 mmHg.
ICI 118,551 (30 meg icv) produced a tachycardia of 22 bpm at
15 minutes and a biphasic change in mean arterial pressure 
ranging from -8 to +8 mmHg. (See figures la and lb).
3.2.2. Intravenous (iv) injection of beta- adrenoceptor 
blocking agents.
12 meg propranolol injected iv produced a bradycardia of 94 
bpm at 5 minutes with a slight increase of mean arterial
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pressure of 15 mmHg.
Atenolol (12 meg iv) reduced heart rate by a maximum of 132 
bpm and mean arterial pressure by 13 mmHg at 15 minutes.
The bradycardia produced by 12 meg ICI 118,551 was maximal at 
5 minutes (24 bpm) and had returned to pre-injection level at 
15 minutes. Mean arterial pressure was increased by 25 mmHg 
over the 15 minute period. (See figures 2a and 2b).
3.2.3. Icv injection of propranolol and adrenaline. (2.2.2.)
Icv injection of 20 meg adrenaline produced a small increase 
in mean arterial pressure (maximum 14 mmHg, 4 minutes after 
injection) which had returned to normal after 10 minutes. 
This was accompanied by a fall in heart rate of 22 bpm after 
10 minutes.
Following previous icv injection of 30 meg propranolol, icv 
injection of adrenaline produced a significantly (p<0.05) 
greater increase in mean arterial pressure, the maximum at 4 
minutes now being 36 mmHg. The bradycardia produced by icv 
adrenaline was not significantly altered following 
pretreatment with propranolol. (See figures 3a and 3b).
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3.2.4. Icv injection of clenbuterol following pretreatment' 
with propranolol. (2.2.2. and 2.2.3.)
Icv injection of clenbuterol (5 meg) produced a fall in mean 
arterial pressure (maximum 30 mmHg) and tachycardia (maximum 
34 bpm). The hypotension was unaffected by pretreatment with 
12 meg propranolol iv, but was significantly (p<0 .0 1 ) reduced 
by the icv injection of 30 meg propranolol. The increase in 
heart rate remained unaffected following pretreatment with 
propranolol injected either iv or icv. (See figures 4a and 
4b) .
3.2.5. Pretreatment with propranolol and icv injection of
xamoterol. (2.2.2. and 2.2.3.)
Icv injection of xamoterol (5 meg) produced a fall in blood 
pressure and an increase in heart rate of 13 mmHg and 33 bpm 
at 20 minutes respectively (see figures 5a and 5b).
Pretreatment with propranolol, both 12 meg iv and 30 meg icv,
significantly reversed the hypotension (p<0.01 for both
groups). 30 meg propranolol icv did not affect the 
tachycardia produced by xamoterol, but this response was 
significantly (p<0 .0 1) potentiated following pretreatment with 
12 meg iv.
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3.2.6. Effect of treatment with 6-hydroxydopamine on the 
responses to icv xamoterol. (2.4.)
Pre-dosing animals with 60 mg/Kg 6-hydroxydopamine iv and 
bilateral vagotomy reduced the hypotensive response to icv 
injection of xamoterol (5 meg), but this reduction did not 
reach statistical significance. The reversal of this 
hypotension by pretreatment with icv propranolol (30 meg) was 
unaffected by 6-hydroxydopamine treatment and bilateral 
vagotomy. In 6-hydroxydopamine treated animals, pretreatment 
with icv propranolol significantly reversed the hypotension 
induced by icv xamoterol. (See figure 6a).
The tachycardia caused by icv xamoterol was significantly 
reduced in animals treated with 6-hydroxydopamine, but this 
significance was lost in the group also pretreated with icv 
propranolol. (See figure 6b).
3.2.7. Effect of pretreatment with beta- adrenoceptor 
blocking agents on the responses to icv isoprenaline.
Following icv injection of isoprenaline, a dose dependant 
hypotension was observed, the maximum occurring 6 minutes 
after start of. injection. This was accompanied by tachycardia 
which was not dose - dependant; heart rate increased rapidly 
over the first 6 to 8 minutes and then remained at this level 
over the remainder of the experiment.
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The maximum values of hypotension and tachycardia following 
icv isoprenaline are shown below.
Dose isoprenaline Max. hypotension Max. tachycardia Figure 
(meg) (mmHg) (bpm)
1.0 18 60 7a & 7b
5.0 22 32 8a & 8b
20.0 51 67 12a & 12b
3.2.7.1. Pretreatment with propranolol and the responses to 1 
meg isoprenaline icv. (2.2.2. and 2.2.3.)
The hypotension produced by 1 meg isoprenaline icv was reduced 
to a similar extent by both 30 meg propranolol icv and 24 meg 
propranolol iv, this reduction only reaching statistical 
significance a.t 4 to 8 minutes following start of injection, 
i.e. at that time at which maximum hypotension was produced by 
icv isoprenaline (sig. p<0.05). However, 60 meg propranolol 
icv significantly reversed the hypotension produced by 1 meg 
isoprenaline (p<0.01), the maximum hypertension being 11 mmHg 
(see figure 7a).
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Pretreatment with 30 meg propranolol icv and 24 meg 
propranolol iv did not significantly affect the tachycardia 
produced by 1 meg isoprenaline, although a slight reduction in 
the increase in heart rate was seen with both pretreatments 
(see figure 7b). Pretreatment with 60 meg propranolol icv 
significantly reduced the tachycardia produced by 1 meg 
isoprenaline icv (p<0.05), the maximum rise in heart rate 
being 25 bpm.
3.2.7.2. Icv injection of 5 meg isoprenaline and the effect 
of pretreatment with beta- adrenoceptor blocking drugs. 
(2.2.2., 2.2.3. and 2.2.4.)
The duration of hypotension produced by 5 meg isoprenaline was 
significantly reduced (p<0.05) by 30 meg propranolol icv, 
whereas the maximum value was not significantly attenuated. 
Pretreatment with 12 meg propranolol iv had no effect on the 
hypotensive response to icv isoprenaline (see figure 8a). In 
animals dosed orally with 60 mg/Kg propranolol daily for 14 
days, icv injection of 5 meg isoprenaline resulted in a marked 
hypertension, maximum 31.5 mmHg, this was highly significant 
from the hypotension seen in untreated animals (p<0 .0 0 1).
The tachycardia induced by 5 meg isoprenaline icv was 
significantly enhanced following pretreatment with icv and iv 
propranolol (p<0.01). Oral dosed animals also showed an 
enhanced tachycardia to icv isoprenaline, this only reaching
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significance 15 minutes after start of injection (p<0.05).





12 meg propranolol iv 100
30 meg propranolol icv 84
60 mg/Kg propranolol po 64
The hypotension and tachycardia seen following 5 meg 
isoprenaline icv were not significantly altered by a single
oral dose of 60 mg/Kg propranolol given one hour before
anaesthesia (see figures 9a and 9b).
Pretreatment with atenolol, 30 meg icv and 12 meg iv, did not
significantly alter the fall in blood pressure produced by 5
meg isoprenaline icv (see figure 10a). Pretreatment with 30 
meg ICI 118,551 icv significantly reduced the hypotension 
(p<0 .0 1 ), whereas 12 meg iv also reduced the hypotension, but
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to a lesser extent (see figure 11a).
Pretreatment with ICI 118,551 had little effect on the 
isoprenaline induced tachycardia; this was also unaffected by 
icv atenolol but significantly (p<0.05) potentiated by iv 
atenolol 10 minjites after injection of isoprenaline (see 
figures lib and 10b respectively).
3.2.7.3. Icv injection of propranolol and 20 meg
isoprenaline (2.2.2.)
The hypotension and tachycardia produced by 20 meg 
isoprenaline icv were not significantly modified by 
pretreatment with 30 meg propranolol icv (see figures 12a and 
12b), although the degree of hypotension was attenuated by 
approximately 30%.
3.2.8. Response to icv propranolol and isoprenaline in 
animals with the vagus nerves and the spinal cord severed. 
(2.3.)
Following severance of both vagus nerves and the spinal cord 
at the C2 level, icv injection of isoprenaline caused a 
greater degree of hypotension, but this did not reach 
significance. Tachycardia was essentially unaffected (see 
figures 13a and 13b).
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However, the increase in mean arterial pressure and the fall' 
in heart rate produced by icv propranolol were abolished by 
severance of the spinal cord and vagus nerves (see figures 14a 
and 14b).
3.2.9. Dose response curves to iv isoprenaline. (2.6.)
Dose response curves to iv isoprenaline were constructed for 
control animals and those dosed orally with propranolol. The 
curves were all shifted to the right for all groups dosed with 
propranolol. In the groups dosed for 14 days, the maximum 
increase in heart rate was much greater than in the control 
group and the group given a single oral dose of propranolol 
(see figure 15).
The dose of isoprenaline that elicited 50% of the maximum 
increase in heart rate (ED50) was calculated for each group, 
and the ratio of the ED50 of each treatment group to the 
control was calculated - this gives a measure of the number of 
folds of dose of isoprenaline needed in each treatment group 
to elicit the same response as obtained in the control group 
and thus a measure of the amount of beta- adrenoceptor 
blockade achieved by propranolol. The values are tabulated 
below.
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Treatment group ED50 Ratio of ED50 with
control group
Control 0.2 ng 1
60 mg/Kg propranolol
Single dose 125.9 ng 630
60 mg/Kg propranolol x 14 days
Last dose 24 hours previously 47.9 ng 240
60 mg/Kg propranolol x 14 days
Last dose 1 hour previously 316.2 ng 1585
3.2.10. Leakage of drugs from the brain following icv 
injection. (2.5.)
Blood levels of isoprenaline measured following icv injection 
of 3H- isoprenaline showed that after 20 minutes, 
approximately 1% of the injected dose was present in the blood 
stream. Figure 16 shows the amount of isoprenaline in 
nanograms present in the blood stream following icv injection 
of 1, 5 and 20 meg isoprenaline. Figure 17 is a measure of 
that present in the blood stream adjusted per milligram of 
injected dose, this illustrates that the amount of drug 
present in the blood is a percentage of that injected
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initially. The amount of propranolol measured in the blood
also approximates to 1% of the 30 meg injected icv (see figure
18).
Tissue levels of isoprenaline following icv injection of 5 meg 
indicate that over the time of the experiment there is at 
least 60% of the injected dose remaining in the brain. There 
are small amounts of isoprenaline present in both the heart 
and lung, whereas in the liver and kidney, the levels of
isoprenaline increase with time (see figure 2 0 ).
Following icv injection of propranolol, a large percentage 
appears to remain in the brain for up to 30 minutes.
Significant amounts were found in heart and lung, but 
extremely small amounts were found in the mesenteric bed. As 
with isoprenaline, the content of propranolol in liver and 
kidney increased with time (see figure 13).
The profiles for isoprenaline and propranolol were found to be 
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Figure la.
Figures la and lb. Change in mean arterial pressure and 
heart rate following icv injection of beta- adrenoceptor 
blocking drugs in anaesthetised New Zealand rats.
x--------- x 30 meg propranolol (n=6 )
x--------- x 30 meg ICI 118,551 (n=6 )































Figures 2a and 2b. Change in mean arterial pressure and 
heart rate following intravenous injection of beta- 
adrenoceptor blocking drugs in anaesthetised New Zealand 
rats.
x-------- -K 12 meg propranolol (n=6 )
X*........x 12 meg ICI 118,551 (n=6 )
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Figure 3a.
Figures 3a and 3b. Change in mean arterial pressure and 
heart rate in anaesthetised New Zealand rats following icv 
injection of 20 meg adrenaline.
o  o No pretreatment (n=7) 139 mmHg, 393 bpm
o--------o 30 meg propranolol icv (n=7) 164 mmHg, 301 bpm
Significant difference from no pretreatment group denoted: 



























Figures 4a and 4b. Change in mean arterial pressure and 
heart rate produced by 5 meg clenbuterol icv in 
anaesthetised New Zealand rats.
q --------- E3 No pretreatment (n=7) 81 mmHg, 411 bpm.
q ------ 30 meg propranolol icv (n=7) 104 mmHg, 424 bpm.
p. Q 12 meg propranolol iv (n=6 ) 112 mmHg, 383 bpm.
Significant difference from no pretreatment group denoted: 
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Figure 5a.
Figures 5a and 5b. Change in mean arterial pressure and 
heart rate following 5 meg xamoterol icv in anaesthetised 
New Zealand rats.
A------- & No pretreatment (n=8 ) 100 mmHg, 431 bpm.
- ^ 30 meg propranolol icv (n=6 ) 88 mmHg, 377 bpm.
A * A 12 meg propranolol iv (n=6 ) 110 mmHg, 382 bpm.
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Figures 6a and 6b. Change in mean arterial pressure and 
heart rate following 5 meg xamoterol icv in anaesthetised 
New Zealand rats.
x--------- x No pretreatment (n=8 ) 100 mmHg, 431 bpm.
x--------- x 30 meg propranolol icv (n=6 ) 88 mmHg, 377 bpm
t   • Animals dosed with 60 mg/Kg 6-hydroxydopamine
and bilateral vagotomy No pretreatment (n=6 ) 69 mmHg,
410 bpm.
•------ Animals dosed with 60 mg/Kg 6-hydroxydopamine
and bilateral vagotomy 30 meg propranolol icv (n=6 )






















Figures 6a and 6b(contd.).
Significant difference between groups denoted:
* p<0.05 ** p<0.01
Differences denoted are between: 
x------- x and x*------- x
• ■ • and •--------•
Significant difference between x--------x and •--------•
denoted:





















Figures 7a and 7b. Change in mean arterial pressure and 
heart rate produced by 1 meg isoprenaline icv in 
anaesthetised New Zealand rats.
x------- x No pretreatment (n=6 ) 99 mmHg, 428 bpm.
x--------x 30 meg propranolol icv (n=6 ) 94 mmHg, 435 bpm.
x.------- x 60 meg propranolol icv (n=6 ) 111 mmHg, 360 bpm.
24 meg propranolol iv (n=6 ) 102 mmHg, 304 bpm. 
Significant difference from no pretreatment group denoted: 
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Figure 8a.
Figures 8a and 8b. Change in mean arterial pressure and 
heart rate produced by 5 meg isoprenaline icv in 
anaesthetised New Zealand rats.
x------- x No pretreatment (n=6 ) 87 mmHg, 427 bpm.
x------- -x 30 meg propranolol icv (n=6 ) 88 mmHg, 395 bpm.
x------- x 12 meg propranolol iv (n=6 ) 103 mmHg, 370 bpm.
• *. ......  60 mg/Kg propanolol po daily for 14 days (n=6 )
124 mmHg, 316 bpm.
Significant difference from no pretreatment group denoted:





































Figures 9a and 9b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in anaesthetised New Zealand rats.
x--------x No pretreatment (n=6 ) 87 mmHg, 427 bpm.
x ------- x 60 mg/Kg propranolol po single dose (n=4)
145 mmHg, 285 bpm.
 • *• 60 mg/Kg propanolol po daily for 14 days (n=6 )
124 mmHg, 316 bpm.
Significant difference from no pretreatment group denoted:
* p<0.05 ** p<0.01 *** p<0.001
2  CHANGE IN HR(bpm)
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Figure 10a.
Figures 10a and 10b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in anaesthetised New Zealand rats.
x-------- x No pretreatment (n=6 ) 87 mmHg, 427 bpm.
 *------- -x 30 meg atenolol icv (n=5) 110 mmHg, 468 bpm.
x-------- x 12 meg atenolol iv (n=6 ) 102 mmHg, 333 bpm.
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Figures 11a and lib. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in anaesthetised New Zealand rats.
x—  x No pretreatment (n=6 ) 87 mmHg, 427 bpm.
x-------- x 30 meg ICI 118,551 icv (n=5) 112 mmHg, 479 bpm.
x-------- x 12 meg ICI 118,551 iv (n=6 ) 109 mmHg, 430 bpm.
Significant difference from no pretreatment group denoted:
* p<0.05 ** p<0.01
CHANGE IN HR(bpm)
















Figures 12a and 12b. Change in mean arterial pressure and 
heart rate following icv injection of 20 meg isoprenaline 
in anaesthetised New Zealand rats.
x------- x No pretreatment (n=7) 110 mmHg, 369 bpm.
x--------x 30 meg propranolol icv (n=6 ) 95 mmHg, 389 bpm.

































Figures 13a and 13b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in anaesthetised New Zealand rats.
x------- x Intact animals (n=6 ) 87 mmHg, 427 bpm.
xr------ -x Spinal cord transected at C2 level and
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Figure 14a.
Figures 14a and 14b. Change in mean arterial pressure and 
heart rate following icv injection of 30 meg propranolol 
in anaesthetised New Zealand rats.
x------- x. Intact animals (n=6 ) 92 mmHg, 441 bpm.
x------- x Spinal cord transected at C2 level and
bilateral vagotomy (n=6 ) 62 mmHg, 398 bpm.
Significant difference from intact animals denoted:
* p<0.05 ** p<0.01 *** p<0.001
CHANGE IN HR(bpm)


























Figure 15. Increase in heart rate against log. dose of 
isoprenaline (ng) injected intravenously.
x k No pretreatment (n=4).
• • 60 mg/Kg propranolol po daily for 14 days, last
dose 24 hours before experiment (n=4).
V--------9 60 mg/Kg propranolol po daily for 14 days, last
dose 1 hour before experiment (n=4).
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Figure 16. Amount of . isoprenaline in the bloodstream of 
the anaesthetised New Zealand rat following icv injection 
of radiolabelled drug.
x----------- x 1 meg isoprenaline icv (n=1 0).
x----------- -x 5 meg isoprenaline icv (n=10).

















Figure 17. Amount of isoprenaline in the bloodstream per 
milligram of isoprenaline injected icv in anaesthetised 
New Zealand rats.
x----------- x 1 meg isoprenaline icv (n=1 0) .
 -x 5 meg isoprenaline icv (n=10).
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Figure 18. Amount of propranolol in the bloodstream 
following icv injection of 30 meg radiolabelled 
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Figure 19. Amount of propranolol present in tissues 
following icv injection of 30 meg 14C propranolol in 
anaesthetised New Zealand rats, expressed as micrograms 
(jig) (mean +/- standard error) and percentage of injected 




















































74.8% 3.8% 3.0% 4.1% 1.9%
Figure 20. Amount of isoprenaline remaining in tissues 
following, icv injection of 5mcg 3H- isoprenaline in 
anaesthetised New Zealand rats, expressed as micrograms 
(jag) (mean +/- standard error) and percentage of injected 
dose at times following icv injection.
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3.2.11. Discussion.
3.2.11.1. Icv injection of beta- adrenoceptor blocking 
agents.
Icv injection of propranolol (30 meg) produced an increase in 
mean arterial pressure and a fall in heart rate (see figures 
la and lb). However, the variation between animals was very 
high, and in some experiments a fall in mean arterial pressure 
was observed, which was thought to be attributable to the 
accompanying large fall in heart rate in these animals.
This increase in mean arterial pressure following icv 
injection of propranolol is in conflict with the results of 
previous studies reported in anaesthetised animals. A fall in 
arterial pressure has been reported in anaesthetised rats 
(Cohen et al, 1979) anaesthetised dogs (Privitera et al, 1979; 
Tackett et al, 1985) and anaesthetised cats (Kievans et al, 
1976).
In all these studies, bradycardia was obtained following icv 
injection of propranolol, as was found in this study.
These effects following icv propranolol appear to be centrally 
mediated, since following transection of the spinal cord and 
vagus nerves, the responses were abolished (see figures 14a 
and 14b).
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lev injection of atenolol had little effect on mean arterial 
pressure and heart rate, suggesting that central betai- 
adrenoceptors may not play an important role in cardiovascular 
regulation. ICI 118,551 produced a biphasic change in mean 
arterial pressure, accompanied by tachycardia. Whether the 
tachycardia was a reflex response to the initial fall in mean 
arterial pressure is not known. There is no information 
available from other workers regarding icv injection of these 
drugs.
3.2.11.2. Iv injection of beta- adrenoceptor blocking agents.
The bradycardia following iv injection of 12 meg propranolol 
was significantly greater than that following icv injection of 
30 meg (p<0.05). This conflicts with results obtained by 
Kievans et al (1976). In anaesthetised vagotomised cats, they 
found that icv injections of 3 and 5 mM dl- propranolol 
produced significantly greater responses than corresponding iv 
injections. The increase in mean arterial pressure was found 
to be comparable following icv or iv injection of propranolol 
(see figures 2a and 2b).
Following iv injection of 12 meg atenolol, a marked 
i>rndycard 1 a and n ^ potenyxoii were e^d. this is a strong
contrast to the slight responses observed following icv 
injection. Atenolol is highly water soluble and unlikely to 
penetrate into the central nervous system to any great extent
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(Barrett, 1977). It is also devoid of any membrane
stabilising action. Thus any effect seen following iv 
injection of atenolol is likely to be from blockade of 
peripheral betai- adrenoceptors.
Taylor and co-workers (1981) found very low levels of atenolol 
in the cerebrospinal fluid of human subjects; it is possible 
that the rate of penetration of atenolol into cerebrospinal 
fluid is so low that renewal of cerebrospinal fluid by bulk 
flow is sufficiently rapid to prevent a 'true' equilibrium 
being established.
Further evidence for the lack of penetration of atenolol into 
the central nervous system arises from the fact that adverse 
reactions such as psychosis, depression, hallucinations and 
nightmares are rare with atenolol (Simpson, 1977; Henningsen 
and Mattiasson, 1979), whereas psychotic problems and central 
nervous system related side effects appear to arise with lipid 
soluble beta- adrenoceptor blocking agents which enter the 
brain in high concentrations (Fleminger, 1978; Hinshelwood, 
1969; Shaw and England, 1977).
In these experiments, it appears that little atenolol leaks 
" r’oTi nr a t n t-o the periphery since f o • lowi >ig icv injection,
the marked bradycardia produced by iv injection was absent. 
However, leakage of atenolol from the brain was not evaluated 
in this study.
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Iv injection of ICI 118,551 produced an increase in mean 
arterial pressure and a transient fall in heart rate; this 
contrasts with the tachycardia observed following icv 
injection of ICI 118,551. There is no information available 
regarding the extent to which ICI 118,551 will cross the blood 
brain barrier following peripheral administration, but it has 
been reported that it has a membrane stabilising action 
similar to that of propranolol (Bilski et al, 1983).
3.2.11.3. Icv injection of propranolol and adrenaline.
Icv injection of 20 meg adrenaline produced a transient 
increase in mean arterial pressure and a significant 
bradycardia (see figures 3a and 3b). The bradycardia was 
unaffected by pretreatment with 30 meg propranolol icv but a 
significant potentiation of the hypertension was seen. These 
findings agree with those reported by Clough et al (1981a; 
1981b) using thiobutobarbitone anaesthetised Wistar rats. 
These authors suggested that icv adrenaline exerted an effect 
on blood pressure and heart rate by interaction with central 
alpha- and beta- adrenoceptors. Blockade of central beta- 
adrenoceptors by icv injection of a beta- adrenoceptor blocker 
would then enable the expression of mainly alpha- adrenocepi.nr 
mediated effects, i.e. an increase in blood pressure.
Borkowski and Finch (1977; 1978; 1979) demonstrated a
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hypotension and bradycardia in conscious and anaesthetised 
spontaneously hypertensive rats following icv injection of 
adrenaline (1-20 meg). The degree of hypotension and 
bradycardia was greater in anaesthetised than in conscious 
rats. In conscious rats the responses were antagonised by 
pretreatment with propranolol, whereas in anaesthetised rats 
the responses were not significantly affected. In both 
groups, pretreatment with alpha- adrenoceptor antagonists did 
not significantly alter the responses. They concluded that 
the depressor effects of icv adrenaline were mediated by 
central adrenoceptors and, in conscious rats, these were 
mediated by beta- rather than alpha- adrenoceptors.
A difference in the response to icv adrenaline observed 
between anaesthetised and conscious rats was also highlighted 
by Correa et al (1982). They found that the hypotension 
observed following icv injection of adrenaline was greater in 
anaesthetised than conscious rats. They also demonstrated a 
reversal of the hypotension produced by 120 nmol adrenaline 
icv by the pretreatment with 400 nmol propranolol icv in 
urethane anaesthetised rats.
In conscious rabbits, Toda et al (1969) found a centrally 
meuidueu hyuonbi.ve sc oiGn _i_n rospoiio^ to 2 o^ meg CidxCiiOLlxii^  
icv.
In conclusion, bradycardia has been reported in all studies of
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the effects of icv adrenaline regardless of species, strain or 
presence of anaesthesia. However, there are conflicting 
results regarding changes in arterial pressure following icv 
adrenaline, although it can be generalised that pretreatment 
with propranolol serves to either reduce hypotension or 
potentiate hypertension, indicating that adrenaline may 
interact with both central alpha- and beta- adrenoceptors. 
Pretreatment with a beta- adrenoceptor blocker would thus 
potentiate alpha- adrenoceptor mediated effects, resulting in 
enhanced increases in blood pressure.
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3.2.11.4. Icv injection of beta- adrenoceptor agonists: 
Effect of pretreatment with beta- adrenoceptor blocking 
drugs.
One of the most important considerations in studies using 
icv injection of drugs is how much will leak into the
peripheral circulation following injection. If this 
variable is unknown, it is difficult to discriminate
between centrally and peripherally mediated actions of a 
drug following icv injection. This can be evaluated in two 
ways :
1. Spinal transection and bilateral vagotomy. It is
reasoned that, if any effect on blood pressure and heart 
rate is abolished by this operation, then the responses to 
an icv injection must be centrally mediated. This
reasoning has one important failing; it only holds true if 
the responses are mediated via the sympathetic or 
parasympathetic nervous systems. It is possible that a 
central action of an icv injected drug may result in a 
release of a humoral transmitter into the peripheral blood 
stream which may then interact with peripheral receptors to 
cause changes in cardiovascular parameters. Transection of 
the f?pi nnl rmrd wap’ijk nerves would not abolish In i k
centrally mediated effect.
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2. Direct evaluation of the amount of drug leaking from 
the brain into the peripheral circulation following icv 
injection. This can be achieved by injection of
radiolabelled drugs into the cerebral ventricle and 
subsequent evaluation of the amount of radioactivity in the 
brain. If the amount of drug leaking into the periphery is 
known, studies can be carried out with peripheral 
injections of equivalent amounts to determine any 
difference in responses following central and peripheral 
injections of the drugs in question.
In this study, the amount of propranolol and isoprenaline 
leaking from the brain to the periphery was measured
following the icv injection of radiolabelled isotopes.
The levels of radioactivity present in the brain indicated 
that, following icv injection into anaesthetised New 
Zealand rats, there was at least 60% of the injected dose
remaining in the brain (see figures 19 and 20). It was
decided that in future studies 40% of the icv dose of a 
beta- adrenoceptor blocking drug could be given 
intravenously to give an equivalent peripheral effect.
It woo f^und Lhat, for both propranolol and isoprenaline, 
similar concentrations of drug were present in both the 
blood stream and various body organs. The amount in the 
blood stream was found to be approximately 1%, regardless
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of the dose or drug injected (see figures 17 and 18).
The passage of drugs from cerebrospinal fluid to the blood 
stream is only partly dependant on lipid solubility, and 
compounds with a low lipid solubility leave the 
cerebrospinal fluid almost as rapidly as those with a high 
lipid solubility (Mayer et al, 1960). Leakage of drugs 
from the cerebrospinal fluid into the systemic circulation 
is by the process of bulk flow across the extremely porous 
arachnoid villi from the sub-arachnoid space into the dural 
venous sinuses (Schanker, 1962). The observation that 
isoprenaline and propranolol appear to leave the brain to 
similar degrees agrees with this principle.
Icv injection of isoprenaline (1-20 meg) produced a dose 
dependant hypotension and accompanying tachycardia in 
anaesthetised New Zealand rats (see figures 7,8 and 12). 
These results agree with other studies using anaesthetised 
animals. Hypotension and tachycardia following icv
isoprenaline have been reported in anaesthetised dogs 
(Bhargava et al, 1972), cats (Gagnon and Melville, 1966; 
1967), rabbits (Toda et al, 1969) and rats (Cohen et al, 
1979; Peres-Polon and Correa, 1984).
Pretreatment with 30 meg propranolol icv did not 
significantly attenuate the hypotension produced by 20 meg 
isoprenaline icv (see figure 12a), whereas that produced
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following icv injection of 1 and 5 meg isoprenaline was 
only significantly reduced at a few time points (see 
figures 7a and 8a). Pretreatment with 12 meg propranolol 
iv had no effect on the hypotension produced by 5 meg 
isoprenaline icv (see figure 8a). Increasing the dose of 
propranolol to 60 meg icv significantly reversed the 
hypotensiofi produced by 1 meg isoprenaline icv. An 
equivalent iv dose of 24 meg propranolol attenuated the 
hypotension to approximately the same degree as that 
following pretreatment with 30 meg propranolol icv.
Icv injection of propranolol attenuated the hypotension 
produced by icv isoprenaline to a greater extent than an 
equivalent iv dose. However, until a very high dose of 
propranolol is injected icv, this response is resistant to 
propranolol. This has previously been reported by Nomura 
(1976) and Peres-Polon and Correa (1984). It is possible 
that there exists a propranolol insensitive central 
component involved in the depressor response to 
isoprenaline, in addition to that caused by interaction 
with central beta- adrenoceptors. This mechanism could 
involve a non-neuronal mechanism in which a humoral 
substance is released into the peripheral bloodstream. 
This is sunoorted by the fact that transection of the 
spinal cord and vagus nerves did not abolish the responses 
to icv isoprenaline, although the possibility that enough 
isoprenaline is present in the bloodstream to exert a
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peripheral response cannot be ruled out entirely (See 
figures 13a and 13b). This propranolol insensitive 
mechanism does not appear to be present in other species 
since the hypotensive response to isoprenaline was blocked
by icv propranolol in the cat (Gagnon and Melville, 1967)
and in the dog (Bhargava et al, 1972).
The tachycardia produced by icv isoprenaline was largely
unaffected by pretreatment with icv propranolol, but can be 
potentiated in some cases (see figure 8b). This
potentiation may be a result of the large bradycardia 
caused by pretreatment with propranolol creating an 
enhanced capacity for increase in heart rate in response to 
icv isoprenaline.
The responses to 5 meg isoprenaline icv were not 
significantly changed by pretreatment with atenolol, either 
30 meg icv or 12 meg iv (see figures 10a and 10b). 
Pretreatment with 30 meg ICI 118,551 significantly reduced 
the duration of hypotension, whereas 12 meg iv had little 
effect. The tachycardia to isoprenaline remained unchanged 
(see figures 11a and lib).
~ ; i ■ i ° .55J i adrenoceptor anLaguiiib I,
with an in vitro beta2/betai- selectivity ratio of 123 
(Bilski et al, 1983). Thus, it appears that the 
hypotensive response to icv isoprenaline is mediated via
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beta2- adrenoceptors. This finding is in agreement with, 
the results of Clough et al (1981b) that the central 
inhibitory effect ’of adrenaline on cardiovascular responses 
may be mediated by beta2- adrenoceptors.
Following icv.injection of 5 meg clenbuterol, hypotension 
and tachycardia were observed which were unaffected by 
pretreatment with 12 meg propranolol iv (see figures 4a and 
4b). Pretreatment with 30 meg propranolol icv
significantly blocked the hypotension but had no effect on 
the tachycardia.
Clenbuterol is a partial beta- adrenoceptor agonist with 
higher affinity for and activity at beta2- adrenoceptors 
than at betai- adrenoceptors (Waldbeck and Widmark, 1985).
It also exerts local anaesthetic activity in high 
concentrations (Engelhardt, 1976). Clenbuterol has been 
found to be highly lipophilic and is therefore very likely 
to pass into the brain; it is very active in reversing 
reserpine induced hypothermia in mice, an effect thought to 
be due to stimulation of central beta- adrenoceptors (Ross, 
1980). Following chronic treatment with clenbuterol, a 
significant decrease in the beta- adrenoceptor density of 
the cerebral cortex of the rat was reported (Hall et al, 
1980; Ordway et al, 1987); suggesting that clenbuterol can 
pass into the brain and stimulate central beta- 
adrenoceptors.
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The hypotension produced by icv clenbuterol was much more 
amenable to attenuation by icv propranolol than that 
following injection of isoprenaline into the cerebral 
ventricle, further supporting the hypothesis that an 
additional mechanism is involved in the isoprenaline 
induced depressor response.
Xamoterol (ICI 118,587) possesses an approximate 100-fold 
selective affinity for betai- adrenoceptors (Mian et al, 
1985) and increases heart rate by about 43% of the maximum 
increase produced by isoprenaline (Nuttall and Snow, 1982). 
It has also been shown to be a competitive antagonist of 
the chronotropic and vasodilator effects of isoprenaline on 
the heart and blood vessels.
Icv injection of 5 meg xamoterol caused a fall in blood 
pressure and increase in heart rate. The hypotension was 
significantly reversed by both 30 meg propranolol icv and 
12 meg propranolol iv, whereas the tachycardia was 
significantly potentiated by 12 meg propranolol iv and 
unchanged by 30 meg propranolol icv (see figures 5a and 
5b). Bilateral vagotomy and pretreatment with
6-hydroxydopamine did not significantly alter the 
hypotension caused by xamoterol alone or the hypertension 
caused by xamoterol following icv injection of propranolol. 
However, the tachycardia produced by xamoterol was
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significantly blocked by bilateral vagotomy and 
6-hydroxydopamine pretreatment (see figures 6a and 6b). It 
would appear that the cardiovascular responses observed 
following icv injection of xamoterol were mediated by 
peripheral effects of drug leaking from the central nervous 
system to the periphery, since the hypotension was reversed 
by both icv and iv administration of propranolol and not 
significantly altered by bilateral vagotomy and treatment 
with 6-hydroxydopamine. Unfortunately, there was no 
radioactive xamoterol available to quantify the amount 
leaking into the periphery following icv injection.
Chronic oral dosing with propranolol significantly reversed 
the depressor response to icv isoprenaline although a 
single oral dose of propranolol did not affect this 
response (see figure 9a). Dose response curves constructed 
for the tachycardia produced by iv isoprenaline indicated 
that a single oral dose of propranolol would block 
peripheral beta- adrenoceptors, although not to the same 
extent as with chronic oral dosing. This suggests that the 
depressor response to icv isoprenaline is centrally 
mediated, since it is unaffected by the single oral dose of 
isoprenaline despite the blockade of peripheral beta- 
adrenoceptars.
Chronic oral dosing with propranolol will block the 
hypotension produced by icv isoprenaline in contrast to the
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resistance of this response to acute dosing or injection of 
propranolol, thus suggesting a central effect of 
propranolol after long term dosing which is not seen in the 
short term. However, at present, there is no evidence as 
to the possible nature of this mechanism.
In conclusion, icv injection of isoprenaline produced 
hypotension and tachycardia which appeared to involve both 
an interaction with central beta2- adrenoceptors and 
possibly a non-neuronal mechanism which may involve the 
release of a humoral transmitter into the bloodstream.
One of the considerations in this section has been whether 
the presence of anaesthesia alters the responses observed. 
In order to eliminate this possibility, the next section 
will describe icv injections in conscious New Zealand rats 
in an attempt to discover if the presence of anaesthesia is 
masking or eliminating responses to icv injected drugs.
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3.3. Icv injection of beta- adrenoceptor agonists and 
pretreatment with beta- adrenoceptor blocking agents in the 
conscious New Zealand rat.
3.3.1. Icv injection of isoprenaline and pretreatment with 
propranolol. .(2.2.2. and 2.2.3.)
Injection of isoprenaline into the cerebral ventricle of 
the conscious New Zealand rat caused a dose dependant 
hypotension and tachycardia. The maximum values are shown 
below.
Dose isoprenaline Max. hypotension Max. tachycardia Figure 
(meg) (mmHg) (bpm)
0.05 6 55 21a & b
1.0 29 77 22a & b
5.0 31 165 23a & b
Animals injected with artificial csf exhibited a small 
variation in blood pressure and heart rate since they are 
allowed to roam freely in the experimental cage.
The hypotension produced by 0.05 meg isoprenaline was not
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significantly different from control animals (see figure, 
21a), but the tachycardia was significantly different over 
the first 8 minutes after start of icv injection (see 
figure 21b).
The hypotension and tachycardia produced by 5 meg 
isoprenaline icv was not significantly altered by 
pretreatment with 30 meg propranolol icv (see figures 23a 
and 23b). Over the 20 minutes of the experiment, the 
responses did not start to return to the baseline, but 
remained at approximately the level of the maximum response 
which had been attained after 6 minutes.
Pretreatment with 30 meg propranolol icv significantly 
reduced the hypotension (p<0.001) and tachycardia (p<0.05) 
produced by 1 meg isoprenaline icv. 30 meg propranolol iv 
did not affect the hypotension, but significantly (p<0.001) 
potentiated the tachycardia over the first 15 minutes of 
the experiment (see figures 22a and 22b).
3.3.2. Icv injection of propranolol and clenbuterol. 
(2.2.2.)
Icv injection of 1 meg clenbuterol produced a fall in mean 
arterial pressure (13 mmHg) and an increase in heart rate 
(92 bpm) which attained a maximum 4 minutes following start 
of icv injection (see figures 24a and 24b). Pretreatment
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with 30 meg propranolol icv significantly reduced the 
hypotension and potentiated the tachycardia (p<0.05) over 
the first 10 minutes of experiment.
3.3.3. Leakage of drugs from the central nervous system 
following icv injection. (2.5.)
Following icv injection of radiolabelled propranolol, 
subsequent analysis of brain samples indicated that 
propranolol leaked rapidly from the brain, only 22% being 
left 15 minutes following injection. Detectable levels 
were measured in heart and lungs. The levels in the liver 
and kidneys were found to increase with increasing time 
(see figure 25).
The amount of isoprenaline left in the brain 15 minutes 
following icv injection was found to be the same as that of 
propranolol, however, isoprenaline seemed to leak from the 
brain at a faster pace than propranolol. Very low levels 
were detected in the heart and a measurable amount detected 
in the lungs. As with propranolol, the levels detected in 
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Figure 21a.
Figures 21a and 21b. Change in mean arterial pressure and 
heart rate following icv injection of 0.05 meg 
isoprenaline in conscious New Zealand rats.
x----- x 0.05 meg isoprenaline icv (n=6) 117 mmHg, 388 bpm.
x---- x Animals injected icv with vehicle only (n=6)
133 mmHg, 404 bpm.
Significant difference from control animals denoted:
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Figure 22a.
Figures 22a and 22b. Change in mean arterial pressure and 
heart rate following icv injection of 1 meg isoprenaline 
in conscious New Zealand rats.
x-------- x No pretreatment (n=6) 158 mmHg, 427 bpm.
x   x 30 meg propranolol icv (n=6) 143 mmHg, 350 bpm.
x-------- x 30 meg propranolol iv (n=4) 139 mmHg, 340 bpm.
Significant difference from control animals denoted:
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Figures 23a and 23b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in conscious New Zealand rats.
x------- x No pretreatment (n=6) 113 mmHg, 405 bpm.
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Figures 24a and 24b. Change in mean arterial pressure and 
heart rate produced by 1 meg clenbuterol icv in conscious 
New Zealand rats.
G------- Q No pretreatment (n=6) 110 mmHg, 437 bpm.
O ------- Q 30 meg propranolol icv (n=7) 122 mmHg, 357 bpm.
,si£’nifi.'?rjce TrotP >>o pret..twent group d^rored’
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22.6% 1.3% 6.1% 10.3% 3.1% 2.8%
Figure 25. Amount of propranolol remaining in the 
bloodstream and tissues following icv injection of 30 meg 
radiolabelled propranolol in conscious New Zealand rats, 
expressed as micrograms (pg) (mean +/- standard error) and 





























































13.9% 0.2% 2.8% 3.4% 1.4% 1.7%
Figure 26. Amount of isoprenaline remaining in the 
bloodstream and tissues following icv injection of 5 meg 
radiolabelled isoprenaline in conscious New Zealand rats, 
expressed as micrograms (pg) (mean +/- standard error) and 




3.3.4.1. Leakage of drugs to the periphery following icv 
injection.
It was found that 10 to 15 minutes after icv injection of 
both isoprenaline and propranolol there was approximately 
20% Of the injected dose remaining in the brain (see 
figures 25 and 26).
Anderson et al (1977) reported that, 10 minutes following 
icv injection of propranolol in conscious rabbits, plasma 
levels were 80% of those following iv injection of the same 
dose. This would produce peripheral cardiac beta- 
adrenoceptor blockade which would in turn confound any 
central component involved in the response to icv 
inj ection.
The rapid leakage to the peripheral bloodstream of icv 
injected propranolol in conscious spontaneously 
hypertensive rats was reported by Smits et al (1979). They 
showed that the plasma propranolol concentration-time curve 
was identical following subcutaneous or icv injection of 1 
mg/Kg propranolol.
The evidence available suggests that, in conscious animals, 
bradycardia following icv injection of propranolol results
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from blockade of cardiac beta- adrenoceptors, although the 
contribution of a central component cannot be excluded 
entirely.
Since the rate at which propranolol and isoprenaline leave 
the brain are similar, it appears that, as in anaesthetised 
animals, leakage occurs via bulk flow across the arachnoid 
villi and is independent of the lipophilicity of the drug 
(Schanker, 1962). Although large amounts of the drugs were 
observed to have leaked to the periphery, no large amounts 
in any one organ were detected. It is possible that 
significant amounts could have been taken up into 
subcutaneous fat or an alternative body compartment which 
had not been analysed in this study.
3.3.4.2. Icv and iv injection of propranolol.
In all animals injected with 30 meg propranolol icv, 
hypotension and bradycardia were observed. Fifteen minutes 
following start of injection the extent of hypotension and 
bradycardia was 7 mmHg and 54 bpm.
Variable changes in mean arterial pressure following icv 
injfcCi.j.on of oroovanolol in conscious anxrualb have bctu 
reported by different authors. This study using rats 
agrees with the results of Day and Roach (1974a) who 
observed sustained falls in blood pressure in conscious
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cats. However, most authors report an increase in arterial 
pressure. Conway and Lang (1974) observed a short lasting 
pressor response followed by a longer lasting hypotension 
after icv injection of 2 mg propranolol in conscious dogs. 
In conscious rabbits, an initial rise in mean arterial 
pressure followed by a hypotension at 4 hours was reported 
(Anderson et al, 1977; Dollery at al, 1973). This initial 
hypertension followed by hypotension at several hours 
following icv injection was also observed in conscious 
spontaneously hypertensive rats (Smits et al, 1979; Sweet 
and Wenger, 1976). It was suggested by Dollery et al 
(1973) that the initial increase in arterial pressure may 
be a result of the membrane stabilising action of 
propranolol, since it was mimicked by icv procaine.
In all studies involving the icv injection of propranolol 
into conscious animals, bradycardia was reported and this 
is consistent with the findings in this study.
Following intravenous injection of 30 meg propranolol, a 
marked bradycardia (120 bpm) and a slight increase in mean 
arterial pressure (15 mmHg) were observed. It is not known 
whether propranolol would be taken up into the brain to any 
sign i riean I «x ten}. in the first 15 minutes following iv 
injection but it is likely that the bradycardia is a result 
of blockade of cardiac beta- adrenoceptors.
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3.3.4.3. Effect of propranolol pretreatment on the
responses to icv isoprenaline and clenbuterol.
Icv injection of isoprenaline produced a dose dependant 
hypotension and tachycardia (see figures 21, 22 and 23). 
The responses to 1 meg isoprenaline icv were significantly 
reduced by 30 meg propranolol icv, but the hypotension was 
unaffected by 30 meg propranolol iv and the tachycardia was 
significantly potentiated. The potentiation of tachycardia 
to 1 meg isoprenaline icv following pretreatment with 30 
meg propranolol iv was probably because the propranolol had 
reduced the baseline heart rate by over 100 bpm prior to 
injection of isoprenaline.
Day and Roach (1974b) reported variable changes in arterial 
pressure following icv injection of isoprenaline in 
conscious cats; whether pressor or depressor, these were 
abolished after icv injection of beta- adrenoceptor 
blocking agents. In all animals, tachycardia accompanied 
the change in blood pressure and this was also abolished by 
beta- adrenoceptor blocking agents.
Hypotension following icv isoprenaline in conscious rats 
was observed by Correa et al (1982) and Peres-Polon and 
Correa (1984). Pretreatment with phentolamine and
significantly potentiated the hypotension 
(Peres-Polon and Correa, 1984).
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In this study, a propranolol insensitive mechanism involved 
in the response produced by icv isoprenaline did not appear 
to be present in the conscious rat, since pretreatment with 
icv propranolol abolished the hypotension and reduced the 
tachycardia. , This mechanism may not be apparent in 
conscious animals if these responses are a result of a 
peripheral action of 'leaked' isoprenaline. However, a 
central action cannot be excluded since the hypotension 
caused by 1 meg isoprenaline icv was reversed by icv, but 
not iv, propranolol.
Icv injection of clenbuterol caused hypotension and 
tachycardia, both significantly reduced by pretreatment 
with icv propranolol (see figures 24a and 24b). Nomura 
(1976) injected salbutamol into the lateral ventricle of 
conscious normotensive and hypertensive rats and observed 
an increase in blood pressure which was blocked by
propranolol pretreatment but not by the betal- adrenoceptor
!
blocker, practolol. The pressor response was significantly
j
increased in hypertensive animals, suggesting the 
involvement of beta2- adrenoceptors in the hypertensive 
state.
In conclusion, icv injection of drugs in conscious animals 
involves the major problem that large amounts of the 
injection appear to leak to the periphery in a short time,
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suggesting that the responses may be mainly peripherally 
mediated, although a central component does seem to exist.
Icv injections in both anaesthetised and conscious animals 
have been shown to carry the implication that there is 
always the possibility of a peripheral action of 'leaked' 
drug masking any central action, and so in the next section 
an attempt to minimise this by injection directly into the 
hypothalamus has been made. It was hoped that by injection 
into discrete brain areas, it would be easier to attribute 
any cardiovascular responses to a central action of the 
injected drug.
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3.4. Injection into the hypothalamus of anaesthetised New 
Zealand rats.
3.4.1. Injection of noradrenaline and the effect of 
pretreatment with propranolol. (2.2.5.)
Injection of noradrenaline into the anterior nucleus of the 
hypothalamus (anterior hypothalamus) resulted in an 
increase in blood pressure with no significant change in 
heart rate (see figures 27a and 27b). The maximum 
hypertension was 23 mmHg, achieved at 6 minutes following 
start of injection. Pretreatment with 30 meg propranolol 
icv did not significantly alter the hypertension, but a 
significant (p<0.05) fall in heart rate occurred following 
injection of noradrenaline.
Injection of noradrenaline into the posterior nucleus of 
the hypothalamus (posterior hypothalamus) caused a fall in 
mean arterial pressure (12 mmHg) and an increase in heart 
rate of 57 bpm 20 minutes after start of injection (see 
figures 28a and 28b). Pretreatment with propranolol icv 
did not significantly alter the tachycardia, but 
significantly (p<0 .0 1 ) reversed the hypotension to a 
hypertension of 16 mmHg occurring 1 minute after start of 
injection of noradrenaline.
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3.4.2. Injection of adrenaline into the hypothalamus andv 
pretreatment with propranolol. (2.2.5.)
Following injection of 5 meg adrenaline into the anterior 
hypothalamus, a biphasic change in mean arterial pressure 
was observed. An initial increase of 4 mmHg was obtained 2 
minutes following start of injection, this was followed by 
a longer-lasting fall in arterial pressure of 10 mmHg at 10 
minutes. This was accompanied by a fall in heart rate of 
40 bpm at 20 minutes (see figures 29a and 29b).
Injection of adrenaline into the posterior hypothalamus 
caused a fall in mean arterial pressure of 20 mmHg after 2 
minutes and a brcudycardia of 59 bpm after 8 minutes, both 
were returning to control levels 20 minutes after injection 
(see figures 30a and 30b). Pretreatment with 30 meg 
propranolol icv significantly (p<0 .0 1 ) reversed the 
hypotension to a hypertension of 25 mmHg and significantly 
(p<0.05) reduced the bradycardia.
3.4.3. Injection of clenbuterol into the hypothalamus and 
pretreatment with propranolol. (2.2.5.)
Injection of 5 meg clenbuterol caused hypotension and 
tachycardia of similar magnitude whether injected into the 
anterior or posterior hypothalamus (see figures 31 and 32). 
Pretreatment with 30 meg propranolol icv reduced the
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hypotension produced by clenbuterol injected into the 
anterior hypothalamus, but this reduction did not reach 
statistical significance over the total duration of the 
experiment. The tachycardia produced by clenbuterol was 
potentiated by pretreatment with icv propranolol, but this 
did not reach statistical significance over the whole 
experiment (see figures 31a and 31b).
The hypotension produced by clenbuterol injected into the 
posterior hypothalamus was significantly (p<0.05) reduced 
by pretreatment with icv propranolol and had returned to 
the baseline value after 20 minutes (see figure 32a). The 
tachycardia was unaffected by propranolol pretreatment over 
the first 8 minutes, but then became significantly (p<0.05) 
potentiated (see figure 32b).
3.4.4. Injection of isoprenaline into the hypothalamus and 
pretreatment with beta- adrenoceptor blockers. (2.2.5. and
2.2.6.)
Injection of 5 meg isoprenaline into the anterior or 
posterior hypothalamus produced a hypotension of 16 and 20 
mmHg respectively. Accompanying this hypotension was a 
tachycardia, of 21 and 15 bpm. Thus, the responses to 
intrahypothalamic isoprenaline were similar in magnitude 
whether injected into the anterior or posterior nuclei (see 
figs. 33 & 34).
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Pretreatment with 30 meg propranolol icv significantly 
(p<0.05) reduced the responses to isoprenaline injected 
into the anterior hypothalamus. Chronic oral dosing with 60 
mg/Kg propranolol daily for 14 days significantly (p<0.001) 
reversed the hypotension and potentiated (p<0.05) the 
tachycardia (see figures 33a and 33b).
The magnitude of hypotension produced by isoprenaline 
injected into the posterior hypothalamus was not attenuated 
by pretreatment with icv propranolol, but the duration of 
hypotension was significantly reduced. The hypotension was 
significantly reduced (p<0.05) by chronic oral dosing with 
60 mg/Kg propranolol daily for 14 days (see figure 34a). 
The tachycardia produced by isoprenaline injected into the 
posterior hypothalamus was significantly potentiated 
(p<0.01) by pretreatment with 60 mg/Kg propranolol daily 
for 14 days (see figure 334b).
The duration of hypotension produced by isoprenaline 
injected into the posterior hypothalamus was significantly 
reduced (p<0.05) by pretreatment with 30 meg atenolol icv. 
The degree of tachycardia was significantly potentiated 
(p<0.01) by atenolol pretreatment (see figures 35a and 
35b) .
Pretreatment with 30 meg ICI 118,551 icv significantly 
potentiated the hypotension at 2 minutes (p<0 .0 1 ), but the
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hypotension quickly returned to a similar degree as that 
seen in non-pretreated animals. Tachycardia to
isoprenaline was significantly potentiated by ICI 118,551 
(p<0.05) over the first 6 minutes of the experiment (see 
figures 36a and 36b).
In animals dosed orally with 50 mg/Kg atenolol daily for 7 
days, injection of isoprenaline into the anterior 
hypothalamus caused a greater degree of hypotension than in 
untreated animals (see figure 37a). Pretreatment with 30 
meg propranolol icv significantly reduced this hypotension 
(p<0.01). The tachycardia produced by isoprenaline in 
atenolol predosed rats was similar to that in untreated 
animals, and further pretreatment with icv propranolol did 
not significantly alter the degree of tachycardia (see 
figure 37b).
Injection of propranolol into the anterior hypothalamus 
caused a small biphasic change in mean arterial pressure 
accompanied by a large bradycardia of over 100 bpm (see 
figures 38a and 38b). Administration of isoprenaline and 
propranolol into the anterior hypothalamus in a single 
injection caused an initial sharp fall in mean arterial 
pressure followed by a longer lasting increase in pressure. 
This did not appear to be the result of simple addition of 
the effects of the two drugs (see figure 38a). A biphasic 
change in heart rate was also observed, and this was a
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closer approximation to a summation of the two drugs actings 
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Figure 27a.
Figures 27a and 27b. Change in mean arterial pressure and 
heart rate produced by 5 meg noradrenaline injected into 
the anterior hypothalamus of anaesthetised New Zealand 
rats.
0 fr No pretreatment (n=6 ) 94 mmHg, 465 bpm.
^ > - -0 30 meg propranolol icv (n=6 ) 100 mmHg, 390 bpm. 
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Figures 28a and 28b. Change in mean arterial pressure and 
heart rate produced by 5 meg noradrenaline injected into 
the posterior hypothalamus of anaesthetised New Zealand 
rats.
0------- — 0 No pretreatment (n=6 ) 105 mmHg, 440 bpm.
q---------o 30 meg propranolol icv (n=6 ) 97 mmHg, 343 bpm.
Significant difference from no pretreatment group denoted: 
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Figures 29a and 29b. Change in mean arterial pressure and 
heart rate produced by 5 meg adrenaline injected into the 
anterior hypothalamus of anaesthetised New Zealand rats.
o o No pretreatment (n=12) 76 mmHg, 443 bpm.
o------- -■© 30 meg propranolol icv (n=6 ) 87 mmHg, 342 bpm.
Significant difference from no pretreatment group denoted:



















Figures 30a and 30b. Change in mean arterial pressure and 
heart rate produced by 5 meg adrenaline injected into the 
posterior nucleus of the hypothalamus in anaesthetised New 
Zealand rats.
e---------o No pretreatment (n=8 ) 79 mmHg, 447 bpm.
o-  -o 30 meg propranolol icv (n=8 ) 126 mmHg, 366 bpm
Significant difference from no pretreatment group denoted: 
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Figure 31a.
Figures 31a and 31b. Change in mean arterial pressure and 
heart rate produced by 5 meg clenbuterol injected into the 
anterior hypothalamus in anaesthetised New Zealand rats.
0 -------- Q No pretreatment (n=7) 87 mmHg, 420 bpm.
O -q 30 meg propranolol lev (n=6 ) 87 mmHg, 395 bpm
Significant difference from no pretreatment group denoted:
*  p < 0 . 0 5  * *  p < 0 . 0 1
•qie sanST .3
(suiuj)3 ^|i































Figures 32a and 32b. Change in mean arterial pressure and 
heart rate produced by 5 meg clenbuterol injected into the 
posterior hypothalamus in anaesthetised New Zealand rats.
0---------q No pretreatment (n=6 ) 75 mmHg, 455 bpm.
3_________ q 30 meg propranolol icv (n=6 ) 77 mmHg, *390 bpm
Significant difference from no pretreatment group denoted:










































Figures 33a and 33b. Change in mean arterial pressure and 
heart rate produced by 5 meg isoprenaline injected into 
the anterior hypothalamus in anaesthetised New Zealand 
rats.
x-------- x No pretreatment (n=ll) 79 mmHg, 432 bpm.
x--- <-----x 30 meg propranolol icv (n=6 ) 108 mmHg, 368 bpm
x--- .-x 60 mg/Kg propranolol po daily for 14 days
(n=6 ) 71 mmHg, 318 bpm.
Significant difference from no pretreatment group denoted: 
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Figure 34a.
Figures 34a and 34b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the posterior hypothalamus of anaesthetised New Zealand 
rats.
x-------- x No pretreatment (n=8 ) 76 mmHg, 422 bpm.
x-------- x 30 meg propranolol icv (n=5) 103 mmHg, 401 bpm.
x  x 60 mg/Kg propranolol po daily for 14 days (n=5)
112 mmHg, 305 bpm. *
Significant difference from no pretreatment group denoted: 



















0 5 10 15 20
TlME(mins)
Figure 35a.
Figures 35a and 35b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the posterior hypothalamus of anaesthetised New Zealand 
rats.
x----------x No pretreatment (n=8 ) 76 mmHg, 422 bpm.
x--------- x 30 meg atenolol icv (n=6 ) 64 mmHg, 465 bpm.
Significant difference from no pretreatment group denoted: 
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Figures 36a and 36b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the posterior hypothalamus of anaesthetised New Zealand 
rats.
x--------x No pretreatment (n=8 ) 76 mmHg, 422 bpm.
x------- -x 30 meg ICI 118,551 icv (n=6 ) 106 mmHg, 496 bpm.
Significant difference from no pretreatment group denoted: 













0 5 10 15 20
TIME(mins)













Figures 37a and 37b. Change in mean arterial pressure and 
heart rate produced by 5 meg isoprenaline injected into 
the anterior hypothalamus of anaesthetised New Zealand 
rats dosed orally with 50 mg/kg atenolol daily for 7 days.
x------ x No pretreatment (n=6) 102 mmHg, 300 bpm.
x------ x . 30 meg propranolol icv (n=6) 110 mmHg, 294 bpm.
Significant difference from no pretreatment group denoted:
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Figure 38a.
Figures 38a and 38b. Change in mean arterial pressure and 
heart rate following injection into the anterior 
hypothalamus of anaesthetised New Zealand rats.
x--------- x 5 meg isoprenaline (n=ll) 79 mmHg, 432 bpm.
x--------- x 30 meg propranolol (n=6) 108 mmHg, 469 bpm.
x------- —x 30 meg propranolol and 5 meg isoprenaline
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Figure 38c. Spread of Evans Blue dye through brain tissue 




The problems associated with differentiating between 
central and peripheral effects following injection into the 
cerebral ventricle led to consideration of injections into 
discrete areas of the brain. It was hoped that during the 
course of the experiment insufficient drug would leak into 
the periphery to exert a peripheral effect. Localised 
injection would also serve to localise the possible sites 
of action within the central nervous system at which drugs 
acting at beta- adrenoceptors may exert an effect.
Following peripheral administration of propranolol, 
significant levels have been detected in the hypothalamus 
of rabbits, cats, dogs and rats (Bakke et al, 1974; Elghozi 
et al, 1979; Garvey and Ram, 1975), suggesting the presence 
of beta- adrenoceptors in the hypothalamus.
The hypothalamus, amygdala and hippocampus appear to 
control the activity of the nuclei in the medulla oblongata 
and belonging to the baroreceptor reflex loop. Direct 
connections to the medulla and spinal cord have been 
demonstrated from various nuclei of the hypothalamus, 
including the posterior and lateral hypothalamic areas and 
dorsomedial and paraventricular nuclei (Loewy and McKellar, 
1980).
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The hypothalamus is implicated as an area within the' 
central nervous system which regulates cardiovascular 
function and it was decided to observe any changes in 
cardiovascular parameters following direct injection into 
the hypothalamus.
Injections were made into the anterior and posterior nuclei 
of the hypothalamus because Gellhorn (1964) postulated the 
presence of two distinct autonomic areas within the 
hypothalamus, the anterior portion containing the 
parasympathetic centre and the sympathetic centre being 
located posteriorly. There appear to be conflicting 
effects upon cardiovascular parameters depending on whether 
injections are made into the anterior or posterior 
hypothalamus, and it was hoped to illustrate any 
differences in this study.
3.4.5.1. Injection of noradrenaline into the hypothalamus 
and pretreatment with propranolol.
Injection of noradrenaline into the anterior hypothalamus 
elicited an increase in mean arterial pressure with no 
significant change in heart rate. Pretreatment with icv 
propranolol did not significantly alter the hypertension 
but did produce a bradycardia following injection of 
noradrenaline (see figures 27a and 27b). In anaesthetised 
rats, Struyker Boudier et al (1974) reported a fall in
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blood pressure and heart rate in response to the injection' 
of 40 nmol noradrenaline into the anterior hypothalamus, 
but a transient increase in blood pressure following the 
injection of 100 nmol noradrenaline. They suggested that 
the increase in blood pressure following the injection of 
the larger dose of noradrenaline was probably due to 
vascular transport of small amounts of noradrenaline to the 
peripheral circulation where it can induce hypertension in 
very low concentrations. The depressor response was 
thought to be a result of stimulation of hypothalamic 
alpha- adrenoceptors by noradrenaline since bradycardia and 
hypotension were induced by phenylephrine and were 
antagonised by phentolamine.
Although hypertensive responses to noradrenaline were 
obtained in this study, it is thought that this was a 
result of an action upon central alpha- adrenoceptors since 
the responses was not antagonised by pretreatment with 
propranolol. Since the maximum response was observed 2 
minutes following the start of injection, it was thought 
unlikely that significant amounts would have leaked to the 
periphery from the hypothalamus in this short time.
Following injection of noradrenaline into the posterior 
hypothalamus, hypotension and tachycardia were observed. 
Pretreatment with propranolol significantly reversed the 
hypotension, but had no effect on the tachycardia.
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Struyker Boudier et al (1974) found no change in 
cardiovascular parameters following injection of 
noradrenaline into the posterior hypothalamus. Since the 
hypotension observed in this study was significantly 
altered by pretreatment with propranolol, it is possible 
that this response could arise from an interaction of 
noradrenaline with beta- adrenoceptors in the posterior
hypothalamus. However, Philippu and Kittel (1977) have 
demonstrated that activation of beta- adrenoceptors in the 
posterior hypothalamus is likely to elicit increases in 
arterial pressure.
Philippu et al (1971) observed dose dependant increases in 
blood pressure following superfusion of the hypothalamus of 
anaesthetised cats with noradrenaline; this effect was
strongly diminished by transection of the spinal cord. The 
response to noradrenaline was found to be resistant to 
phentolamine, but at higher doses this drug caused
ventricular haemorrhage which made interpretation of 
results difficult.
Electrical stimulation of the anterior hypothalamus has
shown varying changes in arterial pressure in different 
species. Decreases in pressure have been observed in dogs 
(Bogaert et al, 1976) cats (Eliasson et al, 1951) and rats 
(Gamble and Patton, 1953) whereas increases in pressure 
have been reported in rats (Faiers et al, 1976).
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Although the cardiovascular changes observed following 
electrical stimulation are almost invariably due to neural 
effector mechanisms, Calaresu and Ciriello (1979) reported 
an increase in arterial pressure following stimulation of 
the paraventricular nucleus which could be due to a humoral 
mechanism. They suggested that the response may be a 
result of the release of vasopressin.
3.4.5.2. Injection of adrenaline into the hypothalamus and 
pretreatment with propranolol.
Struyker Boudier and Bekers (1975) injected adrenaline into 
the anterior hypothalamus of anaesthetised rats and 
observed a dose dependant decrease in arterial pressure and 
heart rate. A small, but significant, rise in arterial 
pressure was observed immediately after injection, this did 
not depend on the dose of adrenaline injected.
In this study, 5 meg adrenaline caused a biphasic change in 
mean arterial pressure with bradycardia (see figures 29a 
and 29b), these findings agree with those of Struyker 
Boudier and Bekers (1975). Pretreatment with icv 
propranolol did not significantly alter the initial 
increase in mean arterial pressure, but did abolish the 
hypotension which occurred 10 minutes following injection. 
The bradycardia was also significantly blocked by
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propranolol. These findings suggest that the hypotension* 
and bradycardia may be mediated via beta- adrenoceptors 
whereas the initial transient increase in pressure is not. 
Struyker Boudier and Bekers (1975) suggested that this 
increase in pressure was probably a result of leakage of 
some adrenaline into the peripheral circulation. However, 
it is unlikely that a leakage to the periphery from the 
hypothalamus would occur only 2 minutes following injection 
and, if so, it is equally likely that leakage would 
continue over the whole duration of the experiment and thus 
mask any centrally mediated effect at a later time. The 
absence of leakage to the periphery is supported by the 
fact that following injection of dye into the hypothalamus, 
the maximum spread through the brain tissue after 30 
minutes is less than 0.2 mm from the injection site. This 
would also indicate that the injected drug remains in the 
individual nucleus of the hypothalamus, suggesting a highly 
localised site of action (See figure 38c). The hypotension 
and bradycardia observed appear to be centrally mediated 
since following peripheral administration, adrenaline 
caused an increase in blood pressure and a reflex 
bradycardia which lasts approximately 5 minutes. In 
addition, it is possible that the initial increase in blood 
pressure may not involve neuronal mechanisms because it is 
not dose dependant.
Following injection of adrenaline into the posterior
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hypothalamus, an immediate hypotension and bradycardia were 
observed. Pretreatment with icv propranolol significantly 
reversed the hypotension and abolished the bradycardia, 
suggesting that these responses were a result of 
interaction at central beta- adrenoceptors.
Philippu et al (1971) reported that following superfusion 
of the hypothalamus of anaesthetised cats with adrenaline, 
a dose dependant rise in blood pressure was recorded which 
was significantly reduced following spinal transection. 
This superfusion of adrenaline also enhanced the release of 
radioactive amines from the hypothalamus suggesting that 
the rise in blood pressure, at least in part, was a result 
of an action within the hypothalamus.
3.4.5.3. Injection of beta- adrenoceptor agonists into the 
hypothalamus and pretreatment with beta- adrenoceptor 
blockers.
Injection of isoprenaline into both the anterior and 
posterior hypothalamus caused hypotension and tachycardia 
(see figures 33 and 34). The duration of hypotension was 
significantly decreased by pretreatment with propranolol 
icv, but the maximum degree of hypotension was unaffected. 
However, chronic treatment with oral propranolol reduced 
the hypotension produced by isoprenaline at both injection 
sites. It is likely that following chronic oral dosing
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with propranolol, there will be significant amountsv 
concentrated in the hypothalamus. Myers et al (1975) 
demonstrated a hypothalamus-to-plasma ratio of 15:1 
following a single iv injection of propranolol in rabbits.
These results.suggest that the presence of propranolol in 
the hypothalamus as a result of chronic oral dosing is much 
more effective at blocking the centrally mediated responses 
to isoprenaline than a single central injection of 
propranolol. This could be a result of insufficient 
propranolol being present in the hypothalamus following icv 
injection, although the response to adrenaline was 
attenuated by icv propranolol (see 3.4.5.2.).
Pretreatment with icv atenolol significantly reduced the 
duration of hypotension produced by isoprenaline injected 
into the posterior hypothalamus, whereas the tachycardia 
was significantly potentiated (see figures 35a and 35b). 
Pretreatment with icv ICI 118,551 significantly potentiated 
the hypotension at 1 and 2 minutes following injection of 
isoprenaline, but this soon returned to similar values as 
the untreated group. The tachycardia was potentiated by 
ICI 118,551 (see figures 36a and 36b).
Superfusion of the posterior hypothalamus of anaesthetised 
cats with isoprenaline has been shown to enhance the 
pressor response to electrical stimulation of the
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hypothalamus (Philippu and Kittel, 1977; Philippu andv 
Stroehl, 1978). This suggests that beta- adrenoceptors are 
present in the posterior hypothalamus and are involved in 
the increase in blood pressure elicited by hypothalamic 
stimulation.
Isoprenaline has also been reported to facilitate 
noradrenaline and dopamine release in the rat hypothalamus, 
thought to be a result of stimulation of pre-synaptic beta- 
adrenoceptors (Ueda et al, 1983). This was also
demonstrated by Dietl et al (1981) in the cat hypothalamus. 
The facilitatory effects were abolished by pretreatment 
with betai- and beta2- antagonists, suggesting the 
co-existence of pre-synaptic betai- and beta2- 
adrenoceptors in the hypothalamus. Alternatively, there is 
the possibility that these beta- adrenoceptors do not 
exhibit the same selectivity as peripheral beta- 
adrenoceptors.
Thus, the majority of information concerning isoprenaline 
in the hypothalamus has examined its effect upon responses 
to electrical stimulation and is thought to involve an 
interaction with pre-synaptic beta- adrenoceptors. In this 
study, I have examined the effect of an injection of 
isoprenaline into the hypothalamus and pretreatment with 
beta- adrenoceptor antagonists. It appears that atenolol 
blocks the hypotension produced by isoprenaline to a
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greater degree than ICI 118,551, suggesting that the 
hypotension produced by isoprenaline may be mediated via 
betai- adrenoceptors in the hypothalamus.
As a result of the low lipophilicity of atenolol, it is 
possible that only low levels are present in the 
hypothalamus following icv injection and this may explain 
why the attenuation of the hypotension to isoprenaline is 
not complete. The possibility of the isoprenaline induced 
hypotension being mediated via betai- adrenoceptors is also 
supported by the fact that blockade of beta2- adrenoceptors 
by ICI 118,551 resulted in a potentiation of hypotension.
However, hypotension and tachycardia are caused by 
injection of the beta2- adrenoceptor agonist, clenbuterol 
(see figures 31 and 32). Pretreatment with propranolol 
more readily antagonises the hypotension produced by 
clenbuterol when injected into the posterior hypothalamus, 
indicating that the involvement of beta2- adrenoceptors 
cannot be ruled out completely.
Since pretreatment with icv propranolol potentiates the 
tachycardia caused by isoprenaline, it is possible that the 
attenuation of hypotension could just be result of this 
enhanced tachycardia. In order to eliminate this
possibility, injections into animals pretreated with 
atenolol were made. It was hoped that pretreatment with
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atenolol would eliminate any increase in heart rate because, 
the cardiac betai- adrenoceptors would have been blocked by 
the drug. It also had the advantage that icv injection of 
propranolol had no effect on blood pressure and heart rate 
in these pretreated animals and so both groups are at the 
same baseline values at the start of injection of
isoprenaline.
Injection of isoprenaline into the anterior hypothalamus of 
animals pretreated with atenolol produced a fall in blood 
pressure and a small increase in heart rate (see figures 
37a and 37b). The degree of hypotension was greater in 
these animals pretreated with atenolol than had been
observed in untreated rats. Pretreatment with icv 
propranolol significantly reduced this hypotension, showing 
that the reduction in hypotension was not simply a
reflection of enhanced tachycardia. It is unlikely that
there would be a significant amount of atenolol in the 
brain following oral dosing since atenolol does not cross 
the blood brain barrier to any great extent by virtue of 
its low lipophilicity. This is also demonstrated by the 
fact that hypotension is still produced by isoprenaline 
injected into the hypothalamus of animals pretreated with 
atenolol, whereas pretreatment with oral propranolol 
significantly reversed the hypotension induced by 
intrahypothalamic isoprenaline.
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Because of the uncertainty of how much beta- adrenoceptor^ 
antagonist would reach the hypothalamus following icv 
injection, it was decided to try an injection of 
propranolol and isoprenaline into the anterior 
hypothalamus. Injection of propranolol alone into the 
anterior hypothalamus caused a small increase in mean 
arterial pressure accompanied by a large bradycardia (see 
figures 38a and 38b). Lavy and Stern (1970) demonstrated 
decreases in heart rate following implantation of 
propranolol into the anterior hypothalamus, which they 
suggested was a result of a reduction in the activity of 
noradrenaline in the anterior hypothalamus causing a 
preponderance of the parasympathetic activity and hence a 
reduction in heart rate.
Injection of propranolol and isoprenaline simultaneously 
into the anterior hypothalamus resulted in biphasic changes 
in blood pressure and heart rate, which could not be 
explained simply by addition of the responses obtained to 
the two drugs injected singly. Thus, the responses to an 
injection of propranolol and isoprenaline together cannot 
be explained by simple competition between propranolol and 
isoprenaline for beta- adrenoceptors in the hypothalamus. 
The difficulty in interpreting the responses in terms of 
the effects of each drug precluded the use of this type of 
experiment. These problems could be overcome by the use of 
multibarrelled cannulae which would enable the injection of
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more than one drug at separate times without the removal of' 
the cannula between injections.
In conclusion, the results of injections into the 
hypothalamus of anaesthetised New Zealand rats implicate 
beta- adrenoceptors in the hypotensive and tachycardic 
responses to beta- adrenoceptor agonists. Adrenaline, 
which acts equally at both alpha- and beta- adrenoceptors, 
caused a biphasic change in arterial pressure when injected 
into the anterior hypothalamus and hypotension when 
injected into the posterior hypothalamus. Noradrenaline, 
which has a greater affinity for alpha- than beta- 
adrenoceptors caused a hypertension in the anterior and 
hypotension in the posterior hypothalamus.
From results obtained from injections into the anterior 
hypothalamus, it would appear that activation of alpha- 
adrenoceptors causes hypertension whereas hypotension is a 
result of an interaction with beta- adrenoceptors. In 
general, injections into the posterior hypothalamus are 
more likely to produce hypotensive responses than 
injections into the anterior hypothalamus.
It is obvious that responses to intrahypothalamic 
injections in conscious animals would be helpful in 
interpreting the central mechanisms involved. However, in 
this study, there was not time to develop a suitable method
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to facilitate injections into the hypothalamus of conscious 
animals.
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3.5. Injections into the cerebral ventricle of
anaesthetised Japanese Okamoto spontaneously hypertensive 
and Wistar Kyoto normotensive rats.
3.5.1. Icv injection of isoprenaline in Wistar rats 
anaesthetised^ with Hypnorm/Hypnovel and pretreatment with 
propranolol.
Injection of 5 meg isoprenaline into the left lateral 
cerebral ventricle of Wistar rats anaesthetised with 
Hypnorm/Hypnovel caused a fall in mean arterial pressure, 
reaching a maximum of 19 mmHg at 4 minutes (see figure 
39a) . The hypotension was not significantly reduced by 12 
meg propranolol iv, but was significantly reduced by 30 meg 
propranolol icv. Following pretreatment with propranolol, 
tachycardia following isoprenaline was observed which was 
not present in untreated animals (see figure 39b).
3.5.2. Icv injection of isoprenaline into Japanese Okamoto 
spontaneously hypertensive and Wistar Kyoto normotensive 
rats. (2.2.2.)
In Japanese Okamoto spontaneously hypertensive rats 
anaesthetised with Hypnorm/Hypnovel no significant change 
in mean arterial pressure was seen following icv injection 
of isoprenaline (see figure 40a), but a tachycardia of 77 
bpm was observed after 20 minutes (see figure 40b).
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In both Wistar and Japanese Okamoto rats anaesthetised with 
Inactin, icv injection (1-5 meg) caused a dose dependant 
hypotension and tachycardia (see figures 41, 42 and 43). 
The degree of hypotension at each dose of isoprenaline was 
greater in the hypertensive animals, however the degree of 
tachycardia was smaller. The maximum values for
hypotension and tachycardia are shown below:
Dose isopren. Wistar Jap. Okamoto Figure
(meg) Hypo ten. Tachycard. Hypoten. Tachycard.
(mmHg) (bpm) (mmHg) (bpm)
1.0 7 47 14 42 41
3.0 7 100 22 80 42
5.0 32 128 44 101 43
3.5.3. The effect of pretreatment with propranolol on 
responses to icv isoprenaline in rats anaesthetised with 
Inactin. (2.2.2. and 2.2.4.)
The hypotension and tachycardia induced by 5 meg 
isoprenaline icv in Wistar rats were significantly 
attenuated by pretreatment with 30 meg propranolol icv to
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13 mmHg and 77 bpm (see figure 44a and 44b). Chronic oral' 
dosing with propranolol for 14 days abolished the 
hypotension to isoprenaline and attenuated the tachycardia 
to a greater extent than 30 meg propranolol icv (44 bpm).
The hypotension observed in Japanese Okamoto rats was 
blocked by pretreatment with 30 meg propranolol icv 
(p<0.01) and 60 mg/Kg orally for 14 days (p<0.001). The 
tachycardia was attenuated by icv propranolol to 56 bpm and 



















0 5 10 15 20
TIME(mins)
Figure 39a.
Figures 39a and 39b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in Wistar rats anaesthetised with Hypnorm/Hypnovel.
x-------- x No pretreatment (n=6) 62 mmHg, 460 bpm.
x-------- x 30 meg propranolol icv (n=6) 89 mmHg, 400 bpm.
* x 12 meg propranolol iv (n=8) 84 mmHg, 350 bpm.
Significant difference from no pretreatment group denoted: 

























Figures 40a and 40b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in rats anaesthetised with Hypnorm/Hypnovel.
x------- x Wistar rats (n=6) 62 mmHg, 460 bpm.
x------- x Japanese Okamoto rats (n=6) 61 mmHg, 440 bpm.
Significant difference from Wistar rats denoted:
*  p < 0 . 0 5  * *  p < 0 . 0 1
N)O
CHANGE IN HR(bpm)
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Figure 41a.
Figures 41a and 41b. Change in mean arterial pressure and 
heart rate following icv injection of 1 meg isoprenaline 
in rats anaesthetised with Inactin.
x------- x Wistar rats (n=6) 96 mmHg, 424 bpm.
x------- x Japanese Okamoto rats (n=6) 153 mmHg, 372 bpm.
Significant difference from Wistar rats denoted:
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Figure 42a.
Figures 42a and 42b. Change in mean arterial pressure and 
heart rate following icv injection of 3 meg isoprenaline 
in rats anaesthetised with Inactin.
x------- x Wistar rats (n=6) 100 mmHg, 410 bpm.
x x Japanese Okamoto rats (n=6) 152 mmHg, 367 bpm.
Significant difference from Wistar rats denoted:
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Figures 43a and 43b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in rats anaesthetised with Inactin.
x x Wistar rats (n=6) 110 mmHg, 404 bpm.
x--------x Japanese Okamoto rats (n=6) 149 mmHg, 375 bpm.
Significant difference from Wistar rats denoted:
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Figure 44a.
Figures 44a and 44b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline 
in Wistar rats anaesthetised with Inactin.
x------- x No pretreatment (n=6) 110 mmHg, 364 bpm.
x------- x 30 meg propranolol icv (n=6) 70 mmHg, 380 bpm.
x------- x 60 mg/Kg propranolol po daily for 14 days
(n=6) 90 mmHg, 332 bpm.
S ig n if ic a n t  d if fe re n c e  from no p re tre a tm e n t group denoted:
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F igure  44b.
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Figures 45a and 45b. Change in mean arterial pressure and 
heart rate following icv injection of 5 meg isoprenaline . 
in Japanese Okamoto rats anaesthetised with Inactin.
x-------- x No pretreatment (n=6) 149 mmHg, 375 bpm.
x-------- x 30 meg propranolol icv (n=6) 95 mmHg, 341 bpm.
x-------- x 60 mg/Kg propranolol po daily for 14 days
(n=6) 139 mmHg, 295 bpm.
S ig n if ic a n t  d if fe re n c e  from no p re tre a tm e n t group denoted:
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3.5.4. Discussion.
3.5.4.1. The influence of anaesthetics upon responses to 
centrally administered drugs.
Experiments using Wistar Kyoto normotensive and Japanese 
Okamoto spontaneously hypertensive rats illustrated the 
fact that not only is the presence of anaesthesia likely to 
alter the responses observed following central 
administration of drugs, but that the anaesthetic used may 
also make a lot of difference. Since this fact was most 
evident during this series of experiments, a more detailed 
discussion will be made.
The possibility that Hypnorm/Hypnovel may not be a suitable 
anaesthetic for use in Japanese Okamoto rats became 
apparent when no hypotension occurred following icv 
injection of isoprenaline into them. It was noted that the 
resting blood pressure and heart rate were approximately 
the same in both these and the Wistar Kyoto rats, 62 and 61 
mmHg and 460 and 440 bpm respectively. From systolic blood 
pressure and heart rate measurements made using the tail 
cuff method (see 2.7 for details), it was known that the 
systolic blood pressure in the spontaneously hypertensive 
rat was around 220 mmHg whereas that of normotensive rats 
was around 150 mmHg. The heart rate for both groups was 
found to be approximately 450 bpm.
236
It is possible that Hypnorm/Hypnovel had reduced the' 
arterial pressure in the spontaneously hypertensive rats to 
such an extent that further hypotension following icv 
injection of isoprenaline was not possible. The reason for 
this large degree of hypotension was thought to be the 
blockade of central or peripheral alpha- adrenoceptors by 
the fluanisone present in Hypnorm. Fluanisone is a 
neuroleptic drug of the butyrophenone class and is known to 
have an affinity resembling that of classic alpha- 
adrenoceptor agonists such as phentolamine and 
phenoxybenzamine (Peroutka et al, 1977). A relationship 
has been shown to exist between the clinical sedative and 
hypotensive effects of butyrophenone neuroleptics and their 
central alpha- adrenoceptor potency. It is possible that 
the hypertension present in Japanese Okamoto spontaneously 
hypertensive rats may in some way involve alpha- 
adrenoceptors and subsequent activity by fluanisone may 
result in the large hypotension seen in this study.
Anaesthesia with Inactin did not appear to affect the 
resting blood pressure of spontaneously hypertensive rats 
to as great an extent as Hypnorm/Hypnovel; the mean 
arterial pressure was approximately 150 mmHg as opposed to 
approximately 100 mmHg for Wistar rats. However, Inactin 
tended to produce a more pronounced bradycardia; the heart 
rate of spontaneously hypertensive rats was approximately 
370 bpm, that of Wistar rats being 410 bpm. A reduction in
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arterial pressure and heart rate has been reported, 
following administration of Inactin (Cupples et al, 1982; 
Walker et al, 1983), with a decrement of renal blood flow 
being particularly apparent (Koeppen et al, 1979).
A particular problem associated with Inactin anaesthesia 
was that animals needed to be artificially respired during 
the experiment. This was thought to be a result of the
animal being incapable of regulating its blood gasses. 
Buelke-Sam et al (1978) reported marked hypercapnia in
animals anaesthetised with Inactin, leading to
irregularities in heart rate and blood pressure.
Inactin has been shown to have a lesser effect upon central 
catecholamines than urethane (Chahl and Walker, 1981), 
although increases in central acetylcholine have been 
reported following anaesthesia with Inactin (Weigel et 
al,1978).
It was decided to use Inactin as the anaesthetic in
subsequent experiments using Wistar and Japanese Okamoto 
rats as, although blood pressure and heart rate may still 
be affected by this anaesthetic, it seemed to be less 
detrimental than the Hypnorm/Hypnovel combination in the 
spontaneously hypertensive rat.
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3.5.4.2. lev injection in rats anaesthetised with'
Hypnorm/Hypnovel.
Injection of 5 meg isoprenaline into the cerebral ventricle 
caused a fall in mean arterial pressure in Wistar rats 
which was comparable to that seen in New Zealand rats, but 
in Wistar rats no accompanying tachycardia was observed. 
Conversely, in Japanese Okamoto rats, tachycardia without 
hypotension occurred following icv isoprenaline. Thus, 
there appears to be a difference in responses between 
strains using the same anaesthetic.
The hypotension in Wistar rats was significantly reduced by 
pretreatment with icv propranolol (see figure 39a), 
suggesting this was a result of activation of beta- 
adrenoceptors by isoprenaline. Intravenous propranolol did 
not significantly alter the degree of hypotension, 
indicating that, at least in part, a centrally mediated 
mechanism is responsible for the response.
Tachycardia was observed following icv injection of 
isoprenaline in Wistar rats pretreated with propranolol 
either iv or icv (see figure 39b). It is possible that the 
bradycardia produced by propranolol facilitates the 
subsequent tachycardic response to icv isoprenaline, since 
no change in heart rate was observed in untreated animals.
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3.5.4.3. Icv injections in rats anaesthetised witlr
Inactin.
Following icv injection of isoprenaline in Wistar and 
Japanese Okamoto rats, hypotension and tachycardia were 
observed (see.figures 41, 42 and 43). „ In general, the
degree of hypotension was greater and tachycardia was less 
in Japanese Okamoto rats. In Wistar rats, the hypotension 
was significantly reduced by pretreatment with icv 
propranolol and abolished by chronic oral dosing with 
propranolol. The tachycardia was significantly reduced by 
both types of pretreatment (see figures 44a and 44b). The 
hypotension produced by 5 meg isoprenaline icv in Japanese 
Okamoto rats was abolished by pretreatment with propranolol 
given either as a single icv injection or chronic oral 
doses (see figure 45a). Both pretreatments reduced the 
degree of tachycardia (see figure 45b).
The degree of hypotension in Wistar rats following 5 meg 
isoprenaline icv was found to be 50% greater in animals 
anaesthetised with Inactin. Regardless of the anaesthetic 
used, pretreatment with icv propranolol in Wistar rats more 
readily attenuates the hypotension produced by icv 
isoprenaline than that observed in New Zealand rats. Thus, 
if a propranolol insensitive mechanism is involved as has 
been reported (Peres-Polon and Correa, 1984) it is not as 
apparent in Wistar rats as in New Zealand rats (see
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3.2.11.4). In Japanese Okamoto rats, the hypotension is^  
completely abolished by pretreatment with propranolol. 
This would agree more closely with studies in the cat 
(Gagnon and Melville, 1967) and the dog (Bhargava et al, 
1972) where propranolol was found to block the response to 
central isoprenaline.
Thus, this series of experiments highlights the fact that 
the responses produced by icv injection of isoprenaline do 
not only rely upon the presence of anaesthesia, but also on 
the strain of animal and choice of anaesthetic.
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3.6. Injection into the hypothalamus of anaesthetised^ 
Japanese Okamoto spontaneously hypertensive and Wistar 
Kyoto normotensive rats.
In this section of experiments, all animals were 
anaesthetised .with Inactin.
3.6.1. Injection of isoprenaline into the hypothalamus of 
anaesthetised Wistar rats and pretreatment with 
propranolol. (2.2.5. and 2.2.6.)
Following injection of 5 meg isoprenaline into the anterior 
or posterior hypothalamus, hypotension and tachycardia were 
observed. The magnitude of these responses was similar for 
each injection site, being 13 mmHg and 112 bpm, and 15 mmHg 
and 109 bpm for the anterior and posterior hypothalamus 
respectively (see figures 46 and 47). Pretreatment with 
propranolol (30 meg icv) abolished the hypotension and 
reduced the tachycardia produced by isoprenaline injected 
into the anterior and posterior hypothalamus. Chronic oral 
dosing with propranolol (60 mg/Kg daily for 14 days) 
further reduced the degree of tachycardia and significantly 
reduced hypotension in both cases.
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3.6.2. Injection of isoprenaline into the hypothalamus of 
anaesthetised Japanese Okamoto rats and pretreatment with 
propranolol. (2.2.5. and 2.2.6.)
Injection of isoprenaline into the anterior hypothalamus 
caused a fall* in mean arterial pressure of 34 mmHg and an 
increase in heart rate of 56 bpm (see figures 48a and 48b). 
The hypotension was significantly (p<0.05) reduced to 10 
mmHg by icv propranolol and abolished by oral dosing with 
propranolol for 14 days. Tachycardia was potentiated to 
125 bpm by pretreatment with icv propranolol but abolished 
by chronic oral dosing with propranolol.
Injection of isoprenaline into the posterior hypothalamus 
caused a fall in mean arterial pressure of 18 mmHg and an 
increase in heart rate of 92 bpm. The degree of 
hypotension was unaffected by pretreatment with icv
propranolol, although the duration of hypotension was 
attenuated. Tachycardia was potentiated by this
pretreatment. Chronic oral dosing with propranolol























Figures 46a and 46b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the anterior hypothalamus of Wistar rats.
x------- sc No pretreatment (n=6) 75 mmHg, 400 bpm.
x------- x 30 meg propranolol icv (n=6) 90 mmHg, 398 bpm.
x------- x 60 mg/Kg propranolol po daily for 14 days
(n=6) 89 mmHg, 300 bpm.
S ig n if ic a n t  d if fe re n c e  from no p re tre a tm e n t group denoted:
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Figure 47a.
Figures 47a and 47b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the posterior hypothalamus of Wistar rats.
x--------x No pretreatment (n=6) 67 mmHg, 377 bpm.
x------- x 30 meg propranolol icv (n=6) 78 mmHg, 400 bpm.
x------- x 60 mg/Kg propranolol po daily for 14 days
(n=6) 124 mmHg, 350 bpm.
S ig n if ic a n t  d iffe re n c e  from no p re tre a tm e n t group denoted:


























Figures 48a and 48b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the anterior hypothalamus of Japanese Okamoto rats.
x-------- x No pretreatment (n=6) 140 mmHg, 372 bpm.
x-------- x 30 meg propranolol icv (n=6) 132 mmHg, 360 bpm.
x-------- x 60 mg/Kg propranolol po daily for 14 days
(n=6) 118 mmHg, 305 bpm.
S ig n if ic a n t  d if fe re n c e  from no p re tre a tm e n t group denoted:





























Figures 49a and 49b. Change in mean arterial pressure and 
heart rate following injection of 5 meg isoprenaline into 
the posterior hypothalamus of Japanese Okamoto rats.
x--------x No pretreatment (n=6) 138 mmHg, 418 bpm.
x--------x 30 meg propranolol icv (n=6) 130 mmHg, 375 bpm.
x   x 60 mg/Kg propranolol po daily for 14 days
(n=6) 123 mmHg, 297 bpm.
S ig n if ic a n t  d if fe re n c e  from no p re tre a tm e n t group denoted:























F ig u re  49b.
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3.6.3. Discussion.
The fact that Inactin was used in this set of experiments 
precludes direct comparison of these results with those 
obtained in New Zealand rats since it is not known whether 
any discrepancy would be a result in strain difference or 
the use of a different anaesthetic. However, it was noted 
that pretreatment with icv propranolol did not 
significantly alter the hypotension produced by 
isoprenaline injected into the hypothalamus of New Zealand 
rats whereas the hypotension was significantly reduced in 
Japanese Okamoto rats and abolished in Wistar rats by 
pretreatment with icv propranolol. In all strains of rat 
studied, chronic oral dosing with propranolol attenuated 
both hypotension and tachycardia.
In Japanese Okamoto rats, oral dosage with propranolol 
abolished both hypotension and tachycardia induced by 
central injection of isoprenaline but icv injection of 
propranolol did not significantly attenuate the initial 
fall in blood pressure produced by isoprenaline. This 
would indicate that, in this strain of rat, it is possible 
that the injected propranolol had not been significantly 
concentrated in the hypothalamus as would be expected to 
happen following chronic oral dosing with propranolol. The 
results seen in Japanese Okamoto rats are comparable with 
those in New Zealand rats (see figures 48 & 49 and 33 &
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34) . In this study, no measurements of the concentration 
of propranolol in the hypothalamus were made, but this 
would be helpful in interpreting discrepancies in results 
between different routes of administration of propranolol 
pretreatment.
These results differed from those in Wistar rats where icv 
propranolol did block the isoprenaline induced hypotension. 
Chronic oral dosage with propranolol was more effective at 
blocking the responses to central isoprenaline in Japanese 
Okamoto rats than in Wistar rats. Whether this is a 
difference of any great importance has not been answered in 
this study, and clearly more work involving hypertensive 
and normotensive rats would have to be carried out before 
any definite conclusions could be drawn.
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3.7. General Discussion.
One of the main problems in a study involving central 
administration of drugs is the difficulty in ascertaining 
the precise mechanism(s) involved in any response. There 
is discrepancy between results recorded by different 
authors depending upon species and/or strain used and 
whether anaesthesia is employed. In addition, studies 
involving icv injection necessitate investigation into 
whether the responses are centrally or peripherally 
mediated.
In this study, attempts were made to eliminate some of 
these problems. Although it was not possible to use more 
than one species of animal, three strains of rat were used 
to investigate any strain differences. Unfortunately, 
direct comparisons could not be made between all three 
since it was found that the anaesthetic employed initially 
was not suitable for the hypertensive strain. This problem 
was overcome to a certain extent by using the same 
anaesthetic for Japanese Okamoto spontaneously hypertensive 
and Wistar Kyoto normotensive rats. The problems
associated with anaesthesia-induced responses were 
eliminated by using conscious New Zealand rats to study 
responses to icv injections. It would be useful to devise 
a method for injections into the hypothalamus of conscious 
rats since this would also serve to localise the area of
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injection and minimise leakage to the periphery as was, 
observed following icv injection in conscious rats. The 
method used for icv injection in conscious rats in this 
study would be unsuitable for injections into the 
hypothalamus because the wash-through volume would be too 
great for a localised injection.
As a major influence in this study was whether anaesthesia 
was present and what anaesthetic, if any, was used, it will 
be further discussed here.
Conscious vs. anaesthetised animals.
The term "conscious' used to describe an animal's condition 
should be replaced by 'unanaesthetised' because the arousal 
state of the animal may vary. Changes in arousal state 
ranging from overt sedation to hyperexcitability may occur 
following the injection of substances into the central 
nervous system. It follows that, in conscious animals,
changes in cardiovascular parameters may be secondary to a 
behavioural alteration. Very few studies in which
conscious animals are used record any changes in arousal of 
the animal. Changes in behaviour in unanaesthetised dogs 
were recorded by Per Bolme et al (1967) following 
electrical stimulation of the hypothalamus. The first sign 
of behavioural reaction was the dog raising its head and 
looking around. Increasing intensity of stimulation led
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progressively to anxiousness, excitement and rage. Clearly 
it can be seen that these changes will lead to a change in 
cardiovascular parameters which may not be a direct result 
of central stimulation. In this study, the animals were 
placed under the minimum amount of stress possible by 
leaving them unrestrained within the experimental cage. 
However, during the injection of drugs, the animals 
exhibited some degree of restlessness. Whether this was a 
cause of distress at being handled, as a result of the 
physical injection or a central effect of the drug is 
unknown. Following completion of the injection, the 
animals tended to settle down within the cage and remain 
relatively immobile over the remainder of the experiment. 
It follows that a slight increase in mean arterial pressure 
and heart rate would result from this initial period of 
restlessness, and this was indeed observed.
Regardless of these problems when working with conscious 
animals, those associated with anaesthesia are greater. 
The most widely recognised differential effect of 
anaesthetics is their greater suppression of cortical and 
diencephalic function than of medullary function; this 
could result in a systemic bias allowing the medulla an 
exaggerated role in the regulation of the cardiovascular 
system (Calaresu et al, 1975).
Gutman et al (1962) demonstrated an increase in blood
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pressure following stimulation of the hypothalamus, \ 
mesencephalon and medulla of unanaesthetised rabbits. 
Following injection of pentobarbitone, these changes were 
suppressed or converted to hypotension. This suggested a 
preferential block of pressor centres by pentobarbitone.
The effects of different general anaesthetics on the 
electrophysiology of central neurones has been reviewed by 
Szabadi (1979). For example, chloralose markedly reduced 
the sensitivity of cortical neurones to acetylcholine and 
excitant amino acids whereas urethane, nitrous oxide and 
halothane had little effect. Excitatory responses to 
noradrenaline in the cortex are seen in animals 
anaesthetised with halothane, but are rarely seen when 
barbiturates are employed.
A more detailed discussion regarding the anaesthetics used 
in this study can be found in section 3.5.4.1.
The value of the anaesthetised preparation rests in the 
ability of the investigator to measure many variables under 
carefully controlled experimental conditions. Small
changes in blood pressure and heart rate may be detected in 
the anaesthetised preparation since these parameters are 
very stable under such circumstances. These small changes 
can easily be masked in the conscious preparation by 
movement of the animal.
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Leakage of drugs from the central nervous system to the 
periphery.
In an attempt to distinguish between centrally and 
peripherally mediated responses following icv injection, 
the amount of drug remaining in the brain was quantified 
using radiolabelled isotopes. Results from this study 
indicated that there was a large difference in the rate of 
disappearance of drug from the central nervous system 
between anaesthetised and unanaesthetised animals. Whereas 
80% of the injected drug was still present in the brain 
after 20 minutes in the anaesthetised animals, only 20% 
still remained after 10 minutes in conscious animals. 
Although no studies have been made in anaesthetised 
animals, the results from conscious animals agree with the 
findings of Anderson et al (1977) in conscious rabbits and 
Smits and Struyker Boudier (1979) in conscious 
spontaneously hypertensive rats. The evidence indicates 
that not only is the presence of anaesthesia likely to 
alter the responses to icv injections, but also this 
difference in leakage from the brain would suggest a 
greater participation of peripherally mediated responses in 
conscious animals.
It is not known why there should be such a great difference 
between anaesthetised and unanaesthetised rats in the rate
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at which drugs leak from the central nervous system to the' 
periphery. There are possible reasons, such as changes in 
cerebrospinal fluid or blood flow, but these were not 
investigated in this study.
Although the* physical natures of isoprenaline and 
propranolol are entirely different, e.g. lipophilicity, the 
two drugs were found to leak from the central nervous 
system to the periphery to approximately the same extent in 
both conscious and anaesthetised animals.
From these results, it would be easy to speculate that 
following icv injection in conscious rats, the responses 
observed would be peripherally mediated. This is not 
entirely true. The existence of a central component in the 
responses was demonstrated by the fact that, in conscious 
New Zealand rats, the hypotension produced by 5 meg 
isoprenaline was abolished by 30 meg propranolol icv, but 
not by 30 meg propranolol iv (see figure 22a).
It remains to be demonstrated if the discrepancy between 
responses observed in conscious and anaesthetised animals 
is an effect of the anaesthetic or perhaps, at least in 
part, a result of this difference in leakage to the 
periphery.
Although authors have not investigated the amount of drug
259
leaking to the periphery in anaesthetised animals, many 
have abolished the responses to icv injection by spinal 
cord and vagus nerve transection indicating that 
insufficient drug had leaked to the periphery to exert an 
effect at peripheral adrenoceptors. This was demonstrated 
in anaesthetised dogs (Bhargava et al, 1972), cats (Gagnon 
and Melville, 1966) and rabbits (Toda et al, 1969). Thus 
the balance of evidence would indicate that this difference 
in rate of leakage of drugs to the periphery is present in 
other species in addition to the rat.
Possible further lines of research.
Many questions are still unanswered by this study and 
indicate further lines of research.
The experiments in this study were concerned only with the 
effects on mean arterial pressure and heart rate 
immediately following injection. There is evidence to 
suggest that, following central injection of drugs, changes 
in cardiovascular parameters may be seen after several 
hours. Following icv injection of propranolol, an initial 
increase in blood pressure followed by a longer lasting 
hypotension after several hours has been reported in 
conscious dogs (Conway and Lang, 1974), rabbits (Anderson 
et al, 1977; Dollery et al, 1973) and spontaneously 
hypertensive rats (Smits et al, 1979; Sweet and Wenger,
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1976). It may be useful, therefore, to observe changes in 
cardiovascular parameters in conscious rats over a longer 
time period than was employed in this study.
The problems associated with the presence of anaesthesia 
and the leakage of drugs to the periphery in conscious 
animals indicate that injection of drugs into discrete
brain areas of conscious rats would be useful since this
would eliminate any alteration in response by anaesthetics 
and also minimise leakage of drug to the periphery. This 
would be particularly useful when considering injections of 
noradrenaline and adrenaline which interact with alpha- 
adrenoceptors. The anaesthetic used for New Zealand rats 
contains fluanisone which is known to block alpha-
adrenoceptors (Peroutka et al, 1977). It is possible that
the inclusion of fluanisone in the anaesthetic would 
abolish or attenuate responses which are a result of 
interaction at central alpha- adrenoceptors. The
possibility of this occurring may also be investigated by 
using an alternative anaesthetic, such as
thiobutobarbitone, although anaesthetics in general are 
thought to block pressor responses preferentially (Bergmann 
and Gutman, 1966; Gutman et al, 1962).
In order to facilitate injection into discrete brain areas 
in the conscious rat, a system would have to be developed 
to allow injection of very small volumes of vehicle
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containing the required amount of drug. This would also 
allow injection of antagonist and agonist into the 
hypothalamus.
Injection of more than one substance into the hypothalamus 
would also be useful in anaesthetised rats. The system 
used in this study did not allow for this. It was found 
that, if the cannula was removed from the hypothalamus to 
reload with the agonist following injection of the 
antagonist, subsequent repositioning in the hypothalamus 
and injection of agonist resulted in leakage of the agonist 
along the track of the cannula. This did not appear to 
occur with a single injection and it was thought that on 
repositioning the cannula, the track through the brain was 
widened thus allowing leakage of injected vehicle. To try 
to overcome this, antagonist and agonist were injected 
together into the hypothalamus, but it was difficult to 
interpret the responses obtained and assign them to one or 
other of the components in the injection. It was decided 
to inject the antagonist into the cerebral ventricle whilst 
injecting agonists into the hypothalamus. However, it is 
not known to what extent the injected antagonist would be 
present in the hypothalamus at the start of injection of 
It. would be possible to evaluate the amount 
of propranolol in the hypothalamus following icv injection 
and oral dosing by administering the radiolabelled isotope 
and subsequent evaluation of radioactivity in the
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hypothalamus.
Although a small amount of work was carried out with 
spontaneously hypertensive rats, this was by no means 
complete. In order to investigate any differences in the 
hypertensive animal, it would be useful to investigate 
responses seen in the conscious animal where the blood 
pressure and heart rate have not been depressed by the 
presence of anaesthesia. The possibility that alpha- 
adrenoceptors may play a part in the development of 
hypertension in the Japanese Okamoto spontaneously 
hypertensive rat (see section 3.5.4.1.) would suggest that 
central injection of substances that interact with alpha- 
adrenoceptors may illustrate a greater strain difference 
than injection of beta- adrenoceptor agonists.
Finally, it would be useful to investigate changes in 
blood pressure and heart rate independently of one another.
The reason for this is it is difficult to assess whether an
attenuation of hypotension is merely a result of 
potentiation of tachycardia as was seen in some 
experiments. Any increase in heart rate could be blocked 
by dosing animals with atenolol for 7 days as was employed 
V'1 jr“ i ng i popr^n.a.] ine i nto the anterior nucleus ( see 
section 3.4.5.3. and figures 37a and 37b). Atenolol given 
as an oral dose is not thought to pass across the blood
brain barrier to a significant extent due to its low
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lipophilicity (Barrett, 1977) and would therefore not 
interfere with any centrally mediated responses occurring 
from subsequent central injections.
3.8. General conclusions.
From the results obtained in this study, it may be 
concluded that activation of central beta- adrenoceptors
results in an increase in heart rate and a decrease in mean 
arterial pressure. The degree of hypotension can be
attenuated or reversed by central beta- adrenoceptor 
blockade. Thus, it seems hard to understand how the
central effects of beta- adrenoceptor blocking drugs could 
be beneficial in the treatment of hypertension. It is 
possible that in clinical use beta- adrenoceptor blocking 
drugs that are capable of crossing the blood brain barrier 
may exert an action within the central nervous system which 
is pro-hypertensive and actually opposes the other, 
antihypertensive actions.
However, it must be remembered that central alpha- and 
beta- adrenoceptors differ from corresponding peripheral 
adrenoceptors in a number of respects. Noradrenaline has 
V.cr> to r.rodjjoe. both exci tatory and depres«^*r>t
responses which appear to be mediated by pharmacologically 
distinct receptors; the excitatory responses by alpha- 
adrenoceptors and the depressant responses by beta-
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adrenoceptors. There is also evidence that the
functionally antagonistic alpha- and beta- adrenoceptors 
may occur on the same neurone. In some areas of the 
central nervous system neuronal responses to noradrenaline 
and isoprenaline can be blocked by both alpha- and beta- 
adrenoceptor blocking agents (Szabadi, 1979). Thus, care 
must be taken not to assume that central administration of 
beta- adrenoceptor agonists or antagonists will lead to 
solely an action on central beta- adrenoceptors.
From the results obtained here, it is clear that central 
beta- adrenoceptors do play a role in the maintenance of 
blood pressure, but many questions still remain unanswered.
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SUMMARY.
1. lev injection of adrenaline in anaesthetised New Zealand rats resulted in an increase 
in blood pressure and bradycardia .whereas injection of drugs which exhibit agonist 
action on ly  at j8-adrenoceptors resulted in a fa ll in blood pressure w ith  tachycardia. 
Adrenaline interacts w ith  both a- and /3-adrenoceptors, suggesting that central a- 
adrenocptors are concerned w ith  hypertension and bradycardia whereas central /3- 
adrenoceptors are concerned w ith  hypotension and tachycardia. In addition, it would  
appear that under these conditions, a-adrenoceptor mediated responses predominate 
over /3-adrenoceptor mediated responses. The hypotensive action of /3-adrenoceptor 
agonists appears to be mediated via central /32-adrenoceptors, as the /32-adrenoceptor 
agonist clenbuterol causes hypotension and the /32-adrenoceptor antagonist ICI 118,551 
blocked the hypotension caused by central isoprenaline. Inconsistent results in studies 
using the /31-adrenoceptor agonist xamoterol m ay have arisen because this drug is a 
partial agonist w ith  some antagonistic properties. (See Table 1)
2. Injection o f isoprenaline into the hypothalamus of anaesthetised N ew  Zealand rats 
resulted in a fa ll in blood pressure w ith  tachycardia. The hypotension was attenuated 
follow ing pretreatment w ith  icv atenolol and potentiated follow ing ICI 118,551, 
suggesting that the hypotension was mediated via /31 -adrenoceptors in the 
hypothalamus. However, hypotension was also elicited by clenbuterol injected into the 
hypothalam us. It is possible that clenbuterol and ICI 118,551 may be interacting w ith  
pre-synaptic /32-adrenoceptors, whereas atenolol may alter isoprenaline induced 
responses by blocking post-synaptic /31-adrenoceptors. Thus the possibility exists that 
both types o f /3-adrenoceptor are present in the hypothalamus and may be involved in 
the regulation o f cardiovascular parameters. This could be confirmed by further 
investigations using selective /3-adrenoceptor agonists and antagonists. (See Table 2)
3. Chronic oral dosage w ith  propranolol blocked the responses to central isoprenaline 
more effectively in Japanese Okamoto rats than in W istar rats. It is possible that, 
follow ing long-term treatment w ith  propranolol, adaptive changes take place which
w ould  not be seen follow ing acute pretreatment. In the hypertensive animal, these 
changes m ay occur more readily follow ing long-term treatment w ith  j8-adrenoceptor 
blocking drugs, or m ay already be present as a consequence of hypertension. In 
addition, it should be noted that antihypertensive drugs are known to have a greater 
blood pressure-lowering elfect in the hypertensive than in the normotensive state. (See 
Table 3)
Agonist
Adrenaline Xamoterol Isoprenaline Clenbuterol
Anaesthetised Anaesthetised Anaesthetised Conscious Anaesthetised Conscious
Antagonist bp hr bp hr bp hr bp hr bp hr bp hr
no pretreatment T 1 11 T 11 T 11 TT 11 T 11 TT
propranolol icv TT 1 T T 1 TT - T - T - T
propranolol iv T TT 11 TT 11 TTT 11 TT
propranolol po T T
atenolol icv 11 T
aten o lo liv 11 TT
ICI 118,551 icv - TT
ICI 118,551 iv 1 TT
Table 1.
Change in mean arterial pressure and heart rate fo llow ing icv injection o f adrenoceptor 
agonists in N ew  Zealand rats: modification by pretreatment w ith  /3-adrenoceptor 
blocking agents.
T Slight change, TT Definite change, TTT Pronounced change.
Agonist

















Antagonist bp hr bp hr bp hr bp hr bp hr bp hr bp hr bp hr
no pretreatment TT - 1 TT 1 u 1 u 11 T 11 T 11 T 11 T
propranololicv TT i TT TT - T T - 1 TT 11 TT 1 TT 1 TT
propranolol po TT - - TT
atenolol icv 1 TT
ICI 118,551 icv H i TT
Table 2.
Change in mean arterial pressure and heart rate fo llow in g injection o f adrenoceptor 
agonists into the hypothalam us of New Zealand rats: modification by pretreatment w ith  
adrenoceptor blocking agents.








W istar JO W istar JO W istar JO
Antagonist bp hr bp hr bp hr bp hr bp hr bp hr
no pretreatment u TT 11 IT 11 TT 11 T 11 TT 11 T
propranolol icv 1 T - T T T 1 TT - 1 TT
propranolol po - T - - 1 T - - 1 T -
Table 3.
Change in mean arterial pressure and heart rate fo llow ing injection o f isoprenaline in 
W istar and Japanese Okamoto (JO) rats: modification by propranolol.
T Slight change, TT Definite change, TTT Pronounced change.
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CARDIOVASCULAR CHANGES FOLLOWING ADMINISTRATION OF ADRENALINE 
AND ISOPRENALINE TO THE HYPOTHALAMUS OF THE ANAESTHETISED RAT
A.J. Draper, P.H. Redfern, Jane Roberts, Pharmacology Group, School of Pharmacy 
and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY.
It has been shown that injection of adrenaline into the anterior hypothalamus 
caused an initial slight increase, followed by a longer lasting decrease, in 
blood pressure accompanied by a fall in heart rate (Struyker Boudier & Bekers, 
1975). In these experiments we have compared the effects of adrenaline and 
isoprenaline injected into both the anterior and the posterior hypothalamus. 
Modification by prior icv propranolol was also investigated.
Male New Zealand normotensive rats (190-200g) were anaesthetised with Hypnorm/ 
midazolam (Flecknell & Mitchell, 1984). The left carotid artery was cannulated 
to allow measurement of blood pressure. Guide cannulae were stereotaxically 
implanted according to the atlas on Kbnig & Klippel (1963). The agonists (5jig in 
lul artificial csf (Merlis, 1940) were injected into the hypothalamus over 2.5 min. 
Where appropriate, 30yg propranolol was injected icv in 10pl artificial csf 15 min 
before the agonist.
Table 1. Maximal change in mean arterial pressure (mmHg) and heart rate (bpm) 
following injection into the hypothalamus.





adrenaline, -9.8 — 3.7 
anterior nucleus (12)
+4.2 - 2.4 
(6) *
-40 - 8 
(12)
+24 -  6 
(6) **
adrenaline, -19.8 - 4.0 
posterior nucleus (8)
+25.2 -  8.8 
(6) **




isoprenaline, -15.5 -  3.4 
anterior nucleus (11)
-12.0 - 6.5 
(6)
+23 i 8 
(11)
+61 i 3 
(6) **
isoprenaline, -19.5 - 4.8 
posterior nucleus (9)
-24.0 -  8.0 
(6)
+14 -  3 +51 - 7
(6) **
Pretreatment with propranolol abolished the depressor response to adrenaline in 
the anterior nucleus, and reversed the response in the posterior nucleus. The
depressor response to isoprenaline was unaffected by pretreatment with
propranolol, although the duration of hypotension was attenuated.
Previous studies involving icv injection of isoprenaline have indicated that the 
central depressor response consists of two elements, one mediated through 
8-receptors and the other involving non-neuronal mechanisms (Peres-Polon & Correa, 
1984; Draper et al, 1986). These results appear to support this hypothesis, since 
the depressor response to adrenaline is readily abolished or reversed by 
propranolol whereas the magnitude of the depressor response to isoprenaline in 
unaffected.
Struyker Boudier HAJ, Bekers AD, (1975) Eur. J. Pharmacol. 31, 153-155 
Flecknell PA, Mitchell M, (1984) Lab. Animals 18, 143-146 
Merlis JK, (1940) Am. J. Physiol. 13, 67-72
Peres-Polon VL, Correa FMA, (1984) Gen. Pharmacol. 15, 505-509 
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HYPOTENSION INDUCED BY CENTRAL IN JEC TIO N  OF ISOPRENALINE AND
c l e n b u t e r o l : m o d i f i c a t i o n  by  c e n t r a l  p r o p r a n o l o l .
A.J. Draper, P.H. Redfern, Jane Roberts, Pharmacology Group, School of Pharmacy 
and Pharmacology, Univers i ty of Bath, Claverton Down, Bath BA2 7AY
Hypotens ion  has  been r e p o r t e d  t o  f o l l o w  icv  i n j e c t i o n  of  i s o p r e n a l i n e  i n  
anaes the t i sed  animals of various  species (Gagnon & Melvil le ,  1967; Toda e t  al ,  
1969; Bhargava  e t  a l ,  1972). In t h e s e  e x p e r i m e n t s  we have a t t e m p t e d  to  
e l u c i d a t e  th e  mechanism invo lved  by compar ing  the e f f e c t s  of two 8- 
adrenoceptors agonis t s ,  isoprenal ine and c lenbute ro l ,  administe red  cen t ra l l y  to 
the  a n a e s t h e t i s e d  r a t .  M o d i f i c a t i o n s  of t h e i r  e f f e c t s  by p r i o r  c e n t r a l  and
snoreceptor an tagonist ,  propranolol ,  was a l so  
Male New Zea land  no rm o ten s iv e  r a t s  (190- 
200g) were  a n a e s t h e t i s e d  w i t h  Hypnorm/ 
midazolam (Flecknell  A Mitchell ,  1984). The 
l e f t  c a r o t i d  a r t e r y  and r i g h t  j u g u l a r  v e i n  
were c a n n u l a t e d  t o  al low measurement  of 
blood pressure  and in j e c t i o n  of drugs respe­
ct ive ly .  A guide cannula was in se r t ed  in t o  
t h e  l e f t  c e r e b r a l  v e n t r i c l e  and drugs  were  
in j e c te d  icv in  a volume of 5ui over 2.5min.
The dose -dependen t  hypotens ion  produced by 
both i s o p r e n a l i n e  and c l e n b u t e r o l  i c v  was 
r e s i s t a n t  to  p r io r  in j e c t i o n  of 12y g propra­
n o lo l  iv  (F ig . l ) .  P r e t r e a t m e n t  w i t h 3 0  g 
p r o p r a n o lo l  icv  15 min b e f o r e  the  a g o n i s t  
a b o l i s h e d  t h e  d e p r e s s o r  r e s p o n s e  t o  
c l e n b u t e r o l ,  but only p a r t i a l l y  p rev en ted  
the  h y p o te ns ion  produced by i s o p r e n a l i n e  
(Fig.  1). This  c o n f i rm s  e a r l i e r  r e p o r t s  
(Nomura, 1976; Peres-Polon and Correa, 1984) 
th a t  in  the anaes the t i sed  r a t ,  the depressor 
r e s p o n s e  t o  c e n t r a l  i s o p r e n a l i n e  i s  
r e s i s t a n t  to  propranolol ,  suggesting th a t  a 
s i g n i f i c a n t  e l e m e n t  of  t h e  d e p r e s s o r  
re sponse  of i s o p r e n a l i n e  i s  no t  m e d ia te d  
th rough  B-adrenoce p t  o r  s. T h e re  i s ,  o f  
cou rse ,  a lways  t h e  p o s s i b i l i t y ,  f o l l o w i n g  
icv  i n j e c t i o n ,  of  l e ak ag e  of  drug to  the  
p e r ip h e ry .  However, c e n t r a l  in j e c t i o n  of
’ H-propranolol and ^H-isoprenaline w i th
subsequen t  a n a l y s i s  of  blood and t i s s u e  i s o t o p e  l e v e l s  i n d i c a t e d  t h a t ,  f o r  
i n s t a n c e ,  i n  t e rm s  of the  amount of  drug a v a i l a b l e  to  the p e r ip h e r y ,  1 2yg 
propranolol  iv was equ ivalent  to  30 pg propranolol  icv.
Taken toge ther,  these r e s u l t s  support  the hypothesis  th a t  the cen t ra l  depressor 
re s p o n s e  t o  I s o p r e n a l i n e  co m p r i se s  two e l e m e n t s ;  one m ed ia ted  th rough  8 -  
a d r e n o c e p t o r s  and mimicked by c l e n b u t e r o l  and the o t h e r  p robab ly  m ed ia ted  
through humoral mechanisms.
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per ipheral  i n j e c t i o n  of the 








Fig. 1. Change in mean arterial 
pressure produced by ICV
isoprenaline 5yg (x x) and
clenbuterol 5|jg (o o) .
Modification by propranolol
30yg ICV (x....x, 0....0)
and 12yg iv (x x, o o). (n = 6)
